<html xmlns="http://www.w3.org/1999/xhtml" class=" js flexbox flexboxlegacy canvas canvastext webgl no-touch geolocation postmessage no-websqldatabase indexeddb hashchange history draganddrop websockets rgba hsla multiplebgs backgroundsize borderimage borderradius boxshadow textshadow opacity cssanimations csscolumns cssgradients no-cssreflections csstransforms csstransforms3d csstransitions fontface generatedcontent video audio localstorage sessionstorage webworkers applicationcache svg inlinesvg smil svgclippaths"><!--MODERNIZED PAGE--><head id="coid_website_head" profile="http://www.w3.org/2005/10/profile"><style type="text/css">@charset "UTF-8";[ng\:cloak],[ng-cloak],[data-ng-cloak],[x-ng-cloak],.ng-cloak,.x-ng-cloak,.ng-hide{display:none !important;}ng\:form{display:block;}.ng-animate-block-transitions{transition:0s all!important;-webkit-transition:0s all!important;}</style>
	<meta http-equiv="content-type" content="text/html; charset=UTF-8">
	<meta http-equiv="X-UA-Compatible" content="IE=edge">
	<meta name="description" content="View on Westlaw or start a FREE TRIAL today, Association for Molecular Pathology v. U.S. Patent and Trademark Office, Cases">







<script>
	

	(function () {
		window['$$errors'] = [];

		//handle js errors (it will be overwritten in GlobalPageHandlers.js. And any error will be processed when this script is loaded on the page.)
		window.onerror = function() {
			window['$$errors'].push(arguments);
		}
	})();
</script>




	<title>Association for Molecular Pathology v. U.S. Patent and Trademark Office | Cases | Westlaw</title>

	
	



	
	
	



	




    
    <link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/utilities.css" type="text/css" rel="stylesheet">
<link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/core.css" type="text/css" rel="stylesheet">
<link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/components.css" type="text/css" rel="stylesheet">
<link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/features.css" type="text/css" rel="stylesheet">
<link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/document.css" type="text/css" rel="stylesheet">
<link href="https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/print.css" type="text/css" rel="stylesheet" media="print">
<!--[if gte IE 6]>
<link href='https://ca.next.westlaw.com/StaticContent_40.1.1015/css/v2/ie.css' type='text/css' rel='stylesheet' />
<![endif]-->


	<link rel="shortcut icon" type="image/vnd.microsoft.icon" href="https://ia.next.westlaw.com/favicon.ico">
	<link rel="apple-touch-icon" href="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/v2/iphone-webclip-icon.png">
<script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="//ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/js/bundle.923c80f054c89ca796f84c4fbed803b0.dll.js"></script><script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="//ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/js/bundle.e94d5ee75e94c1087b529e979a552bed.dll.js"></script><script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="//ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/js/bundle.83634f9482d1ddf27e96c8f1d9498ac3.dll.js"></script><script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="//ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/js/bundle.82967e6fecb235c1f97c6591de01f9f7.dll.js"></script><script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="//ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/js/Website/Views/Document/DocumentTabView.bootstrap.js"></script><link id="Markman_MarkmanDisplayState"><link id="Markman"></head>



<body class="co_t2Left co_docDisplay">
	<div id="co_pageContainer" class="co_bodyToolbar">
		<div id="co_mainContainer">
			











<div id="co_headerWrapper" class="wlnv2 ">
	<div id="co_newHeader"><div id="co_privacyPolicyContainer"> 
	<p id="co_privacyPolicy">
		<b>We've updated our Privacy Statement.</b> Before you continue, please read our new <a id="coid_website_privacyPolicyLinkOut" href="javascript:void(0)">Privacy Statement</a> and familiarize yourself with the terms.
		<button type="button" id="coid_website_privacyPolicyAcknowledged" title="Close message to acknowledge privacy statement" class="co_absolute">
			<span class="icon25 icon_close_x"></span>
		</button>
	</p>
</div>
		<div id="co_headerContainer">
			<div id="co_newHeader_top" class="headerContent" role="banner">
					<div class="skipButtonContainer"><a href="javascript:void(0);" data-jumpto="co_docHeaderTitle" class="co_tbButton skipButton">Skip to Document</a><a href="javascript:void(0);" data-jumpto="co_footerLinks" class="co_tbButton skipButton">Skip to Footer</a></div>
						<ul id="co_mainNav" class="co_inlineList" role="navigation">
							
														<li id="co_kmFirmNameContainer"></li>


	<li id="co_clientIdContainer" class="navigation_link co_menuListFirst"><div id="co_clientID_title_0" class="co_dropdownTabCollapsed"><span class="co_clientID_label" id="co_clientID_label_0">Client ID:</span><span></span></div><div id="co_clientID_list_0" class="co_clientID_list co_hideState" aria-hidden="true">

<div class="co_dropdownBoxExpanded">
	<div class="co_dropdownBoxHeader">
		<span></span>
	</div>
	<div class="co_dropdownBoxContent">
		<button id="co_clientID_close_0" class="co_overlayBox_closeButton" type="button">Close</button>
		<div class="co_dropdownBoxContentRight" id="co_clientID_content_0"></div>
	</div>
	<div class="co_dropdownBoxFooter">
		<span></span>
	</div>
</div></div></li>
									<li id="co_recentHistoryContainer"><div id="tabIndicator" class="co_dropdownTabCollapsed"><div class="co_dropdownTab"><a href="javascript:void(0);" class="co_dropdownBoxanchorLabel"><span class="icon"></span>History</a><button class="co_hasTooltip co_dropdownArrowCollapsed" title="Recent History Menu"><span class="th_simple_icon icon_down_arrow reversed"></span><span class="co_accessibilityLabel" aria-hidden="true" id="coid_dropdownAriaLabel_1">History Menu</span> </button></div></div><div class="co_dropdownBoxCollapsed" aria-hidden="true" aria-labelledby="coid_dropdownAriaLabel_1"><span class="co_accessibilityLabel">Beginning of history window.</span><div class="co_dropdownBoxContent"><div class="co_recentResearch iac-a11y-header-redesign" id="co_recentResearch">
	<div class="co_recentDocuments co_floatLeft">
		<div class="co_globalNavDropdownBox_header">
			<h3 class="co_recentDocumentsHeader">Recent Documents</h3>
			<a class="co_floatRight co_recentDocumentsAll" href="javascript:void(0);" id="co_recentDocumentsLink">View all</a>
		</div>
		<div class="co_scrollWrapper">
			<ul class="co_recentDocumentsList" id="co_recentDocumentsList"></ul>
		</div>
	</div>
	<div class="co_recentSearches co_floatRight">
		<div class="co_globalNavDropdownBox_header">
			<h3 class="co_recentSearchesHeader">Recent Searches</h3>
			<a class="co_floatRight co_recentSearchesAll" href="javascript:void(0);" id="co_recentSearchesLink">View all</a>
		</div>
		<div class="co_scrollWrapper">
			<ul class="co_recentSearchesList" id="co_recentSearchesList"></ul>
		</div>
	</div>
	<div class="co_clear"></div>
</div></div><button class="co_overlayBox_closeButton" type="button" title="Close history menu">Close Recent History window</button><span class="co_accessibilityLabel">End of history window.</span></div></li>
								<li id="co_signOffContainer" class="">

									<div class="co_dropdownTabCollapsed">
										<div class="co_dropdownTab">
											<button id="coid_website_signOffRegion" class="co_dropdownBoxanchorLabel co_hasTooltip iac-a11y-header-redesign" title="Settings &amp; Sign Off">
												<span class="th_simple_icon icon_user reversed"></span>
												<span class="th_simple_icon icon_down_arrow reversed"></span>
												<span class="co_accessibilityLabel" aria-hidden="true">Settings &amp; Sign Off</span>
											</button>
										</div>
									</div>
									<div class="co_dropdownBoxCollapsed co_globalNavDropdownBox" aria-hidden="true" aria-labelledby="coid_dropdownAriaLabel_0"><span class="co_accessibilityLabel">Beginning of profile settings window.</span>
										<div class="co_globalNavDropdownBox_header">
											<h3 id="coid_dropdownAriaLabel_0">Profile Settings</h3>
										</div>
										<div class="co_globalNavDropdownBox_content">
											<div class="co_signOff_profile">
												<h4></h4>
												<ul>
													<li></li>
												</ul>
											</div>

											<div class="co_signOff_links">
												<ul>


	<li>
		<a id="coid_website_mycontent" href="/MyPlan/Show\?transitionType=Default&amp;contextData=(sc.Default)">My Content</a>
	</li>


													<li>
														<a id="coid_website_userSetting" href="javascript:void(0);">My Preferences</a>
													</li>
													<li>
														<a class="co_signOff_updateProfile" href="https://onepass.westlaw.com/v2/profile/general?productid=CBT&amp;viewproductid=&amp;returnto=1.next.westlaw.com">Update OnePass Profile</a>
													</li>
												</ul>

											</div>

											<div class="co_signOff_buttons">
												<div>
													<button type="button" class="co_primaryBtn js_website_signoff">Sign Off</button>
												</div>
											</div>
										</div>
									<button class="co_overlayBox_closeButton" type="button" title="Close profile menu">Close Profile Settings window</button><span class="co_accessibilityLabel">End of profile settings window.</span></div>

								</li>
						</ul>

			</div>
			<div id="co_newHeader_bottom" class="headerContent">







<div id="headerLogo" class="" data-compartment-start-page-id="">

	<a id="coid_website_logo" href="/?transitionType=Default&amp;contextData=(sc.Default)" tabindex="1" class="co_hasTooltip">
		<img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/v2/logo.png" title="Westlaw Home">
		<span class="co_accessibilityLabel" aria-hidden="true">Westlaw Home</span>
	</a>
</div>







<div id="coid_website_searchWidget" style="display:none;"></div>
<div id="co_headerSearch" class="">
	<div id="co_searchWidgetInnerId" class="co_noAdvancedSearch">
		<form action="" onsubmit="return false;">
			<div id="co_searchFormLeft">
				<a href="javascript:void(0);" id="co_categorySearchButton">
					<span id="co_currentSelectedCategoryText">291 PATENTS</span>
					<span id="co_currentSelectedCategoryToggle" class="th_simple_icon icon_down_arrow co_hasTooltip">
						<span class="co_accessibilityLabel">Content Menu</span>
					</span>
				</a>
				<div class="co_dropdownBoxCollapsed" id="co_searchCategoryDropdown"><ul>  <li class="co_tabLeft" id="co_searchWidgetAllWestlawTab" title="Search All Content">    <div class="co_tabRight"><a href="#" onclick="return false;">All Content</a></div>  </li>  <li class="co_tabLeft co_hideState" id="co_searchWidgetCompartmentCustomTab" title="compartmentCustomTab">    <div id="compartmentCustomTabDivId" class="co_tabRight"><a title="Search " href="#" onclick="return false;">{compartmentCustomTabLinkText}</a></div>  </li>  <li class="co_tabActive co_tabLeft" id="co_searchWidgetCustomTab">    <div id="customTabDivId" class="co_tabRight"><a title="Search 291 PATENTS" href="#" onclick="return false;">291 PATENTS</a></div>  </li></ul>

				</div>
			</div>
			<div class="co_searchFormOuter">
				<div class="co_searchInputContainer" id="co_searchInputContainer">
					<div class="co_inputTop">
						<div class="co_inputTopRight"></div>
					</div>
					<div class="co_inputMidLeft">
						<div class="co_inputMidRight">
							<!-- Search text box -->
							<div class="co_textarea">
								<label id="searchInputIdLabel" for="searchInputId">Search:</label>
									<textarea style="" title="Search" name="searchInputId" aria-label="Westlaw Search. Search suggestions available after typing 3 characters. Use arrow keys to navigate suggestions." id="searchInputId" rows="1" spellcheck="false" autocorrect="off" autocapitalize="off" class="co_defaultInput"></textarea>
							</div>

							<!-- Medical litigator check box container -->
							<div id="co_medLitExpandedTerms" class="co_floatRight co_formInline"></div>



<!-- Recent search query toggle -->
<a id="co_searchLast10Link" class="th_simple_icon icon_down_arrow co_hasTooltip" href="#" onclick="return false;" title="Recent Searches Menu">
		<span class="co_accessibilityLabel">Recent Searches Menu</span>
</a>
						</div>
					</div>
					<div class="co_inputBottom">
						<div class="co_inputBottomRight"></div>
					</div>


<!-- Hold recent query drop down -->
<div id="co_recentQueryListBox" class="co_hideState">
	<ul class="co_searchSuggestionContainer" id="co_searchLast10List"></ul>
</div>
				<span role="application" id="searchBoxIndexSpan" style="display: none;"><p class="co_accessibilityLabel" id="co_resultsAvailable">Results are available, use up and down arrow keys to navigate</p><p class="co_accessibilityLabel" id="co_endOfList">End Of List</p><div id="co_typeAheadStatusAlert" aria-live="assertive" role="alert" aria-labelledby="co_resultsAvailable"></div><ul class="co_searchSuggestionContainer" aria-live="polite" aria-relevant="additions removals" id="co_searchSuggestion" style="display: none;" tabindex="-1"><li class="co_autoCompleteSection" id="coid_westlawanswers_elastic_westlawanswers_allcases" style="display:none"></li><li class="co_autoCompleteSection" id="coid_westlawanswers_elastic_westlawanswers" style="display:none"></li><li class="co_autoCompleteSection" id="coid_westlawanswers_elastic_westlawanswers" style="display:none"></li><li class="co_autoCompleteSection" id="coid_snapshotExactMatch_elastic_snapshots" style="display:none"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_categorypage"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_case"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_docket"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_statute"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_regulation"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_admindecision"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_analytical"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_pendingstatute"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_othercourtdocument"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_snapshots"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_westlawanswers"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_westlawanswers_static_questions"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_westlawanswers_static_questions_allcases"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_westlawanswers_it_depends_question"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_antitrust"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_arbitration"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_bankruptcy"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_capmarket_corpgovern"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_commtrans"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_corp_mna"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_empbenefits_excomp"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_fedcivilpract"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_finance"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_inhousecounsel"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_intelprop_tech"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_labor_emp"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_realestate"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_startup_smallbus"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointhier_trust_estate"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointpicks_practicallaw"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointpicks_forms"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepointpicks_secondarysrc"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepoint_rulebooks"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicepoint_categorypage"></li><li class="co_autoCompleteSection" id="coid_autoCompleteSection_elastic_practicallaw"></li></ul></span></div>
			</div>
			<div id="co_searchFormRight">
				<div id="co_searchFormRightWrapper">
					<!-- Jurisdiction selected -->
					<div id="co_jurisdictionWidgetContainer" class="">

<a class="co_jurisdictionSelectorDropDownArrowCollapsed" href="javascript:void(0);" id="jurisdictionId">
    <span id="jurisdictionIdInner">Federal Circuit</span>
</a>
</div>
					<!-- Search button -->
					<button title="Search" id="searchButton" class="co_hasTooltip" aria-label="Search 291 PATENTS">


						Search Westlaw
						<span class="co_accessibilityLabel">Search 291 PATENTS</span>
					</button>
					<!-- Advanced search -->
					<a href="#" onclick="return false;" class="co_hideState" id="co_search_advancedSearchLink" title="Advanced Search">Advanced</a>
					<!-- Holder jurisdiction pop up -->
					<div id="co_searchJurisdictionHoverContainer"></div>
				</div>
			</div>
			<!-- Search error container -->
			<div id="co_searchInputErrorMessageContainer" class="co_hideState"></div>
		</form>
	</div>
</div>
						<div id="coid_website_searchWidget" class="co_hideState"></div>
						<div id="co_researchAcceleratorWrapper">
							
						</div>
						<div class="co_skipToLink">
							<a id="coid_website_startContent" name="coid_website_startContent"></a>
						</div>

			</div><!--newHeader_bottom-->
		</div><!--headerContainer-->
	</div><!--newHeader-->
</div><!--co_headerWrapper-->




	
	
<!-- moved delivery toolbar to separate ascx control -->	








	<div id="co_body">
		<!-- BODY HEADER -->
		<div id="co_bodyHeader"></div>
		

	
	<!-- Reporting Name is "CTA" for document with guid "Iefd1c172e7ba11e1b11ea85d0b248d27". -->
	
	<!-- CENTER COLUMN -->  
	<div id="co_contentWrapper">
		<div id="co_contentColumn">
			<div class="co_innertube">










<div id="co_docHeaderContainer">
	<a class="co_skipToLink" href="#coid_website_errorsSummaryPlaceHolder">
		Skip Page Header
	</a>
	<div id="co_docHeader">
		<div id="co_docFixedHeader"><div id="co_docHeaderCitatorFlag"><span class="co_citatorFlag"><a href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;transitionType=Document&amp;originationContext=docHeaderFlag&amp;contextData=(sc.CustomDigest)"><img class="crsw_DocumentIndicator" alt="KeyCite Red Flag - Severe Negative Treatment" src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/v1/flag_red.png" title="KeyCite Red Flag - Severe Negative Treatment"></a><span class="co_citatorFlagText">KeyCite Red Flag - Severe Negative Treatment</span></span></div><div id="co_docHeaderTitle"><h2 id="co_docHeaderTitleLine" title="Association for Molecular Pathology v. U.S. Patent and Trademark Office"><span id="title"><a class="co_drag" href="https://1.next.westlaw.com/Document/Iefd1c172e7ba11e1b11ea85d0b248d27/View/FullText.html?listSource=Search&amp;navigationPath=Search%2fv1%2fresults%2fnavigation%2fi0ad6ad3e0000016314b8705c8686bce0%3fNav%3dCUSTOMDIGEST%26fragmentIdentifier%3dIefd1c172e7ba11e1b11ea85d0b248d27%26startIndex%3d1%26contextData%3d%2528sc.CustomDigest%2529%26transitionType%3dCustomDigestItem&amp;list=CUSTOMDIGEST&amp;rank=337&amp;listPageSource=1b34510ac2bede0102300be6a61ae1f3&amp;originationContext=docHeader&amp;contextData=(sc.CustomDigest)&amp;transitionType=Document&amp;needToInjectTerms=False&amp;enableBestPortion=True&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f">Association for Molecular Pathology v. U.S. Patent and Trademark Office</a></span></h2><ul id="co_documentStatusIcons" class="co_document_indicators"></ul><h3 id="co_docHeaderCitation" title="United States Court of Appeals, Federal Circuit. | August 16, 2012 | 689 F.3d 1303 | 103 U.S.P.Q.2d 1681&nbsp;(Approx. 53 pages)"><span id="courtline">United States Court of Appeals, Federal Circuit.</span><span id="filedate">August 16, 2012</span><span id="cite0">689 F.3d 1303</span><span id="cite1">103 U.S.P.Q.2d 1681</span><em>&nbsp;(Approx. 53 pages)</em></h3><h4 id="co_docHeaderNegativeTreatment"><span id="co_document_compositeHeader_citatorFlag" class="co_citatorFlag"></span></h4></div></div>
		<div class="co_clear"></div>
		<div id="co_docPrimaryTabNavigationContainer" class="co_docTabs">
				<a id="co_iPadKeyCiteMenuToggle">
					Toggle Menu
				</a>
			<ul id="co_docPrimaryTabNavigation" class="co_tabs">










<li id="DocumentTab" class="co_tabLeft co_tabActive co_dropdownTab">
	<h2 class="co_tabRight">
		<a id="coid_DocumentTab_link" class="co_tabLink" href="javascript:void(0);">
			<span>Document</span>
		</a>
				<div class="co_clear"></div> 
	</h2>
	</li>







<li id="riFilingsTab" class="co_tabLeft" countstatus="" categoryenum="riFilings">
	<h2 class="co_tabRight">
		<a id="coid_relatedInfo_riFilings_link" class="co_tabLink" href="/RelatedInformation/Iefd1c172e7ba11e1b11ea85d0b248d27/riFilings.html?originationContext=documentTab&amp;transitionType=Filings&amp;contextData=(sc.CustomDigest)&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;rulebookMode=false" hiddenhref="/RelatedInformation/Iefd1c172e7ba11e1b11ea85d0b248d27/riFilings.html?originationContext=documentTab&amp;transitionType=Filings&amp;contextData=(sc.CustomDigest)&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;rulebookMode=false">
			
			<span>
				Filings 
			 (225)</span>
		</a>
		<div class="co_clear"></div> 
	</h2>
</li>







<li id="kcNegativeTreatmentTab" class="co_tabLeft" countstatus="" categoryenum="kcNegativeTreatment">
	<h2 class="co_tabRight">
		<a id="coid_relatedInfo_kcNegativeTreatment_link" class="co_tabLink" href="/RelatedInformation/Iefd1c172e7ba11e1b11ea85d0b248d27/kcNegativeTreatment.html?originationContext=documentTab&amp;transitionType=NegativeTreatment&amp;contextData=(sc.CustomDigest)&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;rulebookMode=false" hiddenhref="/RelatedInformation/Iefd1c172e7ba11e1b11ea85d0b248d27/kcNegativeTreatment.html?originationContext=documentTab&amp;transitionType=NegativeTreatment&amp;contextData=(sc.CustomDigest)&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;rulebookMode=false">
			
			<span>
				Negative Treatment 
			 (5)</span>
		</a>
		<div class="co_clear"></div> 
	</h2>
</li>







<li id="kcJudicialHistoryTab" class="co_tabLeft" countstatus="" categoryenum="kcJudicialHistory">
	<h2 class="co_tabRight">
		<a id="coid_relatedInfo_kcJudicialHistory_link" class="co_tabLink" href="/RelatedInformation/Iefd1c172e7ba11e1b11ea85d0b248d27/kcJudicialHistory.html?originationContext=documentTab&amp;transitionType=History&amp;contextData=(sc.CustomDigest)&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;rulebookMode=false" hiddenhref="/RelatedInformation/Iefd1c172e7ba11e1b11ea85d0b248d27/kcJudicialHistory.html?originationContext=documentTab&amp;transitionType=History&amp;contextData=(sc.CustomDigest)&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;rulebookMode=false">
			
			<span>
				History 
			 (148)</span>
		</a>
		<div class="co_clear"></div> 
	</h2>
</li>







<li id="kcCitingReferencesTab" class="co_tabLeft co_dropdownTab" countstatus="" categoryenum="kcCitingReferences">
	<h2 class="co_tabRight">
		<a id="coid_relatedInfo_kcCitingReferences_link" class="co_tabLink" href="/RelatedInformation/Iefd1c172e7ba11e1b11ea85d0b248d27/kcCitingReferences.html?originationContext=documentTab&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;rulebookMode=false" hiddenhref="/RelatedInformation/Iefd1c172e7ba11e1b11ea85d0b248d27/kcCitingReferences.html?originationContext=documentTab&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;rulebookMode=false">
			
			<span>
				Citing References 
			 (664)</span>
		</a>





<span id="co_kcCitingReferencesNavAnchor" class="co_dropdownArrowCollapsed">Navigate Citing References</span>
		<div class="co_clear"></div> 
	</h2>
		<div id="co_kcCitingReferencesNavContent" class="co_dropdownBoxCollapsed" style="display:none;"></div>
</li>







<li id="kcTableOfAuthoritiesTab" class="co_tabLeft" countstatus="" categoryenum="kcTableOfAuthorities">
	<h2 class="co_tabRight">
		<a id="coid_relatedInfo_kcTableOfAuthorities_link" class="co_tabLink" href="/RelatedInformation/Iefd1c172e7ba11e1b11ea85d0b248d27/kcTableOfAuthorities.html?originationContext=documentTab&amp;transitionType=TableOfAuthorities&amp;contextData=(sc.CustomDigest)&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;rulebookMode=false" hiddenhref="/RelatedInformation/Iefd1c172e7ba11e1b11ea85d0b248d27/kcTableOfAuthorities.html?originationContext=documentTab&amp;transitionType=TableOfAuthorities&amp;contextData=(sc.CustomDigest)&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;rulebookMode=false">
			
			<span>
				Table of Authorities 
			</span>
		</a>
		<div class="co_clear"></div> 
	</h2>
</li>




<li id="co_powByKCContainer">
	<a id="co_powByKC" href="javascript:void(0)">
		Powered by KeyCite
	</a>
</li>

			</ul>
		</div>
		<div class="co_clear"></div>
		<div id="co_docToolbarContainer" class="">
			<div id="co_docToolbar"><div><ul id="co_docToolbarMenuLeft"><li id="co_docToolbarBackToResults"><div id="co_documentFooterBreadcrumb"><a class="co_tbButton" href="/Search/Results.html?jurisdiction=CTAF&amp;contentType=CUSTOMDIGEST&amp;querySubmissionGuid=i0ad6ad3e0000016314b8705c8686bce0&amp;tocGuid=I4aee2539c6f64c1812a4c2f3395c2607&amp;categoryPageUrl=Home%2FWestKeyNumberSystem&amp;searchId=i0ad6ad3a0000016314b861eab2033b51&amp;collectionSet=w_cs_cd_toc&amp;transitionType=ReturnToList&amp;contextData=%28sc.CustomDigest%29#Iefd1c172e7ba11e1b11ea85d0b248d27"><span class="icon25 icon_back_arrow btnOffset"></span>Return to list</a></div></li><li id="co_docToolbarDocumentNavigation"><div id="co_documentFooterResultsNavigation" class="co_prevNextNavigation"><button title="Previous Document" id="co_documentFooterResultsNavigationPrevious" class="co_prev co_tbButton">
	                <span class="icon25 icon_prev_arrow">Previous Document</span>
                </button>
                <span class="co_navigationText"><strong>337</strong> of <strong>718 results</strong></span>
                <button title="Next Document" id="co_documentFooterResultsNavigationNext" class="co_next co_tbButton">
                    <span class="icon25 icon_next_arrow">Next Document</span>
                </button></div></li></ul><ul id="co_docToolbarMenuRight"><li id="co_docToolbarMenuRightChildWidget0" class="co_hideState"></li><li id="co_docHeaderSearchGrading"></li><li id="co_docToolbarGoTo"><div class="co_dropdownTabCollapsed"><div class="co_dropdownTab"><a href="javascript:void(0);" class="co_dropdownBoxanchorLabel" role="button">Go to</a><a href="javascript:void(0);" role="button" class="co_dropdownArrowCollapsed">Open Skip to Menu</a></div></div><div id="co_docGoToWidget" class="co_dropdownBoxCollapsed"><div class="co_dropdownBoxContent" id="co_skipTo"><div class="co_dropdownBoxContentRight"><div><div><a href="#co_synopsis">Synopsis</a></div><div><a href="#co_headnoteHeader">West Headnotes</a></div><div><a href="#co_attorneysAndLawFirms">Attorneys and Law Firms</a></div><div><a href="#co_opinion">Opinion</a></div><div><a href="#co_concurrance_opinion">Concurring Opinion</a></div><div><a href="#co_cipdip_opinion">Concurring In Part / Dissenting In Part</a></div><div><a href="#co_allCitations">All Citations</a></div></div></div></div><div id="co_starPage" class="co_dropdownBoxContent"><div class="co_dropdownBoxContentRight"><label for="co_document_starPage_starPageNavInput">Page #</label><input id="co_document_starPage_starPageNavInput" maxlength="6" size="6" type="text"><span id="co_document_starPage_starPageNavGo" class="co_primaryBtn">Go</span><div id="co_document_starPage_starPageNavError"></div><div class="co_clear"></div></div></div></div></li><li id="co_docToolbarTocNavigation"></li><li id="co_docToolbarTocFlyout"></li><li id="co_docToolbarMenuRightChildWidget5"></li><li id="co_docToolbarMenuRightChildWidget6"></li><li id="co_docToolbarMenuRightChildWidget7" class="co_toolbarSeparator"></li><li id="co_docToolbarSearchWithinDocument"><div id="co_docSearchWithinContainer"><a role="button" href="javascript:void(0);" class="co_dropdownTitle" title="Search text in this document">Search Within this Document</a>
<div id="co_docSearchWithinDropdownContainer">
	<div id="co_docSearchWithinDropdownContainerInner">
		<div id="co_docSearchWithinDropdownContainerInnerContent" class="co_dropdownBoxCollapsed">
			<!-- toggle between co_dropDownBoxCollapsed and co_dropdownBoxExpanded to show/hide -->
			<div class="co_dropdownBoxHeader">
				<span></span>
			</div>
			<div class="co_dropdownBoxContent">
				<div class="co_dropdownBoxContentRight">
					<div id="co_docSearchWithin_input">
						
<div id="co_docSearchWithin_searchInputContainer_withRecentSearch">
	<a id="co_searchLast10Link" class="co_recentSearchesLink" href="javascript:void(0);" title="Recent Searches">
		Last 10 Searches
	</a>
	<div class="co_textarea">
		<textarea id="co_docSearchWithin_searchInput_withRecentSearch" rows="1" autocorrect="off" autocapitalize="off" role="textbox" aria-label="Enter term to search for in current document"></textarea>
	</div>
	<div id="co_documentRecentQueryListBox" class="co_hideState"><ul class="co_searchSuggestionContainer" id="co_documentSearchLast10List"></ul></div>
</div>

						<input id="co_docSearchWithin_searchButton" class="co_secondaryBtn" value="Search" role="button" aria-label="Search Within this Document" type="button">
					</div>
					<div class="co_prevNextNavigation co_hideState">
						<button title="Previous Term" class="co_prev co_tbButton">
							<span class="icon25 icon_prev_arrow">Previous Term</span>
						</button>
						<button title="Next Term" class="co_next co_tbButton">
							<span class="icon25 icon_next_arrow">Next Term</span>
						</button>
						<span class="co_navigationText co_hideState"></span>
					</div>
					<button id="co_docSearchWithin_help" class="co_helpLink">Terms &amp;amp; Connectors</button>
					<button id="co_docSearchWithinCloseButton" class="co_widget_closeIcon">Close</button>
					<div id="co_docSearchWithinMessage"></div>
					<div class="co_clear"></div>
				</div>
				<div id="searchWithinTncContainer" class="co_hideState"><div id="co_search_advancedSearch_tncLegendBox">  <h2 id="co_search_advancedSearch_tncHelpTitle">Connectors and Expanders</h2>  <a id="co_search_advancedSearch_tncHelpLink" href="#" class="co_hideState">Help</a>  <dl id="co_search_advancedSearch_tncLegendList">    <dt>&amp;</dt><dd>AND</dd>    <dt>/s</dt><dd>In same sentence</dd>    <dt>or</dt><dd>OR</dd>    <dt>+s</dt><dd>Preceding within sentence</dd>    <dt>/p</dt><dd>In same paragraph</dd>    <dt>""</dt><dd>Phrase</dd>    <dt>+p</dt><dd>Preceding within paragraph</dd>    <dt>%</dt><dd>But not</dd>    <dt>/n</dt><dd>Within n terms of</dd>    <dt>!</dt><dd>Root expander</dd>    <dt>+n</dt><dd>Preceding within n terms of</dd>    <dt>*</dt><dd>Universal character</dd>    <dt>#</dt><dd>Prefix to turn off plurals and equivalents</dd>  </dl></div></div>
			</div>
			<div class="co_dropdownBoxFooter">
				<span></span>
			</div>
		</div>
	</div>
</div></div></li><li id="co_docToolbarDisplayOptions"><a role="button" id="co_displayOptionsLink" class="co_tbButton" href="javascript:void(0);" title="Display Options"><span class="icon25 icon_text_resize">Display Options</span></a></li><li id="co_docToolbarDeliveryWidget"><div id="deliveryWidget1" class="co_dropDownMenu collapsed"><div class="co_dropDownButton"><a role="button" id="deliveryLink1" title="Email" class="co_tbButton" href="javascript:void(0);"><span class="icon25 icon_email">Email</span></a><a href="javascript:void(0);" class="co_tbButton co_dropDownAnchor" role="button" id="deliveryDropButton1" aria-label="Delivery menu" title="Delivery menu" aria-describedby="navigation1"><span class="icon25 icon_down_blue_arrow"></span></a><span id="navigation1" class="co_accessibilityLabel">Enter to open, tab to navigate, enter to select</span></div><div id="deliveryWidgetMenu1" class="co_dropDownMenuContent" role="document"><ul class="co_dropDownMenuList checkmarks icons" role="listbox" aria-multiselectable="true" aria-hidden="false" aria-expanded="true"><li id="deliveryRow1Email" name="Email" role="presentation" class="checked"><a title="Email" id="deliveryLinkRow1Email" role="option" aria-posinset="1" aria-setsize="3" class="co_deliveryLinkOptions" tabindex="0" aria-selected="true"><span class="icon25 icon_email"></span>Email</a></li><li id="deliveryRow1Print" name="Print" role="presentation"><a title="Print" id="deliveryLinkRow1Print" role="option" aria-posinset="2" aria-setsize="3" class="co_deliveryLinkOptions" tabindex="0" aria-selected="false"><span class="icon25 icon_print"></span>Print</a></li><li id="deliveryRow1Download" name="Download" role="presentation"><a title="Download" id="deliveryLinkRow1Download" role="option" aria-posinset="3" aria-setsize="3" class="co_deliveryLinkOptions" tabindex="0" aria-selected="false"><span class="icon25 icon_download"></span>Download</a></li></ul><div class="co_deliveryWidgetMenuFooter"></div></div><div id="co_deliveryWidget_Message1"></div></div></li><li id="co_docToolbarReadingModeWidget"><a role="button" id="co_fullscreenModeLink" class="co_tbButton" href="javascript:void(0);" title="Fullscreen Mode"><span class="icon25 icon_fullscreen">Fullscreen Mode</span></a></li></ul></div></div> 
			<div class="co_clear"></div>
		</div>
	</div>
</div>

				<div id="coid_website_errorsSummaryPlaceHolder"><div class="co_infoBox failure" style="display: none;"><div class="co_infoBox_container"><div class="co_infoBox_outer"><div class="co_infoBox_inner"><a id="co_website_errorSumarryCloseLink" class="co_infoBox_closeButton">Close</a><div class="co_infoBox_message" tabindex="-1">Sorry, there was an error on this page.<a href="javascript:void(0);" id="co_website_errorSummaryToggleLink">More info</a><a href="javascript:void(0);" id="co_website_errorSummaryToggleLinkLessInfo" style="display: none; margin-left: 6px;">Less info</a><ul class="co_website_errorsSummaryList" style="display: none;"></ul></div></div></div></div></div></div>
				<div id="coid_website_messagePlaceholder"></div>







				<div id="test_hplink"></div>
				<div class="co_scrollWrapper">





							<div id="coid_website_documentWidgetDiv" class=" co_khSpeedReadExpandAll">
<div id="co_chunkNavOne"><div class="co_chunkPagination" id="co_topChunkNav"><ul class="co_navFooter_pagination" id="co_topDocumentChunkNavFooter_pagination"><li><strong>Part:</strong></li><li><a id="co_topPreviousChunkButton" class="co_prev co_tbButton co_disabled" href=""><span class="icon25 icon_prev_arrow">Previous Part</span></a></li><li><label><span class="co_accessibilityLabel">Go To Document Part</span><input id="co_topCurrentChunkStatus" size="1" maxlength="4" type="text"></label> of <strong id="co_topChunkCountStatus">2</strong></li><li><a id="co_topNextChunkButton" class="co_next co_tbButton" href=""><span class="icon25 icon_next_arrow">Next Part</span></a></li></ul><div class="co_clear"></div><div></div></div></div><div id="co_briefItDiv" class="co_excludeAnnotations"><button id="co_briefItButton" class="co_primaryBtn co_floatRight">Brief It</button><div class="undefined"></div></div><div id="co_document" class="co_addFocusCorrection"><div id="co_document_0" class="co_document co_caselawNRS"><div id="co_readingModeKC" class="co_keyCiteFlagWidgetContainer co_excludeAnnotations"><div id="co_readingModeCitatorFlag"><span class="co_citatorFlag"><a href="https://1.next.westlaw.com/Link/RelatedInformation/Flag?documentGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;transitionType=Document&amp;originationContext=docHeaderSntTitleFlag&amp;contextData=(sc.CustomDigest)"><img class="crsw_DocumentIndicator" alt="KeyCite Red Flag - Severe Negative Treatment" src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/v1/flag_red.png" title="KeyCite Red Flag - Severe Negative Treatment"></a><span class="co_citatorFlagText">KeyCite Red Flag - Severe Negative Treatment</span></span></div><div id="co_readingModeNegativeTreatment"><span id="NegativeTreatmentWidget_Iefd1c172e7ba11e1b11ea85d0b248d27"><span class="co_snt_treatmentPhrase">Affirmed in Part, Reversed in Part by </span><a href="https://1.next.westlaw.com/Document/Id30a4943d41311e2a98ec867961a22de/View/FullText.html?listSource=RelatedInfo&amp;list=NegativeCitingReferences&amp;rank=0&amp;originationContext=docHeader&amp;transitionType=NegativeTreatment&amp;contextData=%28sc.CustomDigest%29">Association for Molecular Pathology v. Myriad Genetics, Inc.</a><span>, </span><span class="co_snt_courtLine">U.S., </span><span class="co_snt_dateFiled">June 13, 2013</span></span></div></div><input id="co_keyCiteFlagPlaceHolder" type="hidden"><input id="co_document_starPageMetadata" value="{ &quot;citations&quot;: { &quot;S09042298fbd411e1b11ea85d0b248d27&quot;:&quot;689 F.3d 1303&quot; }, &quot;pubs&quot;: { &quot;S09042298fbd411e1b11ea85d0b248d27&quot;:&quot;506&quot; } }" alt="metadata" type="hidden"><div><a href="https://1.next.westlaw.com/Link/Document/Blob/I24CA6A081DD211B29BE0DB00C20F256E/689_F.3d_1303.pdf?targetType=NRS&amp;originationContext=pagepdflink&amp;transitionType=DocumentImage&amp;uniqueId=c13b230c-4a15-4e95-8890-907127378664&amp;contextData=(sc.CustomDigest)" class="co_blobLink" type="application/pdf"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/v1/co_pdf-icon.gif" class="co_pdfIcon" alt="PDF">​Original Image of 689 F.3d 1303 (PDF)</a></div><div class="co_cites">689 F.3d 1303</div><input id="co_document_paraNumbersSourceCiteMetadata" value="{ &quot;paraNumbersSourceCite&quot;: &quot;689 F.3d 1303&quot;, &quot;publicationNumber&quot;: &quot;506&quot; }" alt="metadata" type="hidden"><div class="co_contentBlock co_briefItState co_courtBlock"><div><div class="co_hAlign2">United States Court of Appeals,</div>Federal Circuit.</div></div><div class="co_title"><div class="co_suit"><div class="co_partyLine">The ASSOCIATION FOR MOLECULAR PATHOLOGY, The American College of Medical Genetics, The American Society for Clinical Pathology, The College of American Pathologists, Haig Kazazian, MD, Arupa Ganguly, PhD, Wendy Chung, MD, PhD, <a id="co_link_Iaa783ce8afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5053263005)&amp;saveJuris=False&amp;contentType=BUSINESS-INVESTIGATOR&amp;startIndex=1&amp;contextData=(sc.Default)&amp;categoryPageUrl=Home%2fCompanyInvestigator&amp;originationContext=document&amp;transitionType=DocumentItem">Harry Ostrer</a>, MD, <a id="co_link_Iaa783ce9afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5047548885)&amp;saveJuris=False&amp;contentType=BUSINESS-INVESTIGATOR&amp;startIndex=1&amp;contextData=(sc.Default)&amp;categoryPageUrl=Home%2fCompanyInvestigator&amp;originationContext=document&amp;transitionType=DocumentItem">David Ledbetter</a>, PhD, Stephen Warren, PhD, Ellen Matloff, M.S., Elsa Reich, M.S., Breast Cancer Action, <a id="co_link_Iaa783ceeafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5001597936)&amp;saveJuris=False&amp;contentType=BUSINESS-INVESTIGATOR&amp;startIndex=1&amp;contextData=(sc.Default)&amp;categoryPageUrl=Home%2fCompanyInvestigator&amp;originationContext=document&amp;transitionType=DocumentItem">Boston Women's Health Book Collective</a>, Lisbeth Ceriani, Runi Limary, Genae Girard, Patrice Fortune, Vicky Thomason, and Kathleen Raker, Plaintiffs–Appellees,</div><div>v.</div><div class="co_partyLine"><a id="co_link_Iaa783cf4afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5037341393)&amp;saveJuris=False&amp;contentType=BUSINESS-INVESTIGATOR&amp;startIndex=1&amp;contextData=(sc.Default)&amp;categoryPageUrl=Home%2fCompanyInvestigator&amp;originationContext=document&amp;transitionType=DocumentItem">UNITED STATES PATENT AND TRADEMARK OFFICE</a>, Defendant,</div><div>and</div><div class="co_partyLine">Myriad Genetics, Inc., Defendant–Appellant,</div><div>and</div><div class="co_partyLine">Lorris Betz, Roger Boyer, Jack Brittain, Arnold B. Combe, Raymond Gesteland, James U. Jensen, John Kendall Morris, Thomas Parks, David W. Pershing, and Michael K. Young, in their Official Capacity as Directors of the University of Utah Research Foundation, Defendants–Appellants.</div></div></div><div class="co_docketDate"><div class="co_contentBlock co_briefItState co_docketBlock"><span>No. 2010–1406.</span></div><div class="co_date"><span>Aug. 16, 2012.</span></div></div><div class="co_contentBlock co_briefItState co_synopsis"><h2 id="co_synopsis" class="co_printHeading">Synopsis</h2><div><div class="co_paragraph"><div class="co_paragraphText"><strong>Background:</strong> Medical organizations, researchers, genetic counselors, and patients brought action against patentee and Patent and Trademark Office (PTO), challenging validity of patents for isolated deoxyribonucleic acid (DNA) sequences associated with predisposition to breast and ovarian cancers and for diagnostic methods of identifying mutations in those DNA sequences. Plaintiffs and patentee cross-moved for summary judgment, and <a id="co_link_Iaa783cfaafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2021662409&amp;pubNum=0004637&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">PTO moved for judgment on the pleadings. The United States District Court for the Southern District of New York, Robert W. Sweet, Senior District Judge, 702 F.Supp.2d 181</a>, granted PTO's motion, granted plaintiffs' motion in part, and denied patentee's motion. Patentee appealed. The Court of Appeals, <a id="co_link_Iaa783cfbafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2025793527&amp;pubNum=506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">653 F.3d 1329,</a>affirmed in part and reversed in part.<a id="co_link_Iaa783cfcafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2026688034&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Parties petitioned for certiorari, and the United States Supreme Court, ––– U.S. ––––, 132 S.Ct. 1794, 182 L.Ed.2d 613</a>, granted petition and vacated and remanded.</div></div></div><div class="co_contentBlock co_briefItState co_synopsisHolding"><div class="co_paragraph"><div class="co_paragraphText"><strong>Holdings:</strong> The Court of Appeals, <a id="co_link_Iaa783cfdafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0225327201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Lourie</a>, Circuit Judge, held that:</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F42028417793" class="co_internalLink co_excludeAnnotations co_disableHighlightFeatures">1</a> only competitor with unequivocal intent to resume clinical diagnostic testing of DNA sequences had standing;</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F112028417793" class="co_internalLink co_excludeAnnotations co_disableHighlightFeatures">2</a> various organizational plaintiffs lacked standing;</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F122028417793" class="co_internalLink co_excludeAnnotations co_disableHighlightFeatures">3</a> composition claims covering isolated DNA sequences associated with predisposition to breast and ovarian cancers were directed to patent-eligible subject matter;</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F152028417793" class="co_internalLink co_excludeAnnotations co_disableHighlightFeatures">4</a> claimed complementary deoxyribonucleic acids (cDNAs), which lacked non-coding introns in naturally occurring chromosomal DNA, were eligible for patent;</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F192028417793" class="co_internalLink co_excludeAnnotations co_disableHighlightFeatures">5</a> method claims for comparing or analyzing isolated DNA sequences associated with predisposition to breast and ovarian cancers were not patentable; and</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F212028417793" class="co_internalLink co_excludeAnnotations co_disableHighlightFeatures">6</a> method claim for screening potential cancer therapeutics via changes in cell growth rates claimed patentable subject matter.</div></div></div><div class="co_paragraph"><div class="co_paragraphText">Affirmed in part, reversed in part, and remanded.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a id="co_link_Iaa783cfeafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0368246101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Moore</a>, Circuit Judge, filed opinion concurring in part.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a id="co_link_Iaa783cffafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0112582701&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Bryson</a>, Circuit Judge, filed opinion concurring in part and dissenting in part.</div></div></div><div id="co_headnotes" class="co_headnotes co_fancyHeadnotes"><h2 id="co_headnoteHeader" class="co_headnoteHeader co_printHeading"><span class="co_headnoteHeaderSpan">West Headnotes (23)</span><a id="co_headnoteExpandCollapseLink" class="co_accLink co_excludeAnnotations co_disableHighlightFeatures" href="javascript:void(0);" role="button">Collapse West Headnotes</a></h2><div class="co_headnotesContentContainer"><div id="co_expandedHeadnotes"><div id="co_headnoteTools"><a id="co_headnotesShowOrHideFancy" href="javascript:void(0);" class="co_fancyHeadnotesShowHide co_excludeAnnotations co_disableHighlightFeatures">Change View</a></div><div class="co_headnoteRow" id="co_anchor_2028417793001"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F12028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_1"><a href="#co_anchor_B12028417793" class="co_internalLink">1</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E4PAC" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Federal Civil Procedure</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EXBAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Ak103.2/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">In general;  injury or interest</a></span></div><div class="co_secondaryHeadnoteNodes"> <span class="co_hiddenKeyText"><strong><a id="co_link_ID0EJCAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Federal Civil Procedure</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ECEAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Ak103.3/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Causation;  redressability</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">The irreducible constitutional minimum of standing requires a plaintiff to have suffered an injury in fact, which is an invasion of a legally protected interest which is concrete and particularized, and actual or imminent, not conjectural or hypothetical, there must be a causal connection between the injury and the conduct complained of, i.e., the injury has to be fairly traceable to the challenged action of the defendant, and it must be likely, as opposed to merely speculative, that the injury will be redressed by a favorable decision. <input id="co_docMarker_0" type="hidden"><a id="co_link_Iaa783d0aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000583&amp;cite=USCOARTIIIS1&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S.C.A. Const. Art. 3, § 1</a> et seq.</div></div><div id="co_headnoteId_202841779300120171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EUEAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779300120171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 1"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">1 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d00afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170A</a></span><span class="co_headnoteTopicKey">Federal Civil Procedure</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d01afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170AII/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170AII</a></span><span class="co_headnoteTopicKey">Parties</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d02afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170AII(A)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170AII(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d03afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Ak103.1/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Ak103.1</a></span><span class="co_headnoteTopicKey">Standing in General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d04afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Ak103.2/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Ak103.2</a></span><span class="co_headnoteTopicKey">In general;  injury or interest</span></div></div></div></div></div><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d05afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170A</a></span><span class="co_headnoteTopicKey">Federal Civil Procedure</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d06afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170AII/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170AII</a></span><span class="co_headnoteTopicKey">Parties</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d07afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170AII(A)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170AII(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d08afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Ak103.1/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Ak103.1</a></span><span class="co_headnoteTopicKey">Standing in General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d09afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/170Ak103.3/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">170Ak103.3</a></span><span class="co_headnoteTopicKey">Causation;  redressability</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793002"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F22028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_2"><a href="#co_anchor_B22028417793" class="co_internalLink">2</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EPFAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/106/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Courts</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ETHAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/106k96(7)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Particular questions or subject matter</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Whether an actual case or controversy exists so that a district court may entertain an action for a declaratory judgment of patent non-infringement or invalidity is governed by Federal Circuit law. <a id="co_link_Iaa783d11afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS2201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_8b3b0000958a4">28 U.S.C.A. § 2201(a)</a>.</div></div><div id="co_headnoteId_202841779300220171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0ECIAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779300220171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 2"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">6 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d0bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/106/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">106</a></span><span class="co_headnoteTopicKey">Courts</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d0cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/106II/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">106II</a></span><span class="co_headnoteTopicKey">Establishment, Organization, and Procedure</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d0dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/106II(G)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">106II(G)</a></span><span class="co_headnoteTopicKey">Rules of Decision</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d0eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/106k88/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">106k88</a></span><span class="co_headnoteTopicKey">Previous Decisions as Controlling or as Precedents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d0fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/106k96/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">106k96</a></span><span class="co_headnoteTopicKey">Decisions of United States Courts as Authority in Other United States Courts</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d10afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/106k96(7)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">106k96(7)</a></span><span class="co_headnoteTopicKey">Particular questions or subject matter</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793003"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F32028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_3"><a href="#co_anchor_B32028417793" class="co_internalLink">3</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E5IAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Declaratory Judgment</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EUKAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak393/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Scope and extent of review in general</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">In a patent case, the exercise of declaratory judgment jurisdiction in light of a particular set of facts is reviewed de novo.</div></div><div id="co_headnoteId_202841779300320171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EDLAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779300320171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 3"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">0 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d12afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118A</a></span><span class="co_headnoteTopicKey">Declaratory Judgment</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d13afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118AIII/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118AIII</a></span><span class="co_headnoteTopicKey">Proceedings</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d14afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118AIII(H)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118AIII(H)</a></span><span class="co_headnoteTopicKey">Appeal and Error</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d15afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak392/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118Ak392</a></span><span class="co_headnoteTopicKey">Appeal and Error</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d16afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak393/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118Ak393</a></span><span class="co_headnoteTopicKey">Scope and extent of review in general</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793004"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F42028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_4"><a href="#co_anchor_B42028417793" class="co_internalLink">4</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EVLAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Declaratory Judgment</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ELNAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak300/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Subjects of relief in general</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Only competitor with unequivocal intent to resume clinical diagnostic testing of deoxyribonucleic acid (DNA) sequences had standing to bring action for declaratory judgment that patents for DNA sequences and methods of testing sequences for cancer were invalid; competitor's injury was traceable to patentee's enforcement actions that forced him to stop DNA testing, and favorable judgment on challenged claims would remove absolute barrier to competitor's ability to resume testing, but injury to other competitors who alleged only they would consider resuming testing was insufficiently immediate to support their standing. <a id="co_link_Iaa783d1cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS2201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_8b3b0000958a4">28 U.S.C.A. § 2201(a)</a>.</div></div><div id="co_headnoteId_202841779300420171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E1NAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779300420171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 4"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">0 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d17afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118A</a></span><span class="co_headnoteTopicKey">Declaratory Judgment</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d18afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118AIII/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118AIII</a></span><span class="co_headnoteTopicKey">Proceedings</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d19afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118AIII(C)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118AIII(C)</a></span><span class="co_headnoteTopicKey">Parties</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d1aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak299/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118Ak299</a></span><span class="co_headnoteTopicKey">Proper Parties</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d1bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak300/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118Ak300</a></span><span class="co_headnoteTopicKey">Subjects of relief in general</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793005"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F52028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_5"><a href="#co_anchor_B52028417793" class="co_internalLink">5</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EWOAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Declaratory Judgment</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EMQAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak300/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Subjects of relief in general</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Inability to afford a patented invention could not establish invasion of a legally protected interest for purposes of standing in action seeking declaratory judgment that patent was invalid. <a id="co_link_Iaa783d22afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000583&amp;cite=USCOARTIIIS1&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S.C.A. Const. Art. 3, § 1</a> et seq.</div></div><div id="co_headnoteId_202841779300520171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E2QAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779300520171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 5"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">0 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d1dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118A</a></span><span class="co_headnoteTopicKey">Declaratory Judgment</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d1eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118AIII/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118AIII</a></span><span class="co_headnoteTopicKey">Proceedings</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d1fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118AIII(C)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118AIII(C)</a></span><span class="co_headnoteTopicKey">Parties</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d20afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak299/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118Ak299</a></span><span class="co_headnoteTopicKey">Proper Parties</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d21afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak300/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118Ak300</a></span><span class="co_headnoteTopicKey">Subjects of relief in general</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793006"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F62028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_6"><a href="#co_anchor_B62028417793" class="co_internalLink">6</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EWRAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EWTAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1736/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Laches</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Laches bars the recovery of pre-filing damages; it does not preclude a patent action for prospective relief.</div></div><div id="co_headnoteId_202841779300620171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EZUAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779300620171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 6"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">0 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d23afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d24afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII</a></span><span class="co_headnoteTopicKey">Patent Infringement</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d25afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)</a></span><span class="co_headnoteTopicKey">Actions</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d26afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VII(C)1/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VII(C)1</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d27afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1733/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1733</a></span><span class="co_headnoteTopicKey">Time to Sue</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d28afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1736/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1736</a></span><span class="co_headnoteTopicKey">Laches</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d29afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1736(1)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1736(1)</a></span><span class="co_headnoteTopicKey">In general</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k289(2.1))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793007"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F72028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_7"><a href="#co_anchor_B72028417793" class="co_internalLink">7</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0ELVAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Declaratory Judgment</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ETWAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak255/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Limitations and laches</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Just as active enforcement of patent rights against others can maintain a real and immediate controversy despite the passage of time, so too can the successful assertion of such rights when the relevant circumstances remain unchanged. <a id="co_link_Iaa783d2eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000583&amp;cite=USCOARTIIIS1&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S.C.A. Const. Art. 3, § 1</a> et seq.</div></div><div id="co_headnoteId_202841779300720171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0ECXAE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779300720171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 7"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">1 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d2aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118A</a></span><span class="co_headnoteTopicKey">Declaratory Judgment</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d2bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118AIII/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118AIII</a></span><span class="co_headnoteTopicKey">Proceedings</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d2cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118AIII(A)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118AIII(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d2dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak255/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118Ak255</a></span><span class="co_headnoteTopicKey">Limitations and laches</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793008"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F82028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_8"><a href="#co_anchor_B82028417793" class="co_internalLink">8</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E4XAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Declaratory Judgment</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EFZAE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak231/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">A competitor need not risk liability and treble damages for patent infringement before seeking a declaration of his contested legal rights. <a id="co_link_Iaa783d34afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS2201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_8b3b0000958a4">28 U.S.C.A. § 2201(a)</a>.</div></div><div id="co_headnoteId_202841779300820171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EF1AE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779300820171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 8"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">3 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d2fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118A</a></span><span class="co_headnoteTopicKey">Declaratory Judgment</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d30afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118AII/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118AII</a></span><span class="co_headnoteTopicKey">Subjects of Declaratory Relief<input id="co_docMarker_1" type="hidden"></span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d31afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118AII(L)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118AII(L)</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d32afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak231/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118Ak231</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d33afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak231.1/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118Ak231.1</a></span><span class="co_headnoteTopicKey">In general</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793009"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F92028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_9"><a href="#co_anchor_B92028417793" class="co_internalLink">9</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EB2AE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Declaratory Judgment</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EX3AE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak232/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Validity of patents</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Competitors' challenge to only portion of composition and method claims of patents for isolated deoxyribonucleic acid (DNA) sequences associated with predisposition to breast and ovarian cancers and for diagnostic methods of identifying mutations in those DNA sequences was not speculative, despite admitting that other unchallenged claims would still prevent them from engaging in sequencing, since court declined to construe asserted claims and declined to hold on current record that proposed activities would infringe unchallenged claims and alleged injury could be redressed by favorable decision. <a id="co_link_Iaa783d3aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS2201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_8b3b0000958a4">28 U.S.C.A. § 2201(a)</a>.</div></div><div id="co_headnoteId_202841779300920171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EG4AE" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779300920171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 9"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">1 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d35afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118A</a></span><span class="co_headnoteTopicKey">Declaratory Judgment</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d36afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118AII/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118AII</a></span><span class="co_headnoteTopicKey">Subjects of Declaratory Relief</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d37afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118AII(L)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118AII(L)</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d38afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak231/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118Ak231</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d39afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak232/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118Ak232</a></span><span class="co_headnoteTopicKey">Validity of patents</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793010"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F102028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_10"><a href="#co_anchor_B102028417793" class="co_internalLink">10</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EC5AE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Declaratory Judgment</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EK6AE" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak231/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Simply disagreeing with the existence of a patent on isolated deoxyribonucleic acid (DNA) sequences or even suffering an attenuated, non-proximate, effect from the existence of a patent does not meet the requirement for an adverse legal controversy of sufficient immediacy and reality to warrant the issuance of a declaratory judgment. <a id="co_link_Iaa783d40afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS2201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_8b3b0000958a4">28 U.S.C.A. § 2201(a)</a>.</div></div><div id="co_headnoteId_202841779301020171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0ELAAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779301020171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 10"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">7 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d3bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118A</a></span><span class="co_headnoteTopicKey">Declaratory Judgment</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d3cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118AII/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118AII</a></span><span class="co_headnoteTopicKey">Subjects of Declaratory Relief</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d3dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118AII(L)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118AII(L)</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d3eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak231/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118Ak231</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d3fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak231.1/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118Ak231.1</a></span><span class="co_headnoteTopicKey">In general</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793011"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F112028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_11"><a href="#co_anchor_B112028417793" class="co_internalLink">11</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EHBAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/41/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Associations</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E2BAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/41k20/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Actions by or Against Associations</a></span></div><div class="co_secondaryHeadnoteNodes"> <span class="co_headnoteNode"><strong><a id="co_link_ID0EYCAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Declaratory Judgment</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EOEAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak300/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Subjects of relief in general</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Various organizational plaintiffs that were not target of any enforcement action or offered license agreements by patentee and had not made preparation to undertake potentially infringing activities did not suffer any injury and thus lacked standing to bring declaratory judgment action against patentee and Patent and Trademark Office (PTO) to challenge validity of patents for isolated deoxyribonucleic acid (DNA) sequences associated with predisposition to breast and ovarian cancers and for diagnostic methods of identifying mutations in those DNA sequences. <a id="co_link_Iaa783d49afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS2201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_8b3b0000958a4">28 U.S.C.A. § 2201(a)</a>.</div></div><div id="co_headnoteId_202841779301120171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E4EAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779301120171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 11"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">9 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d41afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/41/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">41</a></span><span class="co_headnoteTopicKey">Associations</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d42afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/41k20/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">41k20</a></span><span class="co_headnoteTopicKey">Actions by or Against Associations</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d43afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/41k20(1)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">41k20(1)</a></span><span class="co_headnoteTopicKey">In general</span></div></div></div></div></div><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d44afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118A/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118A</a></span><span class="co_headnoteTopicKey">Declaratory Judgment</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d45afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118AIII/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118AIII</a></span><span class="co_headnoteTopicKey">Proceedings</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d46afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118AIII(C)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118AIII(C)</a></span><span class="co_headnoteTopicKey">Parties</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d47afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak299/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118Ak299</a></span><span class="co_headnoteTopicKey">Proper Parties</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d48afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/118Ak300/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">118Ak300</a></span><span class="co_headnoteTopicKey">Subjects of relief in general</span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793012"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F122028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_12"><a href="#co_anchor_B122028417793" class="co_internalLink">12</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EZFAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EPHAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k468/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Genes and genetic technology</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Composition claims covering isolated deoxyribonucleic acid (DNA) sequences associated with predisposition to breast and ovarian cancers were directed to patent-eligible subject matter; isolated DNA was not only removed from its native cellular and chromosomal environment, but was also chemically manipulated to produce a molecule that was markedly different from that existing in the body. (Per Lourie, Circuit Judge, with one Circuit Judge concurring in part and concurring in the judgment.) <a id="co_link_Iaa783d4fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 101</a>.</div></div><div id="co_headnoteId_202841779301220171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EEIAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779301220171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 12"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">5 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d4aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d4bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d4cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(B)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(B)</a></span><span class="co_headnoteTopicKey">Eligible Subject Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d4dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k466/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k466</a></span><span class="co_headnoteTopicKey">Biological Subject Matter;  Biotechnology</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d4eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k468/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k468</a></span><span class="co_headnoteTopicKey">Genes and genetic technology</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k14)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793013"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F132028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_13"><a href="#co_anchor_B132028417793" class="co_internalLink">13</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E6IAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EVKAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k452/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Laws of nature, natural phenomena, and abstract ideas;  fundamental principles</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Laws of nature, natural phenomena, and abstract ideas are not patentable. <a id="co_link_Iaa783d55afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 101</a>.</div></div><div id="co_headnoteId_202841779301320171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EMLAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779301320171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 13"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">3 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d50afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d51afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d52afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(B)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(B)</a></span><span class="co_headnoteTopicKey">Eligible Subject Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d53afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k450/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k450</a></span><span class="co_headnoteTopicKey">Exceptions to Eligibility;  Ineligible Subject Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d54afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k452/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k452</a></span><span class="co_headnoteTopicKey">Laws of nature, natural phenomena, and abstract ideas;  fundamental principles</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k6, 291k5)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793014"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F142028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_14"><a href="#co_anchor_B142028417793" class="co_internalLink">14</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EHMAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EPNAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1439/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Scope of Exclusive Rights as to Making, Use, or Sale of Invention<input id="co_docMarker_2" type="hidden"></a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">The basic right provided by a patent is to exclude others from practicing the patented subject matter.</div></div><div id="co_headnoteId_202841779301420171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0ESOAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779301420171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 14"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">0 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d56afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d57afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VI/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VI</a></span><span class="co_headnoteTopicKey">Patent Rights and Duties</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d58afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291VI(A)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291VI(A)</a></span><span class="co_headnoteTopicKey">In General</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d59afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1439/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1439</a></span><span class="co_headnoteTopicKey">Scope of Exclusive Rights as to Making, Use, or Sale of Invention</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d5aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1440/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1440</a></span><span class="co_headnoteTopicKey">In general</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k191)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793015"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F152028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_15"><a href="#co_anchor_B152028417793" class="co_internalLink">15</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EEPAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E1QAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k468/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Genes and genetic technology</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Claimed complementary deoxyribonucleic acids (cDNAs), which lacked non-coding introns in naturally occurring chromosomal DNA, were eligible for patent as compositions of matter distinct from natural DNA, since they were result of human intervention into nature. <a id="co_link_Iaa783d60afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 101</a>.</div></div><div id="co_headnoteId_202841779301520171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EPRAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779301520171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 15"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">5 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d5bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d5cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d5dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(B)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(B)</a></span><span class="co_headnoteTopicKey">Eligible Subject Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d5eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k466/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k466</a></span><span class="co_headnoteTopicKey">Biological Subject Matter;  Biotechnology</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d5fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k468/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k468</a></span><span class="co_headnoteTopicKey">Genes and genetic technology</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k14)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793016"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F162028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_16"><a href="#co_anchor_B162028417793" class="co_internalLink">16</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EKSAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EAUAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k468/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Genes and genetic technology</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">The distinctive nature of deoxyribonucleic acid (DNA) molecules as isolated compositions of matter determines their patent eligibility rather than their physiological use or benefit; uses of chemical substances may be relevant to the nonobviousness of these substances or to method claims embodying those uses, but the patent eligibility of an isolated DNA is not negated because it has similar informational properties to a different, more complex natural material. (Per Lourie, Circuit Judge, with Moore, Circuit Judge, concurring in the judgment.) <a id="co_link_Iaa783d66afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 101</a>.</div></div><div id="co_headnoteId_202841779301620171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EVUAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779301620171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 16"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">1 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d61afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d62afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d63afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(B)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(B)</a></span><span class="co_headnoteTopicKey">Eligible Subject Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d64afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k466/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k466</a></span><span class="co_headnoteTopicKey">Biological Subject Matter;  Biotechnology</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d65afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k468/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k468</a></span><span class="co_headnoteTopicKey">Genes and genetic technology</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k14)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793017"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F172028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_17"><a href="#co_anchor_B172028417793" class="co_internalLink">17</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EVVAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ELXAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1378/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Genes and genetic technology</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Genes are materials having a chemical nature and, as such, are best described in patents by their structures rather than by their functions, although biologists may think of molecules in terms of their uses.</div></div><div id="co_headnoteId_202841779301720171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EAYAG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779301720171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 17"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">0 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d67afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d68afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V</a></span><span class="co_headnoteTopicKey">Construction and Operation of Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d69afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291V(C)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291V(C)</a></span><span class="co_headnoteTopicKey">Particular Fields of Invention</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d6aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1376/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1376</a></span><span class="co_headnoteTopicKey">Biological Subject Matter;  Biotechnology</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d6bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k1378/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k1378</a></span><span class="co_headnoteTopicKey">Genes and genetic technology</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k179)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793018"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F182028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_18"><a href="#co_anchor_B182028417793" class="co_internalLink">18</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0ESYAG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EI1AG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k468/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Genes and genetic technology</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Isolating genes to provide useful diagnostic tools and medicines is surely what the patent laws are intended to encourage and protect.</div></div><div id="co_headnoteId_202841779301820171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E41AG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779301820171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 18"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">0 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d6cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d6dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d6eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(B)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(B)</a></span><span class="co_headnoteTopicKey">Eligible Subject Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d6fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k466/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k466</a></span><span class="co_headnoteTopicKey">Biological Subject Matter;  Biotechnology</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d70afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k468/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k468</a></span><span class="co_headnoteTopicKey">Genes and genetic technology</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k14)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793019"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F192028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_19"><a href="#co_anchor_B192028417793" class="co_internalLink">19</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EP2AG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EF4AG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k468/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Genes and genetic technology</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Method claims for comparing or analyzing isolated DNA sequences associated with predisposition to breast and ovarian cancers were directed to abstract mental process, and thus were not patentable; claims did not include step of determining DNA sequence by isolating genes from blood sample and sequencing them, or any other necessarily transformative step, but, rather, comparison between sequences could be accomplished by mere inspection alone. <a id="co_link_Iaa783d76afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 101</a>.</div></div><div id="co_headnoteId_202841779301920171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0E14AG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779301920171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 19"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">3 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d71afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d72afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d73afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(B)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(B)</a></span><span class="co_headnoteTopicKey">Eligible Subject Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d74afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k466/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k466</a></span><span class="co_headnoteTopicKey">Biological Subject Matter;  Biotechnology</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d75afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k468/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k468</a></span><span class="co_headnoteTopicKey">Genes and genetic technology</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k7.14)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793020"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F202028417793" tabindex="0"><span class="co_headnoteNumber" id="co_anchor_headNote_20"><a href="#co_anchor_B202028417793" class="co_internalLink">20</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0EV5AG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0ELABG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k452/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Laws of nature, natural phenomena, and abstract ideas;  fundamental principles</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">The application of a formula or abstract idea in a process may describe patent-eligible subject matter. <a id="co_link_Iaa783d7cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 101</a>.</div></div><div id="co_headnoteId_202841779302020171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EABBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779302020171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 20"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">4 </span>Cases that cite this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d77afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d78afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d79afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(B)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(B)</a></span><span class="co_headnoteTopicKey">Eligible Subject Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d7aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k450/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k450</a></span><span class="co_headnoteTopicKey">Exceptions to Eligibility;  Ineligible Subject Matter<input id="co_docMarker_3" type="hidden"></span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d7bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k452/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k452</a></span><span class="co_headnoteTopicKey">Laws of nature, natural phenomena, and abstract ideas;  fundamental principles</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k7.12)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793021"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_F212028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_21"><a href="#co_anchor_B212028417793" class="co_internalLink">21</a></span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E2BBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0EDDBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k463/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Health Care and Medical Products</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText">Method claim for screening potential cancer therapeutics via changes in cell growth rates claimed patentable subject matter; although claim included steps of determining cells' growth rates and comparing growth rates, claim applied certain steps to man-made, non-naturally occurring transformed cells that were product of man, not of nature, and it was tied to specific host cells transformed with specific genes and grown in presence or absence of specific type of therapeutic. <a id="co_link_Iaa783d82afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C.A. § 101</a>.</div></div><div id="co_headnoteId_202841779302120171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EGEBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779302120171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 21"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">0 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d7dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d7eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II</a></span><span class="co_headnoteTopicKey">Patentability and Validity</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d7fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291II(B)/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291II(B)</a></span><span class="co_headnoteTopicKey">Eligible Subject Matter</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d80afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k463/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k463</a></span><span class="co_headnoteTopicKey">Health Care and Medical Products</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d81afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k464/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k464</a></span><span class="co_headnoteTopicKey">In general</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k7.14)</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793501"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_2028417793"><span class="co_headnoteNumber" id="co_anchor_headNote_22">22</span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E6EBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E4FBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k2091/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">In general;  utility</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText"><a id="co_link_Iaa783d86afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1997377490&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I0e737f30746811d7a94bace56a9eba1c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">US Patent 5,693,473</a>, <a id="co_link_Iaa783d87afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">US Patent 5,747,282</a>, <a id="co_link_Iaa783d88afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998422488&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=Ia9d8eb20724e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">US Patent 5,837,492</a>. Valid.</div></div><div id="co_headnoteId_202841779350120171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0ESGBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779350120171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 22"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">0 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d83afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d84afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291X/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291X</a></span><span class="co_headnoteTopicKey">Patents Enumerated</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d85afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k2091/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k2091</a></span><span class="co_headnoteTopicKey">In general;  utility</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k328(2))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div><div class="co_headnoteRow" id="co_anchor_2028417793502"><div class="co_headnoteCell"><div class="co_headnoteCellInner"><div class="co_primaryHeadnoteNodes"><span class="co_headnoteNumber co_excludeAnnotations co_disableHighlightFeatures" id="co_anchor_2028417793_0"><span class="co_headnoteNumber" id="co_anchor_headNote_23">23</span></span><span class="co_headnoteNode"><strong><a id="co_link_ID0E4HBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Patents</a></strong></span><div class="co_keyIcon co_excludeAnnotations co_disableHighlightFeatures"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Display Key Number Topics" title="Display Key Number Topics"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_popupHeadnote"></div></div></div></div></div><span class="co_lastKeyText"><a id="co_link_ID0E2IBG" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k2091/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">In general;  utility</a></span></div> <div class="co_headnote"><div class="co_headnoteParagraph"><div class="co_paragraphText"><a id="co_link_Iaa783d8cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998294381&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I65906730720e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">US Patent 5,709,999</a>, <a id="co_link_Iaa783d8dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998276467&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I00a2a120720511d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">US Patent 5,710,001</a>, <a id="co_link_Iaa783d8eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998348225&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">US Patent 5,753,441</a>, <a id="co_link_Iaa783d8fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2000348614&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=Ifd36f5d071f611d796fabc35f7796f7a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">US Patent 6,033,857</a>. Invalid in Part.</div></div><div id="co_headnoteId_202841779350220171013022134" class="co_headnoteCitedCaseRef"><a id="co_link_ID0EQJBG" class="co_link co_excludeAnnotations co_disableHighlightFeatures co_hideState" href="https://1.next.westlaw.com/Link/RelatedInformation/DocHeadnoteLink?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;headnoteId=202841779350220171013022134&amp;originationContext=document&amp;docSource=1b15b8ff27ee46e3968baecc2f04316f&amp;rank=337&amp;transitionType=CitingReferences&amp;contextData=(sc.CustomDigest)" title="Cases that cite headnote 23"><span class="co_citedRefCount co_excludeAnnotations co_disableHighlightFeatures">0 </span>Case that cites this headnote</a></div></div></div></div> <div class="co_headnoteTopicsCell"><div class="co_headnoteTopics co_excludeAnnotations co_disableHighlightFeatures"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/headnoteKey.png" class="co_headnoteKeyIcon" alt="Key Number Symbol" title="Key Number Symbol"><div class="co_fancyKeyciteContainerBottom"><div class="co_fancyKeyciteContainer"><div class="co_topicKeyContentTable"><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d89afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291</a></span><span class="co_headnoteTopicKey">Patents</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d8aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291X/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291X</a></span><span class="co_headnoteTopicKey">Patents Enumerated</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteRefNumber"><a id="co_link_Iaa783d8bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Browse/Home/KeyNumber/291k2091/View.html?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">291k2091</a></span><span class="co_headnoteTopicKey">In general;  utility</span></div><div class="co_headnoteKeyPair"><span class="co_headnoteTopicKey"><span class="co_headnotePriorClassification">(Formerly 291k328(2))</span></span></div></div></div></div></div></div><div class="co_clear"></div></div></div></div><div> </div></div><a id="co_headnotesEnd"></a><h2 class="co_attorneyBlockLabel co_printHeading co_briefItState" id="co_attorneysAndLawFirms">Attorneys and Law Firms</h2><div class="co_contentBlock co_briefItState co_attorneyBlock"><div> <span class="co_starPage" id="co_pp_sp_506_1306"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1306&quot; }" alt="metadata" type="hidden">*1306</span> <a id="co_link_Iaa783d90afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0282158201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Christopher A. Hansen</a>, American Civil Liberties Union Foundation, of New York, NY, argued for plaintiffs-appellees. With him on the brief were <a id="co_link_Iaa783d91afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0374368401&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Sandra S. Park</a>, <a id="co_link_Iaa783d92afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0201664901&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Aden Fine</a>, and <a id="co_link_Iaa783d93afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0364917701&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Lenora M. Lapidus</a>. Of counsel on the brief were <a id="co_link_Iaa783d94afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0319322201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Daniel B. Ravicher</a> and <a id="co_link_Iaa783d95afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0334812301&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Sabrina Y. Hassan</a>, Public Patent Foundation, <a id="co_link_Iaa783d96afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0251968001&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Benjamin N. Cardozo</a>, School of Law, of New York, NY.</div><div><a id="co_link_Iaa783d97afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0177077901&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Gregory A. Castanias</a>, <a id="co_link_Iaa783d98afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0177049701&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Jones Day</a>, of Washington, DC, argued for all defendant-appellants. With him on the brief were <a id="co_link_Iaa783d99afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0307179901&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Jennifer L. Swize</a>, of Washington, DC, <a id="co_link_Iaa783d9aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0397907401&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Israel Sasha Mayergoyz</a> and <a id="co_link_Iaa783d9bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0478769301&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Dennis Murashko</a>, of Chicago, IL, <a id="co_link_Iaa783d9cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0165106501&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Brian M. Poissant</a>, <a id="co_link_Iaa783d9dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0216658001&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Laura A. Coruzzi</a> and <a id="co_link_Iaa783d9eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0325027501&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Eileen Falvey</a>, of New York, NY. Of counsel were Benjamin Jackson, and <a id="co_link_Iaa783da0afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0409949601&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Jay Z. Zhang</a>, Myriad Genetics, of Salt Lake City, UT.</div><div><a id="co_link_Iaa783da1afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0491804299&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Melissa N. Patterson</a>, Attorney, Civil Division, Appellate Staff, United States Department of Justice, of Washington, DC, argued for amicus curiae, United States. With her on the brief were <a id="co_link_Iaa783da2afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0242390001&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Stuart F. Delery</a>, Acting Assistant Attorney General, <a id="co_link_Iaa783da3afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0144250201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Beth S. Brinkmann</a>, Deputy Assistant Attorney General and Scott R. McItosh, Attorney. Of counsel was <a id="co_link_Iaa783da5afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0363130601&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Mark R. Freeman</a>.</div><div><a id="co_link_Iaa783da6afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0123170601&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Thomas J. Kowalski</a>, Vedder Price PC, of New York, New York, for amicus curiae Protein Sciences Corporation. With him  <span class="co_starPage" id="co_pp_sp_506_1307"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1307&quot; }" alt="metadata" type="hidden">*1307</span> on the brief were <a id="co_link_Iaa783da7afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0325030001&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Deborah L. Lu</a>; and <a id="co_link_Iaa783da8afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0208763301&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Robert S. Rigg</a>, of Chicago, IL.</div><div><a id="co_link_Iaa783da9afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0174888001&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Robert A. Armitage</a>, Eli Lilly and Company, Indianapolis, IN, for amicus curiae, Eli Lilly and Company. With him on the brief was <a id="co_link_Iaa783daaafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0297918101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">James J. Kelley</a>.</div><div>Christopher M. Holman, University of Missouri–Kansas City School of Law, of Kansas City, MO, for amicus curiae Law Professor Christopher M. Holman.</div><div><a id="co_link_Iaa783dacafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0172764601&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Charles R. Macedo</a>, Amster Rothstein &amp; Ebenstein, LLP, of New York, NY, for amicus curiae, New York Intellectual Property Law Association. Of counsel on the brief were <a id="co_link_Iaa783dadafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0206089401&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Ronald M. Daignault</a> and <a id="co_link_Iaa783daeafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0366977301&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Matthew B. McFarlane</a>, Robins, Kaplan, Miller &amp; Ciresi, L.L.P. of New York, NY.</div><div><a id="co_link_Iaa783dafafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0278610801&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Lori B. Andrews, II</a>T Chicago–Kent College of Law, of Chicago, IL, for amicus curiae, The American College of Embryology, et al. Of counsel was <a id="co_link_Iaa783db0afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0244580401&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Joshua D. Sarnoff</a>, DePaul University College of Law, of Chicago, IL.</div><div>Debra L. Greenfield, UCLA Institute for Society and Genetics, of Los Angeles, CA, for amici curiae, The National Women's Health Network, et al.</div><div>Krista L. Cox, Knowledge Ecology International, of Washington, DC, for amicus curiae, Knowledge Ecology International, et al.<input id="co_docMarker_4" type="hidden"></div><div><a id="co_link_Iaa783db3afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0194121001&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Richard F. Phillips</a>, Intellectual Property Owners Association, of Washington, DC, for amicus curiae, Intellectual Property Owners Association. With him on the brief was <a id="co_link_Iaa783db4afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0336921101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Kevin H. Rhodes</a>. Of counsel on the brief were <a id="co_link_Iaa783db5afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0124559801&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Paul H. Berghoff</a>, <a id="co_link_Iaa783db6afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0187063601&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Kevin E. Noonan</a> and <a id="co_link_Iaa783db7afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0386746301&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Jeffrey P. Armstrong</a>, McDonnell Boehnen Hulbert &amp; Berghoff, LLP, of Chicago, IL. Of counsel were <a id="co_link_Iaa783db8afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0282506201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Herbert C. Wamsley</a>, Intellectual Property Owners, of Washington, DC, and <a id="co_link_Iaa783db9afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0156075801&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Douglas Kent Norman</a>, Eli Lilly &amp; Company, of Indianapolis, IN.</div><div><a id="co_link_Iaa783dbaafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0102594601&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Barbara R. Rudolph</a>, Finnegan, Henderson, Farabow, Garrett &amp; Dunner, LLP, of Washington, DC, for amicus curiae, American Intellectual Property Law Association. With her on the brief were <a id="co_link_Iaa783dbbafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0106461701&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Robert D. Litowitz</a>, <a id="co_link_Iaa783dbcafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0325752601&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Erika Harmon Arner</a> and David S. Forman. Of counsel on the brief was <a id="co_link_Iaa783dbeafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0175178201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">William G. Barber</a>, American Intellectual Property Law Association, of Arlington, VA. Of counsel were David Warren Hill, American Intellectual Property, of Arlington, VA, and <a id="co_link_Iaa783dc0afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0335803201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Robert C. Stanley</a>, Finnegan, Henderson, Farabow, Garrett &amp; Dunner, LLP, of Atlanta, GA.</div><div>William T. Robinson, III, American Bar Association, of Chicago, IL, for amicus curiae, American Bar Association. Of counsel on the brief were <a id="co_link_Iaa783dc2afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0245281101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">John P. Elwood</a>, Vinson &amp; Elkins, LLP, of Washington, DC; and <a id="co_link_Iaa783dc3afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0359870501&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Michael A. Valek</a>, <a id="co_link_Iaa783dc4afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0390500701&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Stephen C. Stout</a>, of Austin, TX.</div><div><a id="co_link_Iaa783dc5afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0330173001&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Mark J. Gatschet</a>, Mark John Gatschet, P.L.L.C., of Houston, TX, for amicus curiae, Mark J. Gatschet and Richard W. Knight. Of counsel on the brief was <a id="co_link_Iaa783dc6afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0323472501&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Richard W. Knight</a>, R.W. Knight P.C. of San Antonio, TX.</div><div><a id="co_link_Iaa783dc7afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0236470001&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Claire Laporte</a>, Foley Hoag, LLP, of Boston, MA, for amicus curiae Federal Circuit Bar Association. With her on the brief was <a id="co_link_Iaa783dc8afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0329503601&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">James M. Flaherty, Jr.</a></div><div><a id="co_link_Iaa783dc9afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0242831401&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">John L. Hendricks</a>, Hitchcock Evert, LLP, of Dallas, TX, for amicus curiae, AARP, et al. With him on the brief were <a id="co_link_Iaa783dcaafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0325368001&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Megan M. O'Laughlin</a> and <a id="co_link_Iaa783dcbafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0409560901&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">John T. Tower</a>. Of counsel was <a id="co_link_Iaa783dccafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0155098401&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Michael R. Schuster</a>.</div><div><a id="co_link_Iaa783dcdafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0359259801&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">J. Timothy Keane</a>, Harness, Dickey &amp; Pierce, PLC, of St. Louis, MO, for amicus curiae, BioGenerator, et al.</div><div><a id="co_link_Iaa783dceafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0252075001&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Susan E. McBee</a>, Baker, Donelson, Bearman, Caldwell, and Berkowitz, P.C., of Washington, DC, for amicus curiae, Immatics Biotechnologie, GmbH. With her on the brief was <a id="co_link_Iaa783dcfafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0386408401&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Bryan W. Jones</a>.</div><div><a id="co_link_Iaa783dd0afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0106644001&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Seth P. Waxman</a>, Wilmer Cutler Pickering Hale and Dorr, LLP, of Washington, DC, for amicus curiae, Biotechnology Industry <span class="co_starPage" id="co_pp_sp_506_1308"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1308&quot; }" alt="metadata" type="hidden">*1308</span>  Organization, et al. With him on the brief was <a id="co_link_Iaa783dd1afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0359941501&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Thomas G. Saunders</a>. Of counsel on the brief was <a id="co_link_Iaa783dd2afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0360227001&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Mark C. Fleming</a>, of Boston, MA, and Hansjorg Salter, Biotechnology Industry Organization, of Washington, DC. Of counsel was <a id="co_link_Iaa783dd3afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0325519701&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Allen C. Nunnally</a>, Wilmer Cutler Pickering Hale and Dorr, LLP, of Boston, MA.</div><div><a id="co_link_Iaa783dd4afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0217306701&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Jennifer Gordon</a>, Baker Botts, L.L.P. of New York, NY, for amicus curiae, Croplife International. With her on the brief were <a id="co_link_Iaa783dd5afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0350637501&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Steven Lendaris</a> and <a id="co_link_Iaa783dd6afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0364947601&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Jennifer C. Tempesta</a>.</div><div><a id="co_link_Iaa783dd7afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0336353301&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Matthew J. Dowd</a>, Wiley Rein LLP, of Washington, DC, for amicus curiae, James D. Watson. With him on the brief was <a id="co_link_Iaa783dd8afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0322787301&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">James H. Wallace, Jr.</a></div><div><a id="co_link_Iaa783dd9afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0196386801&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Kurt G. Calia</a>, Covington &amp; Burling, LLP, of Redwood Shores, CA, for amicus curiae, Pharmaceutical Research and Manufacturers of America. With him on the brief were <a id="co_link_Iaa783ddaafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0143309901&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Robert A. Long, Jr.</a> and <a id="co_link_Iaa783ddbafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0428089001&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Allison E. Kerndt</a>, of Washington, DC, and <a id="co_link_Iaa783ddcafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0428176801&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Alexa R. Hansen</a>, of San Francisco, CA.</div><div><a id="co_link_Iaa783dddafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0408905001&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Eileen M. Kane</a>, Penn State Dickinson School of Law, of University Park, PA, for amicus curiae, Professor Eileen M. Kane.</div><div>Genevieve E. Scott, Yale School of Law, of Brooklyn, NY, for amicus curiae, Information Society Project at Yale Law School Scholars. With her on the brief was <a id="co_link_Iaa783ddfafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0123746001&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Priscilla J. Smith</a>.</div><div><a id="co_link_Iaa783de0afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0226354101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Robert Sachs</a>, Fenwick &amp; West, LLP, of San Francisco, CA, for amicus curiae, Advanced Biological Laboratories, SA.<input id="co_docMarker_5" type="hidden"></div></div><div class="co_contentBlock co_briefItState co_panelBlock"><div>Before <a id="co_link_Iaa783de1afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0225327201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">LOURIE</a>, <a id="co_link_Iaa783de2afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0112582701&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">BRYSON</a>, and <a id="co_link_Iaa783de3afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0368246101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">MOORE</a>, Circuit Judges.</div></div><div class="co_contentBlock co_briefItState co_opinionBlock"><h2 id="co_opinion" class="co_printHeading">Opinion</h2><div class="co_docDelivery_dottedLine"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/co_docDelivery_dottedLine.png" alt=""></div><div class="co_contentBlock x_opinionBlockBody"><div class="co_contentBlock x_opinionUndesignated"><div class="co_contentBlock x_voteBlock"><div class="co_contentBlock x_voteLine">Opinion for the court filed by Circuit Judge <a id="co_link_Iaa783de4afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0225327201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">LOURIE</a>. Opinion concurring in part filed by Circuit Judge <a id="co_link_Iaa783de5afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0368246101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">MOORE</a>. Opinion concurring in part and dissenting in part filed by Circuit Judge <a id="co_link_Iaa783de6afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0112582701&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">BRYSON</a>.</div></div><div class="co_contentBlock x_opinionBody"><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768dcbafef11e79bef99c0ee06c731"></div></div></div><div class="co_contentBlock x_opinionLead"><div class="co_contentBlock x_leadAuthorLineBlock"><div class="co_contentBlock x_leadAuthorLine"><a id="co_link_Iaa783de7afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0225327201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">LOURIE</a>, Circuit Judge.</div></div><div class="co_contentBlock x_opinionBody"><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768dceafef11e79bef99c0ee06c731"><div class="co_paragraph"><div class="co_paragraphText">Myriad Genetics, Inc. and the Directors of the University of Utah Research Foundation (collectively, “Myriad”) appeal from the decision of the United States District Court for the Southern District of New York holding that an assortment of medical organizations, researchers, genetic counselors, and patients (collectively, “Plaintiffs”) have standing under the Declaratory Judgment Act to challenge Myriad's patents. <a id="co_link_Iaa783de8afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2020295212&amp;pubNum=0004637&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Ass'n for Molecular Pathology v. U.S. Patent &amp; Trademark Office,</em> 669 F.Supp.2d 365 (S.D.N.Y.2009)</a> (“<a id="co_link_Iaa783de9afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2020295212&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>DJ Op.</em></a>”). Myriad also appeals from the district court's decision granting summary judgment that all of the challenged claims are drawn to non-patentable subject matter under <a id="co_link_Iaa783deaafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 101</a>. <a id="co_link_Iaa783debafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2021662409&amp;pubNum=0004637&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Ass'n for Molecular Pathology v. U.S. Patent &amp; Trademark Office,</em> 702 F.Supp.2d 181 (S.D.N.Y.2010)</a> (“<a id="co_link_Iaa783decafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2021662409&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>SJ Op.</em></a>”). We affirm in part and reverse in part.</div></div><div class="co_paragraph"><div class="co_paragraphText">This appeal has returned to us as, a petition for certiorari having been filed from our decision of July 29, 2011, the Supreme Court of the United States granted the petition, vacated our decision, and remanded the case to us for further consideration in light of its decision in <a id="co_link_Iaa783dedafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo Collaborative Services v. Prometheus, Inc.,</em> 566 U.S. ––––, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)</a>. <a id="co_link_Iaa783deeafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2026688034&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Ass'n for Molecular Pathology v. Myriad Genetics, Inc.,</em> –––U.S. ––––, 132 S.Ct. 1794, 182 L.Ed.2d 613 (2012)</a>. We invited and received briefing by the parties and interested amici and held oral argument on July 20, 2012. Our decision on remand follows. It both decides the issues that were before us in the original appeal and evaluates the effect of <em>Mayo</em> on those issues.</div></div><div class="co_paragraph"><div class="co_paragraphText">On the threshold issue of jurisdiction, we affirm the district court's decision to exercise declaratory judgment jurisdiction because we conclude that at least one plaintiff, <span class="co_starPage" id="co_pp_sp_506_1309"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1309&quot; }" alt="metadata" type="hidden">*1309</span>  Dr. Harry Ostrer, has standing to challenge the validity of Myriad's patents. On the merits, we reverse the district court's decision that Myriad's composition claims to “isolated” DNA molecules cover patent-ineligible products of nature under <a id="co_link_Iaa783df0afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> because each of the claimed molecules represents a nonnaturally occurring composition of matter. We also reverse the district court's decision that Myriad's method claim to screening potential <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a">cancer</a> therapeutics via changes in cell growth rates of transformed cells is directed to a patent-ineligible scientific principle. We affirm the court's decision, however, that Myriad's method claims directed to “comparing” or “analyzing” DNA sequences are patent ineligible; such claims include no transformative steps and cover only patent-ineligible abstract, mental steps.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768dcfafef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">Background</span></div><div class="co_paragraph"><div class="co_paragraphText">Plaintiffs brought suit against Myriad, challenging the patentability of certain composition and method claims relating to human genetics. <a id="co_link_Iaa783df2afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2020295212&amp;pubNum=0004637&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_4637_369&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_369"><em>See DJ Op.,</em> 669 F.Supp.2d at 369–76</a>. Specifically, Plaintiffs sought a declaration that fifteen claims from seven patents assigned to Myriad are drawn to patent-ineligible subject matter under <a id="co_link_Iaa783df3afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 101</a>: claims 1, 2, 5, 6, 7, and 20 of <a id="co_link_Iaa783df4afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S. Patent 5,747,282 (“the ′282 patent”)</a>; claims 1, 6, and 7 of <a id="co_link_Iaa783df5afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998422488&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=Ia9d8eb20724e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S. Patent 5,837,492 (“the ′492 patent”)</a>; claim 1 of <a id="co_link_Iaa783df6afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1997377490&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I0e737f30746811d7a94bace56a9eba1c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S. Patent 5,693,473 (“the ′473 patent”)</a>; claim 1 of <a id="co_link_Iaa783df7afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998294381&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I65906730720e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S. Patent 5,709,999 (“the ′999 patent”)</a>; claim 1 of <a id="co_link_Iaa783df8afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998276467&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I00a2a120720511d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S. Patent 5,710,001 (“the ′001 patent”)<input id="co_docMarker_6" type="hidden"></a>; claim 1 of <a id="co_link_Iaa783df9afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998348225&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S. Patent 5,753,441 (“the ′441 patent”)</a>; and claims 1 and 2 of <a id="co_link_Iaa783dfaafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2000348614&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=Ifd36f5d071f611d796fabc35f7796f7a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S. Patent 6,033,857 (“the ′857 patent”)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The challenged composition claims cover two “isolated” human genes, <em>BRCA1</em> and <em>BRCA2</em> (collectively, “<em>BRCA1/2</em> ” or “<em>BRCA</em> ”), and certain alterations, or mutations, in these genes associated with a predisposition to breast and ovarian <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_0">cancers</a>. Representative composition claims include claims 1, 2, and 5 of the ′<a id="co_link_Iaa783dfcafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a>:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">1. An isolated DNA coding for a BRCA1 polypeptide, said polypeptide having the amino acid sequence set forth in SEQ ID NO:2.</div></div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">2. The isolated DNA of claim 1, wherein said DNA has the nucleotide sequence set forth in SEQ ID NO:1.</div></div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText">5. An isolated DNA having at least 15 nucleotides of the DNA of claim 1.</div></div><div class="co_paragraphText co_flush">′<a id="co_link_Iaa783dfdafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a> col. 153 1.55—col. 154 1.56.<sup id="co_footnoteReference_B00112028417793_ID0E52AI"><a href="#co_footnote_B00112028417793" class="co_footnoteReference">1</a></sup> SEQ ID NO:2 depicts the amino acid sequence of the BRCA1 protein, and SEQ ID NO:1 depicts the nucleotide sequence of the <em>BRCA1</em> DNA coding region; the latter sequence is colloquially referred to as cDNA. <a id="co_link_Iaa783dfeafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> col. 19 ll.48–50.</div></div><div class="co_paragraph"><div class="co_paragraphText">All but one of the challenged method claims cover methods of “analyzing” or “comparing” a patient's <em>BRCA</em> sequence with the normal, or wild-type, sequence to identify the presence of cancer-predisposing mutations. Representative method claims include claims 1 of the ′999 and ′<a id="co_link_Iaa783e03afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998276467&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I00a2a120720511d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">001 patents</a>:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>1. A method for detecting a germline alteration in a BRCA1 gene, said alteration selected from the group consisting of the alterations set forth in Tables 12A, 14, 18 or 19 in a human which comprises <em>analyzing</em> a sequence of a BRCA1 gene or BRCA1 RNA from a human sample or <em>analyzing</em> a sequence of BRCA1 cDNA made from mRNA from said human sample with the proviso that said germline alteration is not a deletion of 4 nucleotides corresponding to base numbers 4184–4187 of SEQ ID NO: 1.</div></blockquote></div></div><div class="co_paragraphText co_flush"> <span class="co_starPage" id="co_pp_sp_506_1310"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1310&quot; }" alt="metadata" type="hidden">*1310</span> ′<a id="co_link_Iaa783e04afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998294381&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I65906730720e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">999 patent</a> col. 161 ll.17–25 (emphases added).</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>1. A method for screening a tumor sample from a human subject for a somatic alteration in a BRCA1 gene in said tumor which comprises [ ] <em>comparing</em> a first sequence selected from the group consisting of a BRCA1 gene from said tumor sample, BRCA1 RNA from said tumor sample and BRCA1 cDNA made from mRNA from said tumor sample with a second sequence selected from the group consisting of BRCA1 gene from a nontumor sample of said subject, BRCA1 RNA from said nontumor sample and BRCA1 cDNA made from mRNA from said nontumor sample, wherein a difference in the sequence of the BRCA1 gene, BRCA1 RNA or BRCA1 cDNA from said tumor sample from the sequence of the BRCA1 gene, BRCA1 RNA or BRCA1 cDNA from said nontumor sample indicates a somatic alteration in the BRCA1 gene in said tumor sample.</div></blockquote></div></div><div class="co_paragraphText co_flush">′<a id="co_link_Iaa783e05afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998276467&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I00a2a120720511d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">001 patent</a> col.155 ll.2–17 (emphasis added).<sup id="co_footnoteReference_B00222028417793_ID0ELCBI"><a href="#co_footnote_B00222028417793" class="co_footnoteReference">2</a></sup></div></div><div class="co_paragraph"><div class="co_paragraphText">The final method claim challenged by Plaintiffs is directed to a method of screening potential <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_1">cancer</a> therapeutics. Specifically, claim 20 of the ′<a id="co_link_Iaa783e09afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"> 282 patent</a> reads as follows:</div><div class="co_paragraph co_indentLeft1"><div class="co_paragraphText"><blockquote><div>20. A method for screening potential <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_2">cancer</a> therapeutics which comprises: growing a <em>transformed eukaryotic host cell</em> containing an altered BRCA1 gene causing <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_3">cancer</a> in the presence of a compound suspected of being a <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_4">cancer</a> therapeutic, growing said <em>transformed eukaryotic host cell</em> in the absence of said compound, determining the rate of growth of said host cell in the presence of said compound and the rate of growth of said host cell in the absence of said compound and comparing the growth rate of said host cells, wherein a slower rate of growth of said host cell in the presence of said compound is indicative of a <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_5">cancer</a> therapeutic.</div></blockquote></div></div><div class="co_paragraphText co_flush">′<a id="co_link_Iaa783e0eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a> col. 156 ll.13–24 (emphases added).<input id="co_docMarker_7" type="hidden"></div></div><div class="co_paragraph"><div class="co_paragraphText">The challenged claims thus relate to isolated gene sequences and diagnostic methods of identifying mutations in these sequences. To place this suit in context, we take a step back to provide background on the science involved, including the identification of the <em>BRCA</em> genes, and the Plaintiffs' connections to the invention and to Myriad.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768dd0afef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">I.</span></div><div class="co_paragraph"><div class="co_paragraphText">Human genetics is the study of heredity in human beings.<sup id="co_footnoteReference_B00332028417793_ID0EEIBI"><a href="#co_footnote_B00332028417793" class="co_footnoteReference">3</a></sup> The human genome, the entirety of human genetic information, contains approximately 22,000 genes, which form the basis of human inheritance. The majority of genes act by guiding the production of polypeptide chains that form proteins. Proteins in turn make up having matter and catalyze a variety of cellular processes.</div></div><div class="co_paragraph"><div class="co_paragraphText">Chemically, the human genome is composed of deoxyribonucleic acid (“DNA”). Each DNA molecule is made up of repeating units of four nucleotide bases—adenine (“A”), thymine (“T”), cytosine (“C”), and guanine (“G”)—which are covalently linked, or bonded,<sup id="co_footnoteReference_B00442028417793_ID0EUJBI"><a href="#co_footnote_B00442028417793" class="co_footnoteReference">4</a></sup> together via a sugar- <span class="co_starPage" id="co_pp_sp_506_1311"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1311&quot; }" alt="metadata" type="hidden">*1311</span> phosphate, or phosphodiester, backbone. DNA generally exists as two DNA strands intertwined as a double helix in which each base on a strand pairs, or hybridizes, with a complementary base on the other strand: A pairs with T, and C with G. Figure 1 below depicts the structure of a DNA double helix and the complementary pairing of the four nucleotide bases, represented by A, T, C, and G.</div></div><div class="co_contentBlock x_figure" id="co_anchor_Iaa768dd1afef11e79bef99c0ee06c731"><div><div class="co_imageBlock"><a class="co_imageLink" type="image/x-png" href="https://1.next.westlaw.com/Link/Document/Blob/I87b71400e82211e19995010000000000.png?originationContext=document&amp;transitionType=DocumentImage&amp;uniqueId=c13b230c-4a15-4e95-8890-907127378664&amp;contextData=(sc.CustomDigest)"><img alt="Image 1 within Association for Molecular Pathology v. U.S. Patent and Trademark Office" src="https://1.next.westlaw.com/Link/Document/Blob/I87b71400e82211e19995010000000000.png?maxHeight=227&amp;originationContext=document&amp;transitionType=DocumentImage&amp;uniqueId=c13b230c-4a15-4e95-8890-907127378664&amp;contextData=(sc.CustomDigest)" class="co_shrunkImage" width="505" height="227">​</a></div></div></div><div class="co_paragraph"><div class="co_paragraphText">The linear order of nucleotide bases in a DNA molecule is referred to as its “sequence.” The sequence of a gene is thus denoted by a linear sequence of As, Ts, Gs, and Cs. “DNA sequencing” or “gene sequencing” refers to the process by which the precise linear order of nucleotides in a DNA segment or gene is determined. A gene's nucleotide sequence in turn encodes for a linear sequence of amino acids that comprise the protein encoded by the gene, <em>e.g.,</em> the <em>BRCA1</em> gene encodes for the BRCA1 protein. Most genes have both “exon” and “intron” sequences. Exons are DNA segments that are necessary for the creation of a protein, <em>i.e.,</em> that code for a protein. Introns are segments of DNA interspersed between the exons that, unlike exons, do not code for a protein.</div></div><div class="co_paragraph"><div class="co_paragraphText">The creation of a protein from a gene comprises two steps: transcription and translation. First, the gene sequence is “transcribed” into a different nucleic acid called ribonucleic acid (“RNA”). RNA has a chemically different sugar-phosphate backbone than DNA, and it utilizes the nucleotide base uracil (“U”) in place of thymine (“T”). During transcription, the DNA double helix is unwound and each nucleotide on the non-coding, or template, DNA strand is used to make a complementary, single-stranded RNA molecule that mirrors the coding DNA strand, <em>i.e.,</em> adenine on the template DNA strand results in uracil in the RNA molecule, thymine results in adenine, guanine in cytosine, and cytosine in guanine. The resulting “pre-RNA,” like the DNA from which it was generated, contains both exon and intron sequences. Next, the introns are physically excised from the pre-RNA molecule, followed by “splicing” the exons to produce a messenger RNA (“mRNA”). Figure 2 below shows the steps of transcribing a gene that contains three exons (exon 1–3) and two introns (intron 1 and 2) into a pre-RNA, followed by RNA excising the introns and splicing of the exons to produce an mRNA containing only exon sequences.</div></div><div class="co_contentBlock x_figure" id="co_anchor_Iaa768dd3afef11e79bef99c0ee06c731"><div><div class="co_imageBlock"><a class="co_imageLink" type="image/x-png" href="https://1.next.westlaw.com/Link/Document/Blob/I87bf9f80e82211e19995010000000000.png?originationContext=document&amp;transitionType=DocumentImage&amp;uniqueId=c13b230c-4a15-4e95-8890-907127378664&amp;contextData=(sc.CustomDigest)"><img alt="Image 2 within Association for Molecular Pathology v. U.S. Patent and Trademark Office" src="https://1.next.westlaw.com/Link/Document/Blob/I87bf9f80e82211e19995010000000000.png?maxHeight=336&amp;originationContext=document&amp;transitionType=DocumentImage&amp;uniqueId=c13b230c-4a15-4e95-8890-907127378664&amp;contextData=(sc.CustomDigest)" class="co_shrunkImage" width="310" height="336">​</a></div></div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_506_1312"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1312&quot; }" alt="metadata" type="hidden">*1312</span> Following transcription and splicing, the resulting mRNA is “translated” into the encoded protein. Genes, and their corresponding mRNAs, encode proteins via three-nucleotide combinations called codons. Each codon triplet corresponds to one of the twenty amino acids that make up all proteins or a “stop” signal that terminates protein translation. For example, the codon adenine-thymine-guanine (ATG, or AUG in the corresponding mRNA), encodes the amino acid <input id="co_docMarker_8" type="hidden"><a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3af158f9475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3af158f9475111db9765f9243f53508a">methionine</a>. The relationship between the sixty-four possible codon sequences and their corresponding amino acids is known as the genetic code. Figure 3 below represents an mRNA molecule that translates into a protein of six amino acids (Codon 1, AUG, <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3af158f9475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3af158f9475111db9765f9243f53508a_0">methionine</a>; Codon 2, ACG, <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3b37b088475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3b37b088475111db9765f9243f53508a">threonine</a>; Codon 3, GAG, glutamic acid; Codon 4, CUU, leucine; Codon 5, CGG, arginine; Codon 6, AGC, serine), and ends with one of the three stop codons, UAG.</div></div><div class="co_contentBlock x_figure" id="co_anchor_Iaa768dd5afef11e79bef99c0ee06c731"><div><div class="co_imageBlock"><a class="co_imageLink" type="image/x-png" href="https://1.next.westlaw.com/Link/Document/Blob/I87bcb950e82211e19995010000000000.png?originationContext=document&amp;transitionType=DocumentImage&amp;uniqueId=c13b230c-4a15-4e95-8890-907127378664&amp;contextData=(sc.CustomDigest)"><img alt="Image 3 within Association for Molecular Pathology v. U.S. Patent and Trademark Office" src="https://1.next.westlaw.com/Link/Document/Blob/I87bcb950e82211e19995010000000000.png?originationContext=document&amp;transitionType=DocumentImage&amp;uniqueId=c13b230c-4a15-4e95-8890-907127378664&amp;contextData=(sc.CustomDigest)" class="co_image" width="536" height="1005">​</a></div></div></div><div class="co_paragraph"><div class="co_paragraphText">Changes, or mutations, in the sequence of a human gene can alter the production, structure, and/or function of the resulting protein. Small-scale changes include point mutations in which a change to a single nucleotide alters a single amino acid in the encoded protein. For example, a base change in the codon GCU to CCU changes an alanine in the encoded protein to a proline. Larger scale variations include the deletion, rearrangement, or <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=I777c6af7995711de9b8c850332338889&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I777c6af7995711de9b8c850332338889">duplication</a> of larger DNA segments—ranging from several hundreds to over a million nucleotides <span class="co_starPage" id="co_pp_sp_506_1313"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1313&quot; }" alt="metadata" type="hidden">*1313</span> —and can result in the elimination, misplacement, or <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=I777c6af7995711de9b8c850332338889&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I777c6af7995711de9b8c850332338889_0">duplication</a> of an entire gene or genes. While some mutations have little or no effect on the body's processes, others result in disease or an increased risk of developing a particular disease. DNA sequencing is used in clinical diagnostic testing to determine whether a gene contains mutations associated with a particular disease or disease risk.</div></div><div class="co_paragraph"><div class="co_paragraphText">Nearly every cell in the human body contains an individual's entire genome. DNA in the cell, called “native” or “genomic” DNA, is packaged into twenty-three pairs of chromosomes. Chromosomes are complex structures comprising a single extended DNA molecule wrapped around proteins called histones, as shown in Figure 4 below.</div></div><div class="co_contentBlock x_figure" id="co_anchor_Iaa768dd7afef11e79bef99c0ee06c731"><div><div class="co_imageBlock"><a class="co_imageLink" type="image/x-png" href="https://1.next.westlaw.com/Link/Document/Blob/I879cd540e82211e19995010000000000.png?originationContext=document&amp;transitionType=DocumentImage&amp;uniqueId=c13b230c-4a15-4e95-8890-907127378664&amp;contextData=(sc.CustomDigest)"><img alt="Image 4 within Association for Molecular Pathology v. U.S. Patent and Trademark Office" src="https://1.next.westlaw.com/Link/Document/Blob/I879cd540e82211e19995010000000000.png?maxHeight=452&amp;originationContext=document&amp;transitionType=DocumentImage&amp;uniqueId=c13b230c-4a15-4e95-8890-907127378664&amp;contextData=(sc.CustomDigest)" class="co_shrunkImage" width="374" height="452">​</a></div></div></div><div class="co_paragraph co_flush"><div class="co_paragraphText">Each chromosome contiguously spans millions of bases and encompasses many discrete genes. Humans have twenty-two pairs of autosomal chromosomes, numbered one to twenty-two according to size from largest to smallest, and one pair of sex chromosomes, two X chromosomes in females and one X and one Y chromosome in males.</div></div><div class="co_paragraph"><div class="co_paragraphText">Genomic DNA can be extracted from its cellular environment using a number of well-established laboratory techniques. A particular segment of DNA, such as a gene, can then be excised or amplified from the DNA to obtain the isolated DNA segment of interest. DNA molecules can also be synthesized in the laboratory. One type of synthetic DNA molecule is complementary DNA (“cDNA”). cDNA is synthesized from mRNA using complementary base pairing in a manner analogous to RNA transcription. The process results in a double-stranded DNA molecule with a sequence corresponding to the sequence of an mRNA produced by the body. Because it is synthesized from mRNA, cDNA contains only the exon sequences, and thus  <span class="co_starPage" id="co_pp_sp_506_1314"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1314&quot; }" alt="metadata" type="hidden">*1314</span> none of the intron sequences, from a chromosomal gene sequence.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768dd9afef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">II.</span></div><div class="co_paragraph"><div class="co_paragraphText">Certain mutations in the <em>BRCA</em> genes correlate with an increased risk of breast and ovarian <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_6">cancer</a>. The average woman in the United States has around a twelve to thirteen percent risk of developing <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ib73a5554475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ib73a5554475411db9765f9243f53508a">breast cancer</a> in her lifetime. Women with <em>BRCA</em> mutations, in contrast, face a cumulative risk of between fifty to eighty percent of developing <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ib73a5554475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ib73a5554475411db9765f9243f53508a_0">breast cancer</a> and a cumulative risk of ovarian <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_7">cancer</a> of between twenty to fifty percent. Diagnostic genetic testing for the existence of <em>BRCA</em> mutations is therefore an important consideration in the provision of clinical care for breast or ovarian <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_8">cancer</a>. This testing provides a patient with information on her risk for <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ic5e75ac4475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ic5e75ac4475411db9765f9243f53508a">hereditary breast and ovarian cancers</a>, and thus aids in the difficult decision regarding whether to undertake preventive options, including prophylactic surgery. Diagnostic results can also be an important factor in structuring an appropriate course of <input id="co_docMarker_9" type="hidden"><a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_9">cancer</a> treatment, since certain forms of therapy are more effective in treating <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_10">cancers</a> related to <em>BRCA</em> mutations.</div></div><div class="co_paragraph"><div class="co_paragraphText">The inventors of the patents in suit identified the genetic basis of <em>BRCA1</em>–and <em>BRCA2</em>-related <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_11">cancers</a> using an analysis called positional cloning. Relying on a large set of DNA samples from families with inherited breast and ovarian <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_12">cancers</a>, the inventors correlated the occurrence of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_13">cancer</a> in individual family members with the inheritance of certain marker DNA sequences. This allowed the inventors to identify, or “map,” the physical location of the <em>BRCA</em> genes within the human genome and to isolate the <em>BRCA</em> genes and determine their exact nucleotide sequences. This in turn allowed Myriad to provide <em>BRCA</em> diagnostic testing services to women.<sup id="co_footnoteReference_B00552028417793_ID0EVUBI"><a href="#co_footnote_B00552028417793" class="co_footnoteReference">5</a></sup></div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768ddaafef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">III.</span></div><div class="co_paragraph"><div class="co_paragraphText">Myriad, however, was not the only entity to implement clinical <em>BRCA</em> testing services. Starting in 1996, the University of Pennsylvania's Genetic Diagnostic Laboratory (“GDL”), co-directed by plaintiffs Haig H. Kazazian, Jr., M.D. and Arupa Ganguly, Ph.D., provided <em>BRCA1/2</em> diagnostic services to women. By 1999, however, accusations by Myriad that GDL's <em>BRCA</em> testing services infringed its patents forced the lab to stop providing such services.</div></div><div class="co_paragraph"><div class="co_paragraphText">The first sign of a dispute came in early 1998. At that time, Dr. Kazazian recalls a dinner with Dr. Mark Skolnick, inventor and Chief Science Officer at Myriad. At the dinner, Skolnick informed Kazazian that Myriad was planning to stop GDL from providing clinical <em>BRCA</em> testing in light of Myriad's patents. A month or two later, in May 1998, Kazazian received a letter from William A. Hockett, Director of Corporate Communications at Myriad. The letter stated that Myriad knew that Kazazian was currently providing <em>BRCA1</em> diagnostic testing services, and that Myriad, as patent holder of five U.S. patents covering the isolated <em>BRCA1</em> gene and diagnostic testing, was making available to select institutions a collaborative license. Attached to the letter was a copy of Myriad's collaborative  <span class="co_starPage" id="co_pp_sp_506_1315"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1315&quot; }" alt="metadata" type="hidden">*1315</span> agreement, which proposed severely limiting GDL's testing services to certain tests for patients of Ashkenazi Jewish descent. Plaintiff Harry Ostrer, M.D., a researcher at New York University (“NYU”) School of Medicine, received the same letter and collaborative agreement in May 1998, although his laboratory did not, at the time, provide such testing services. Rather, Ostrer sent patient samples to GDL for <em>BRCA</em> genetic testing.</div></div><div class="co_paragraph"><div class="co_paragraphText">Months later, in August 1998, Dr. Kazazian received a second letter, this time from George A. Riley of the law firm O'Melveny &amp; Myers LLP. The letter identified by number five Myriad patents “covering, among other things, the BRCA1 gene sequence ... and methods for detecting alterations in the BRCA1 sequence.” J.A. 1145. The letter also indicated that it “has come to Myriad's attention that you are engaged in commercial testing activities that infringe Myriad's patents,” and that “[u]nless and until a licensing arrangement is completed ... you should cease all infringing testing activity.” <a id="co_link_Iaa783e22afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998422488&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> The letter noted, however, that the cease-and-desist notification did not apply to research testing “for the purpose of furthering non-commercial research programs, the results of which are not provided to the patient and for which no money is received from the patient or the patient's insurance.” <a id="co_link_Iaa783e23afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998422488&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a></div></div><div class="co_paragraph"><div class="co_paragraphText">In June 1999, Robert Terrell, the General Counsel for the University of Pennsylvania, received a similar cease-and-desist letter from Christopher Wight, Myriad's General Counsel. The letter stated, <input id="co_docMarker_10" type="hidden">“It has come to our attention that Dr. Haig H. Kazazian, Jr. of the University of Pennsylvania is continuing to willfully engage in commercial BRCA1 and BRCA2 genetic testing activities, in violation of the University of Pennsylvania's previous assurances that such commercial testing activities would be discontinued.” J.A. 2890. Terrell responded to Wight by letter on September 10, 1999, stating that “the University agrees that it will not accept samples for BRCA1 research testing from third parties.” J.A. 2891. Kazazian thus informed Dr. Ostrer that GDL would no longer be accepting patient samples for <em>BRCA</em> testing from him or anyone else as a result of the patent infringement assertions made by Myriad. As a result, Ostrer started sending patient samples for <em>BRCA</em> genetic testing to Myriad, which became (and remains today) the only provider of such services in the United States.</div></div><div class="co_paragraph"><div class="co_paragraphText">During this period, Myriad also initiated several patent infringement suits against entities providing clinical <em>BRCA</em> testing. Myriad filed suit against Oncormed Inc. in 1997 and again in 1998, <em>Myriad Genetics v. Oncormed,</em> Nos. 2:97–cv–922, 2:98–cv–35 (D.Utah), and the University of Pennsylvania in 1998, <em>Myriad Genetics v. Univ. of Pa.,</em> No. 2:98–cv–829 (D.Utah). Both lawsuits were later dismissed without prejudice after each defendant agreed to discontinue all allegedly infringing activity.</div></div><div class="co_paragraph"><div class="co_paragraphText">None of the plaintiffs besides Drs. Kazazian, Ganguly, and Ostrer, allege that Myriad directed any letters or other communications regarding its patents at them. Rather, the other researchers and medical organization members state simply that knowledge of Myriad's vigorous enforcement of its patent rights against others stopped them from engaging in clinical <em>BRCA</em> genetic testing, although they have the personnel, expertise, and facilities as well as the desire to provide such testing. The patient plaintiffs state that they have been unable to obtain any <em>BRCA</em> genetic testing or their desired <em>BRCA</em> testing, either covered by their insurance or at a price that they can afford, because of Myriad's patent protection.</div></div><div class="co_paragraph"><div class="co_paragraphText">Like the other researchers, Dr. Kazazian states that if Myriad's patents were  <span class="co_starPage" id="co_pp_sp_506_1316"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1316&quot; }" alt="metadata" type="hidden">*1316</span> held invalid, he and Dr. Ganguly would be able to resume <em>BRCA</em> testing within a matter of a few weeks. He notes, however, that this is only if they “decided to resume BRCA testing.” J.A. 2852. Ganguly concurs, stating that if the patents were invalidated, “I would immediately consider resuming BRCA testing in my laboratory.” J.A. 2892. Dr. Ostrer<sup id="co_footnoteReference_B00662028417793_ID0E24BI"><a href="#co_footnote_B00662028417793" class="co_footnoteReference">6</a></sup> also indicates that his lab has all the personnel, facilities, and expertise necessary to undertake clinical <em>BRCA</em> testing and emphatically states that his lab “would immediately begin to perform BRCA1/2–related genetic testing upon invalidation of the Myriad patents.” J.A. 2936–38.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768ddbafef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">IV.</span></div><div class="co_paragraph"><div class="co_paragraphText">After Plaintiffs filed suit, Myriad moved to have the case dismissed, alleging that the Plaintiffs lacked standing to bring a declaratory judgment suit challenging the validity of its patents. The district court disagreed, however, holding that the Plaintiffs had established <a id="co_link_Iaa783e26afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=USCOARTIIIS1&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Article III</a> standing under the “all the circumstances” test articulated by the Supreme Court in <a id="co_link_Iaa783e27afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2011142967&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>MedImmune, Inc. v. Genentech, Inc.,</em> 549 U.S. 118, 127, 127 S.Ct. 764, 166 L.Ed.2d 604 (2007)</a>. <a id="co_link_Iaa783e28afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2020295212&amp;pubNum=4637&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_4637_385&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_385"><em>DJ Op.,</em> 669 F.Supp.2d at 385–92.</a> The court first found that Myriad had engaged in sufficient “affirmative acts” based on the company's assertion of its “right to preclude others from engaging in <em>BRCA1/2</em> genetic testing through personal communications, cease-and-desist letters, licensing offers, and litigation,”<input id="co_docMarker_11" type="hidden"> the result of which was “the widespread understanding that one may engage in <em>BRCA1/2</em> testing at the risk of being sued for infringement liability by Myriad.” <a id="co_link_Iaa783e29afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2020295212&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 390.</a> Myriad's actions, the court concluded, had placed “the Plaintiffs in precisely the situation that the Declaratory Judgment Act was designed to address: the Plaintiffs have the ability and desire to engage in <em>BRCA1/2</em> testing as well as the belief that such testing is within their rights, but cannot do so without risking infringement liability.” <a id="co_link_Iaa783e2aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2020295212&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a></div></div><div class="co_paragraph"><div class="co_paragraphText">In so holding, the court rejected Myriad's argument that there must be some act directed toward the Plaintiffs, noting that Myriad had, in fact, taken affirmative acts toward plaintiffs Dr. Kazazian and Dr. Ganguly. <a id="co_link_Iaa783e2bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2020295212&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 387–88.</a> The court also rejected Myriad's arguments that the cease-and-desist letter sent to plaintiff Kazazian was too old to support declaratory judgment jurisdiction and that the legal actions brought against third parties could not be considered in the jurisdictional analysis. <a id="co_link_Iaa783e2cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2020295212&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 388–89.</a> The court concluded that rigid adherence to either of these requirements would be inconsistent with <em>MedImmune's</em> mandate that the court assess the facts alleged under all the circumstances. <a id="co_link_Iaa783e2eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2020295212&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a></div></div><div class="co_paragraph"><div class="co_paragraphText">The district court also found that the Plaintiffs had alleged sufficient meaningful preparations for infringement to establish declaratory judgment jurisdiction. <a id="co_link_Iaa783e2fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2020295212&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 390–92.</a> With respect to the researchers, the court held it was sufficient that they were all “ready, willing, and able” to begin  <span class="co_starPage" id="co_pp_sp_506_1317"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1317&quot; }" alt="metadata" type="hidden">*1317</span> <em>BRCA1/2</em> testing within the normal course of their laboratories' research, rejecting Myriad's argument that they needed to allege specific preparatory activities. <a id="co_link_Iaa783e30afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2020295212&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 390–91.</a> The court also rejected Myriad's argument that plaintiffs Kazazian and Ganguly testified only that they would “consider” engaging in allegedly infringing activities, concluding that the proper focus of the inquiry is whether they are meaningfully prepared, not whether they have made a final, conclusive decision to engage in such activities. <a id="co_link_Iaa783e31afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2020295212&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 391 n. 18.</a></div></div><div class="co_paragraph"><div class="co_paragraphText">The parties then moved for summary judgment on the merits of Plaintiffs' <a id="co_link_Iaa783e32afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> challenge to Myriad's patent claims. The district court held for Plaintiffs, concluding that the fifteen challenged claims were drawn to non-patentable subject matter and thus invalid under <a id="co_link_Iaa783e33afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>. <a id="co_link_Iaa783e34afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2021662409&amp;pubNum=4637&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_4637_220&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_220"><em>SJ Op.,</em> 702 F.Supp.2d at 220–37.</a> Regarding the composition claims, the court held that isolated DNA molecules fall within the judicially created “products of nature” exception to <a id="co_link_Iaa783e35afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> because such isolated DNAs are not “markedly different” from native DNAs. <a id="co_link_Iaa783e36afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2021662409&amp;pubNum=0004637&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_4637_222&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_222"><em>Id.</em> at 222, 232</a> (quoting <a id="co_link_Iaa783e37afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Diamond v. Chakrabarty,</em> 447 U.S. 303, 100 S.Ct. 2204, 65 L.Ed.2d 144 (1980)</a>). The court relied on the fact that, unlike other biological molecules, DNAs are the “physical embodiment of information,” and that this information is not only preserved in the claimed isolated DNA molecules, but also essential to their utility as molecular tools. <a id="co_link_Iaa783e38afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2021662409&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 228–32.</a></div></div><div class="co_paragraph"><div class="co_paragraphText">Turning to the method claims, the court held them patent ineligible under this court's then-definitive machine-or-transformation test. <a id="co_link_Iaa783e39afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2021662409&amp;pubNum=0004637&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_4637_233&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_233"><em>Id.</em> at 233</a> (citing <a id="co_link_Iaa783e3aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2017388082&amp;pubNum=0000506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>In re Bilski,</em> 545 F.3d 943 (Fed.Cir.2008)</a> (en banc), <em>aff'd on other grounds, </em><a id="co_link_Iaa783e3bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2022394590&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_3225&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_3225"><em>Bilski v. Kappos,</em> ––– U.S. ––––, 130 S.Ct. 3218, 3225, 177 L.Ed.2d 792 (2010)</a>). The court held that the claims covered “analyzing” or “comparing” DNA sequences by any method, and thus covered mental processes independent of any physical transformations. <a id="co_link_Iaa783e3cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2021662409&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 233–35.</a> In so holding, the court distinguished Myriad's claims from those at issue in <input id="co_docMarker_12" type="hidden"><em>Mayo</em> based on the “determining” step in the latter being construed to include the extraction and measurement of metabolite levels from a patient sample. <a id="co_link_Iaa783e3eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2021662409&amp;pubNum=0004637&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_4637_234&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_234"><em>SJ Op.,</em> 702 F.Supp.2d at 234–35</a> (citing <a id="co_link_Iaa783e3fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2024172308&amp;pubNum=0000506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_1350&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1350"><em>Prometheus Labs., Inc. v. Mayo Collaborative Servs.,</em> 628 F.3d 1347, 1350 (Fed.Cir.2010)</a>, <em>rev'd,</em> <a id="co_link_Iaa783e40afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">––– U.S. ––––, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)</a>). Alternatively, the court continued, even if the claims could be read to include the transformations associated with isolating and sequencing human DNA, these transformations would constitute no more than preparatory data-gathering steps. <a id="co_link_Iaa783e41afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2021662409&amp;pubNum=0004637&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_4637_236&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_236"><em>Id.</em> at 236</a> (citing <a id="co_link_Iaa783e42afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1989156874&amp;pubNum=0000350&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_350_840&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_840"><em>In re Grams,</em> 888 F.2d 835, 840 (Fed.Cir.1989)</a>). Finally, the court held that the one method claim to “comparing” the growth rate of cells claimed a basic scientific principle and that the transformative steps amounted to only preparatory data gathering. <a id="co_link_Iaa783e43afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2021662409&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 237.</a></div></div><div class="co_paragraph"><div class="co_paragraphText">Myriad appealed. We have jurisdiction pursuant to <a id="co_link_Iaa783e44afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS1295&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_7b9b000044381">28 U.S.C. § 1295(a)(1)</a>.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768ddcafef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">Discussion</span></div><div class="co_headtext co_hAlign2">I. Declaratory Judgment Jurisdiction</div><div class="co_headtext co_hAlign2"><span class="co_smallCaps">A.</span></div><div class="co_paragraph"><div class="co_paragraphText">The first question we must address is whether the district court correctly exercised declaratory judgment jurisdiction over this suit. The Declaratory Judgment Act provides that, “In a case of actual controversy within its jurisdiction ... any court of the United States ... may declare the rights and other legal relations of any interested party seeking such declaration, whether or not further relief is or could be sought.” <a id="co_link_Iaa783e45afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=28USCAS2201&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_8b3b0000958a4">28 U.S.C. § 2201(a)</a>. The phrase “a case of actual controversy” in the Act refers to the types of “cases” and “controversies” that are justiciable under  <span class="co_starPage" id="co_pp_sp_506_1318"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1318&quot; }" alt="metadata" type="hidden">*1318</span> Article III of the U.S. Constitution. <a id="co_link_Iaa783e47afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1937122322&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Aetna Life Ins. v. Haworth,</em> 300 U.S. 227, 239–40, 57 S.Ct. 461, 81 L.Ed. 617 (1937)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Although no bright-line rule exists for determining whether a declaratory judgment action satisfies Article Ill's case-or-controversy requirement, the Supreme Court has held that the dispute must be “definite and concrete, touching the legal relations of parties having adverse legal interests,” “real and substantial,” and “admi[t] of specific relief through a decree of a conclusive character, as distinguished from an opinion advising what the law would be upon a hypothetical state of facts.” <a id="co_link_Iaa783e48afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2011142967&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>MedImmune,</em> 549 U.S. at 127, 127 S.Ct. 764</a> (quoting <a id="co_link_Iaa783e49afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1937122322&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Aetna Life,</em> 300 U.S. at 240–41, 57 S.Ct. 461).</a> “Basically, the question in each case is whether the facts alleged, under all the circumstances, show that there is a substantial controversy, between parties having adverse legal interests, of sufficient immediacy and reality to warrant the issuance of a declaratory judgment.” <em>Id.</em> (quoting <a id="co_link_Iaa783e4bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1941124592&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Md. Cas. Co. v. Pac. Coal &amp; Oil Co.,</em> 312 U.S. 270, 273, 61 S.Ct. 510, 85 L.Ed. 826 (1941)</a>).</div></div><div class="co_paragraph"><div class="co_paragraphText">In applying <em>MedImmune's</em> all-the-circumstances test to a declaratory judgment action, we are guided by the Supreme Court's three-part framework for determining whether an action presents a justiciable Article III controversy: standing, ripeness, and mootness. <em>See </em><a id="co_link_Iaa783e4eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2015647167&amp;pubNum=0000506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_1291&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1291"><em>Caraco Pharm. Labs., Ltd. v. Forest Labs., Inc.,</em> 527 F.3d 1278, 1291 (Fed.Cir.2008)</a>. In this case, the parties have framed the jurisdictional issue as one of standing. <em>See </em><a id="co_link_Iaa783e4fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2011142967&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>MedImmune,</em> 549 U.S. at 128 n. 8, 127 S.Ct. 764.</a> (“The justiciability problem that arises, when the party seeking declaratory relief is himself preventing the complained-of injury from occurring, can be described in terms of standing ... or ... ripeness.” (internal citations omitted)).</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F12028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF1">1</a><a id="co_anchor_B12028417793"></a> “[T]he irreducible constitutional minimum of standing contains three elements.” <a id="co_link_Iaa783e50afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1992106162&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Lujan v. Defenders of Wildlife,</em> 504 U.S. 555, 560, 112 S.Ct. 2130, 119 L.Ed.2d 351 (1992)<input id="co_docMarker_13" type="hidden"></a>. “First, the plaintiff must have suffered an injury in fact—an invasion of a legally protected interest which is (a) concrete and particularized, and (b) actual or imminent, not conjectural or hypothetical.” <em>Id.</em> (internal citations and quotations omitted). “Second, there must be a causal connection between the injury and the conduct complained of—the injury has to be ‘fairly ... trace [able] to the challenged action of the defendant....’ ” <a id="co_link_Iaa783e52afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1992106162&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> (quoting <a id="co_link_Iaa783e53afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1976142383&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Simon v. E. Ky. Welfare Rights Org.,</em> 426 U.S. 26, 41–42, 96 S.Ct. 1917, 48 L.Ed.2d 450 (1976)</a>). “Third, it must be ‘likely,’ as opposed to merely ‘speculative,’ that the injury will be ‘redressed by a favorable decision.’ ” <a id="co_link_Iaa783e54afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1992106162&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 561, 112 S.Ct. 2130</a> (quoting <a id="co_link_Iaa783e55afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1976142383&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Simon,</em> 426 U.S. at 38, 43, 96 S.Ct. 1917).</a></div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F22028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF2">2</a><a id="co_anchor_B22028417793"></a><a href="#co_anchor_F32028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF3">3</a><a id="co_anchor_B32028417793"></a> “Whether an actual case or controversy exists so that a district court may entertain an action for a declaratory judgment of non-infringement and/or invalidity is governed by Federal Circuit law.” <a id="co_link_Iaa783e56afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2006712955&amp;pubNum=0000506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_1378&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1378"><em>MedImmune, Inc. v. Centocor, Inc.,</em> 409 F.3d 1376, 1378 (Fed.Cir.2005)</a>, <em>overruled on other grounds, </em><a id="co_link_Iaa783e57afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2011142967&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>MedImmune,</em> 549 U.S. at 130–31, 127 S.Ct. 764.</a> Following <em>MedImmune,</em> this court has held that, to establish an injury in fact traceable to the patentee, a declaratory judgment plaintiff must allege both (1) an affirmative act by the patentee related to the enforcement of his patent rights, <a id="co_link_Iaa783e59afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2011771224&amp;pubNum=0000506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_1380&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1380"><em>SanDisk Corp. v. STMicroelecs., Inc.,</em> 480 F.3d 1372, 1380–81 (Fed.Cir.2007)</a>, and (2) meaningful preparation to conduct potentially infringing activity, <a id="co_link_Iaa783e5aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2016188934&amp;pubNum=0000506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_880&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_880"><em>Cat Tech LLC v. TubeMaster, Inc.,</em> 528 F.3d 871, 880 (Fed.Cir.2008)</a>. We review the exercise of declaratory judgment jurisdiction in light of a particular set of facts <em>de novo. </em><a id="co_link_Iaa783e5bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2011771224&amp;pubNum=0000506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_1377&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1377"><em>SanDisk Corp.,</em> 480 F.3d at 1377</a>.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768dddafef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps"> <span class="co_starPage" id="co_pp_sp_506_1319"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1319&quot; }" alt="metadata" type="hidden">*1319</span> B.</span></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F42028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF4">4</a><a id="co_anchor_B42028417793"></a> Myriad challenges the district court's jurisdictional decision on the grounds that Myriad and the Plaintiffs do not have adverse legal interests and that Plaintiffs have failed to allege a controversy of sufficient immediacy and reality to warrant the issuance of a declaratory judgment. Specifically, Myriad argues that Plaintiffs have failed to allege any “affirmative acts” by Myriad within the past ten years relating to the patents in suit or directed at any Plaintiff. According to Myriad, the district court erred by relying on “stale communications” directed at Drs. Kazazian, Ganguly, and Ostrer over a decade ago, as well as ten-year-old licensing and litigation activities directed at third parties, and thus exercised jurisdiction based solely on Plaintiffs' subjective fear of suit, arising from rumor and innuendo in the research community.</div></div><div class="co_paragraph"><div class="co_paragraphText">Plaintiffs respond that they have standing under <em>MedImmune's</em> all-the-circumstances test because, not only are they undisputedly prepared to immediately undertake potentially infringing activities, but also Myriad took sufficient affirmative acts with respect to the patents in suit. Regarding the latter, Plaintiffs assert that Myriad sued, threatened to sue, or demanded license agreements from every known institution offering <em>BRCA</em> clinical testing, including university labs directed by plaintiffs Kazazian, Ganguly, and Ostrer, forcing each to cease such testing. And, according to Plaintiffs, the awareness of Myriad's vigorous assertion of its patent rights still continues to suppress their ability to perform clinical <em>BRCA</em> testing, placing Plaintiffs in the very dilemma the Declaratory Judgment Act was intended to address: they must either proceed with <em>BRCA</em>-related activities and risk liability for patent infringement, or refrain from such activities despite believing Myriad's patents are invalid.<input id="co_docMarker_14" type="hidden"></div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F52028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF5">5</a><a id="co_anchor_B52028417793"></a> Under the facts alleged in this case, we conclude that one Plaintiff, Dr. Ostrer, has established standing to maintain this declaratory judgment suit. All Plaintiffs claim standing under the Declaratory Judgment Act based on the same alleged injury: that they cannot undertake the <em>BRCA</em>-related activities that they desire because of Myriad's enforcement of its patent rights covering <em>BRCA1/2.</em><sup id="co_footnoteReference_B00772028417793_ID0E4BDI"><a href="#co_footnote_B00772028417793" class="co_footnoteReference">7</a></sup> Only three plaintiffs, however, allege an injury traceable to Myriad; only Drs. Kazazian, Ganguly, and Ostrer allege affirmative patent enforcement actions directed at them by Myriad. Of these three, Dr. Ostrer clearly alleges a sufficiently real and imminent injury because he alleges an intention to actually and immediately engage in allegedly infringing <em>BRCA</em>-related activities. We address each in turn.</div></div><div class="co_paragraph"><div class="co_paragraphText">Although <em>MedImmune</em> relaxed this court's more restrictive “reasonable apprehension of suit” test for declaratory judgment jurisdiction, <a id="co_link_Iaa783e5fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2011771224&amp;pubNum=506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_1380&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1380"><em>SanDisk,</em> 480 F.3d at 1380,</a> it did not alter “the bedrock rule that a case or controversy must be based on a <em>real</em> and <em>immediate</em> injury or threat of future injury that is <em>caused by the defendants,</em>” <a id="co_link_Iaa783e60afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2016764215&amp;pubNum=0000506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_1339&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1339"><em>Prasco, LLC v. Medicis Pharm. Corp.,</em> 537 F.3d 1329, 1339 (Fed.Cir.2008)</a>. Accordingly, following <em>MedImmune,</em> this court has continued to hold that declaratory judgment jurisdiction will not arise merely on the basis that a party learns of  <span class="co_starPage" id="co_pp_sp_506_1320"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1320&quot; }" alt="metadata" type="hidden">*1320</span> the existence of an adversely held patent, or even perceives that such a patent poses a risk of infringement, in the absence of some affirmative act by the patentee. <a id="co_link_Iaa783e62afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2011771224&amp;pubNum=506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_1380&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1380"><em>SanDisk,</em> 480 F.3d at 1380–81.</a> Thus, without defining the outer boundaries of declaratory judgment jurisdiction, we have held that “where a patentee asserts rights under a patent based on certain identified ongoing or planned activity of another party, and where that party contends that it has the right to engage in the accused activity without license, an Article III case or controversy will arise....” <a id="co_link_Iaa783e64afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2011771224&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1381;</a> <em>see also </em><a id="co_link_Iaa783e65afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2016764215&amp;pubNum=0000506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_1338&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1338"><em>Prasco,</em> 537 F.3d at 1338</a> (“A patentee can cause ... an injury [sufficient to create an actual controversy] in a variety of ways, for example, by creating a reasonable apprehension of an infringement suit, [or] demanding the right to royalty payments.” (internal citations omitted)).</div></div><div class="co_paragraph"><div class="co_paragraphText">In this case, Myriad demanded a royalty under its patents from Dr. Ostrer based on his clinical <em>BRCA</em>-related activities. In May 1998, Myriad's Director of Corporate Communications sent Ostrer a letter proposing a collaborative license. The letter stated that Myriad was aware that Ostrer was either currently providing, or was interested in initiating, <em>BRCA1</em> diagnostic testing services and that Myriad, as holder of U.S. patents covering the <em>BRCA1</em> gene and diagnostic testing of <em>BRCA1,</em> was making available to his institution, NYU Medical Center, a limited collaborative license. The collaborative license required NYU to make a payment to Myriad for each non-research <em>BRCA</em> test performed.</div></div><div class="co_paragraph"><div class="co_paragraphText">At the same time, as Ostrer was aware, Myriad was asserting its patent rights against other similarly situated parties, a fact to be considered in assessing the existence of an actual controversy under the totality of circumstances. <em>See </em><a id="co_link_Iaa783e66afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2015367384&amp;pubNum=0000506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_901&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_901"><em>Micron Tech., Inc. v. Mosaid Techs., Inc.,</em> 518 F.3d 897, 901 (Fed.Cir.2008)</a>. Soon after Ostrer received Myriad's letter, Dr. Kazazian informed him that, because of Myriad's assertion of its patent rights against him, GDL would no longer be accepting patient samples for <em>BRCA</em> genetic testing. Myriad's assertion of its patent rights against Kazazian escalated into a patent infringement suit by Myriad against the University of Pennsylvania, which was later dismissed without prejudice after the University agreed to cease all accused <input id="co_docMarker_15" type="hidden"><em>BRCA</em> testing services. Myriad also sued Oncormed for patent infringement based on its <em>BRCA</em> genetic testing services. As a result of Myriad's patent enforcement actions, Dr. Ostrer was forced to send all patient samples to Myriad, now the sole provider of <em>BRCA</em> diagnostic testing services.</div></div><div class="co_paragraph"><div class="co_paragraphText">Dr. Ostrer, on the other hand, maintains that he could have proceeded with his <em>BRCA</em>-related clinical activities without taking a license from Myriad. This assertion is based on his belief that the patents Myriad claims cover such activities are invalid because genes are patent-ineligible products of nature. Acting on his belief, Ostrer seeks in this lawsuit a declaration of his right to undertake <em>BRCA</em>-related clinical activities without a license. Accordingly, Myriad and Dr. Ostrer have taken adverse legal positions regarding whether or not Ostrer can engage in <em>BRCA</em> genetic testing without infringing any valid claim to “isolated” <em>BRCA</em> DNAs or methods of “analyzing” or “comparing” <em>BRCA</em> sequences, as recited in Myriad's patents. <em>See </em><a id="co_link_Iaa783e67afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1937122322&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Aetna Life,</em> 300 U.S. at 242, 57 S.Ct. 461</a> (holding declaratory judgment jurisdiction existed when “the parties had taken adverse positions with respect to their existing obligations” on an insurance contract).</div></div><div class="co_paragraph"><div class="co_paragraphText">Dr. Ostrer has also alleged a controversy of sufficient reality and immediacy,  <span class="co_starPage" id="co_pp_sp_506_1321"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1321&quot; }" alt="metadata" type="hidden">*1321</span> <a id="co_link_Iaa783e68afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2011142967&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>MedImmune,</em> 549 U.S. at 127, 127 S.Ct. 764;</a> he has alleged a concrete and actual injury traceable to Myriad's assertion of its patent rights, <em>see </em><a id="co_link_Iaa783e69afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1992106162&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Lujan,</em> 504 U.S. at 560, 112 S.Ct. 2130.</a> First, Ostrer seeks to undertake specific <em>BRCA</em>-related activities—<em>BRCA</em> diagnostic testing—for which Myriad has demanded a license under specific patents—those that cover the isolated <em>BRCA</em> genes and <em>BRCA</em> diagnostic testing. Thus, Ostrer does not request “an opinion advising what the law would be upon a hypothetical state of facts,” <a id="co_link_Iaa783e6aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1937122322&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Aetna Life,</em> 300 U.S. at 241, 57 S.Ct. 461,</a> but rather whether his proposed <em>BRCA</em> testing services are covered by valid patent claims to “isolated” <em>BRCA</em> genes and methods of “comparing” the genes' sequences. Second, Ostrer not only has the resources and expertise to immediately undertake clinical <em>BRCA</em> testing, but also states unequivocally that he will immediately begin such testing. In contrast to Ostrer, who alleges an actual and imminent injury for purposes of standing, Drs. Kazazian and Ganguly allege only that they will “consider” resuming <em>BRCA</em> testing. These “ ‘some day’ intentions” are insufficient to support an “actual or imminent” injury for standing “without ... any specification of <em>when</em> the some day will be.” <a id="co_link_Iaa783e6bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1992106162&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Lujan,</em> 504 U.S. at 564, 112 S.Ct. 2130.</a> As a result, Drs. Kazazian and Ganguly do not have standing.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F62028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF6">6</a><a id="co_anchor_B62028417793"></a> Myriad seeks to avoid this result based on the timing of its enforcement actions. Specifically, Myriad argues that time has extinguished the immediacy and reality of any controversy, relying on language that hearkens back to our pre-<em>MedImmune</em> reasonable apprehension of suit test. <em>See, e.g.,</em> <a id="co_link_Iaa783e6dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2023743738&amp;pubNum=999&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Appellants' Br., 2010 WL 4600106, at 26</a> (“[A] patentee's ten-year silence presumptively extinguishes any reasonable objective fear of suit.”). We disagree. In many cases a controversy made manifest by a patentee's affirmative assertion of its patent rights will dissipate as market players and products change. In this case, however, the relevant circumstances surrounding Myriad's assertion of its patent rights have not changed despite the passage of time.<sup id="co_footnoteReference_B00882028417793_ID0EXQDI"><a href="#co_footnote_B00882028417793" class="co_footnoteReference">8</a></sup></div></div><div class="co_paragraph"><div class="co_paragraphText">Myriad's active enforcement of its patent rights forced Dr. Ostrer, as well as every other similarly situated researcher and institution, to cease performing the challenged <input id="co_docMarker_16" type="hidden"><em>BRCA</em> testing services, leaving Myriad as the sole provider of <em>BRCA</em> clinical testing to patients in the United States. Since that time, neither the accused activities nor the parties' positions have changed. First, Myriad does not allege that genetic testing technology has changed in any way that renders its past assertions of its patent rights irrelevant to Ostrer's currently proposed <em>BRCA</em> testing. Rather, the patents cover, as Myriad asserted in the late 1990s, the basic components of any such test: the isolated <em>BRCA</em> genes and the diagnostic step of comparing the genes' sequences.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F72028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF7">7</a><a id="co_anchor_B72028417793"></a><a href="#co_anchor_F82028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF8">8</a><a id="co_anchor_B82028417793"></a> Second, ever since Myriad's enforcement efforts eliminated all competition, Myriad and Ostrer have not altered their respective positions. Ostrer, still laboring under Myriad's threat of infringement liability, has not attempted to provide <em>BRCA</em> testing; yet, as a researcher, he remains in the same position with respect to his ability and his desire to provide <em>BRCA</em> testing as in the late 1990s. Furthermore, nothing in the record suggests that any researcher or institution has  <span class="co_starPage" id="co_pp_sp_506_1322"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1322&quot; }" alt="metadata" type="hidden">*1322</span> successfully attempted to compete with Myriad, or that Myriad has in any way changed its position with regard to its patent rights. Just as active enforcement of one's patent rights against others can maintain a real and immediate controversy despite the passage of time, <em>see </em><a id="co_link_Iaa783e6fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2015367384&amp;pubNum=506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_901&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_901"><em>Micron,</em> 518 F.3d at 901,</a> so too can the successful assertion of such rights when the relevant circumstances remain unchanged. Thus, consistent with the purpose of the Declaratory Judgment Act, Ostrer need not risk liability and treble damages for patent infringement before seeking a declaration of his contested legal rights. <em>See </em><a id="co_link_Iaa783e70afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2011142967&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>MedImmune,</em> 549 U.S. at 134, 127 S.Ct. 764</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Myriad also argues that the record refutes Ostrer's claim that he has been restrained from engaging in <em>BRCA</em>-related gene sequencing. Specifically, Myriad argues that since Myriad published its discoveries of the <em>BRCA1</em> and <em>BRCA2</em> genes in October 1994 and March 1996, respectively, over 18,000 scientists have conducted research on the <em>BRCA</em> genes and over 8,600 research papers have been published. Furthermore, according to Myriad, plaintiff Wendy Chung concedes that her lab currently conducts sequencing of <em>BRCA</em> genes. Yet, both Drs. Chung and Ostrer state that, although they conduct gene sequencing, they are forbidden from informing their research subjects of the results of their <em>BRCA</em> tests without first sending the samples to Myriad. Accordingly, Ostrer is restrained from the <em>BRCA</em>-related activity that he desires to undertake: clinical diagnostic testing.</div></div><div class="co_paragraph"><div class="co_paragraphText">Myriad's communications with Dr. Ostrer confirm this understanding. The licensing letter Myriad sent to Ostrer proposed a collaborative agreement giving NYU the right to perform “Research Tests” without payment to Myriad. J.A. 2967. “Research Tests” are defined as tests that further “non-commercial research programs, the results of which <em>are not provided to the patient</em> and for which no money is received.” J.A. 2965 (emphasis added). In contrast, the agreement requires payment to Myriad for each “Testing Service” performed, with “Testing Services” defined as “medical laboratory testing ... for the presence or absence of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ib0dd2702475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ib0dd2702475411db9765f9243f53508a">BRCA1 mutations</a> for the purpose of determining or predicting predisposition to, or assessing the risk of breast or ovarian <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_14">cancer</a> in humans.” J.A. 2966–67. Thus, Myriad's patent enforcement actions never targeted the non-clinical <em>BRCA</em> research now cited by Myriad, and Ostrer's ability to perform such research does not address the injury asserted here.<input id="co_docMarker_17" type="hidden"></div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F92028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF9">9</a><a id="co_anchor_B92028417793"></a> Finally, Myriad argued in its reply brief and at oral argument that Plaintiffs' declaratory action will not afford them the relief they want, a requirement for standing. <a id="co_link_Iaa783e73afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1992106162&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Lujan,</em> 504 U.S. at 560–61, 112 S.Ct. 2130;</a> <em>see also </em><a id="co_link_Iaa783e74afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2011142967&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>MedImmune,</em> 549 U.S. at 127 n. 7, 127 S.Ct. 764</a> (“[A] litigant may not use a declaratory-judgment action to obtain piecemeal adjudication of defenses that <em>would not finally and conclusively resolve</em> the underlying controversy.”). Specifically, Myriad asserts that because Plaintiffs have challenged just fifteen composition and method claims, while admitting that other unchallenged claims to <em>BRCA</em> probes and primers will still prevent them from engaging in <em>BRCA</em> sequencing, a favorable decision will not redress the Plaintiffs' alleged injury. Again, we disagree.</div></div><div class="co_paragraph"><div class="co_paragraphText">The Supreme Court has required only that it is “likely,” rather than “merely ‘speculative,’ ” that the alleged injury will be “redressed by a favorable decision.” <a id="co_link_Iaa783e75afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1992106162&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Lujan,</em> 504 U.S. at 561, 112 S.Ct. 2130.</a> The Court has not required certainty. For example, in <em>Village of Arlington Heights v. Metropolitan Housing Development Corp.,</em> the Court held that the plaintiffs had standing to challenge a suburb's  <span class="co_starPage" id="co_pp_sp_506_1323"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1323&quot; }" alt="metadata" type="hidden">*1323</span> exclusionary zoning ordinance, as the ordinance stood as “an absolute barrier” to the housing development Metropolitan Housing Development Corp. (“MHDC”) had contracted to provide in the village. <a id="co_link_Iaa783e77afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977118707&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">429 U.S. 252, 261, 97 S.Ct. 555, 50 L.Ed.2d 450 (1977)</a>. The Court noted that injunctive relief, while removing the “barrier” of the ordinance, would not “guarantee” that the housing would be built since MHDC still had to secure financing, qualify for federal subsidies, and carry through with construction. <em>Id.</em> The Court nevertheless recognized that “all housing developments are subject to some extent to similar uncertainties,” and concluded that it was sufficient that there was a “substantial probability” that the housing development would be built. <a id="co_link_Iaa783e79afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977118707&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 261, 264, 97 S.Ct. 555.</a></div></div><div class="co_paragraph"><div class="co_paragraphText">In this case, Myriad's challenged composition and method claims undisputedly provide “an absolute barrier” to Dr. Ostrer's ability to undertake <em>BRCA</em> diagnostic testing activities, and a declaration of those claims' invalidity would remove that barrier. <em>See </em><a id="co_link_Iaa783e7aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1977118707&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>id.</em> at 261, 97 S.Ct. 555.</a> Moreover, while there may be other patent claims directed to <em>BRCA</em> probes and primers that prevent Ostrer from performing <em>BRCA</em> diagnostic testing free of infringement liability, Myriad has failed to direct us to any specific unchallenged claim that will have that effect. And Plaintiffs' counsel stated at the first oral argument in this case that his clients can sequence the <em>BRCA</em> genes without using <em>BRCA</em> probes and primers. Oral Arg. at 34:07–25, 34:53–35:29 <em>available at</em> http://www.cafc.uscourts.gov/oral–argument–recordings/2010–1406/all. Accordingly, we decline to construe the asserted claims and decline to hold on this record that Dr. Ostrer's proposed <em>BRCA</em>-related activities would infringe unchallenged claims to primers and probes. We thus conclude that it is likely, not merely speculative, that Dr. Ostrer's injury will be redressed by a favorable decision.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F102028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF10">10</a><a id="co_anchor_B102028417793"></a><a href="#co_anchor_F112028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF11">11</a><a id="co_anchor_B112028417793"></a> Although we affirm the district court's decision to exercise declaratory judgment jurisdiction over this case, we do so on narrower grounds. The district court failed to limit its jurisdictional holding to affirmative acts by the patentee directed at specific Plaintiffs, <em>see </em><a id="co_link_Iaa783e7bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2011771224&amp;pubNum=506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_1380&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1380"><em>SanDisk,</em> 480 F.3d at 1380–81,</a> erroneously holding all the Plaintiffs had standing based on “the widespread understanding that one may engage in <input id="co_docMarker_18" type="hidden"><em>BRCA1/2</em> testing at the risk of being sued for infringement liability by <a id="co_link_Iaa783e7cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2020295212&amp;pubNum=0004637&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_4637_390&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_390">Myriad,” <em>DJ Op.,</em> 669 F.Supp.2d at 390</a>. We disagree, and thus we reverse the district court's holding that the various plaintiffs other than Dr. Ostrer have standing to maintain this declaratory judgment action. Simply disagreeing with the existence of a patent on isolated DNA sequences or even suffering an attenuated, non-proximate, effect from the existence of a patent does not meet the Supreme Court's requirement for an adverse legal controversy of sufficient immediacy and reality to warrant the issuance of a declaratory judgment. <em>See </em><a id="co_link_Iaa783e7dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2011142967&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>MedImmune,</em> 549 U.S. at 127, 127 S.Ct. 764.</a> The various organizational plaintiffs in this suit in particular were not the target of any enforcement action or offered license agreements by Myriad and had made no preparation to undertake potentially infringing activities. They accordingly suffered no injury and thus lack standing to bring this action. <em>See </em><a id="co_link_Iaa783e7eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2016764215&amp;pubNum=506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_1338&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1338"><em>Prasco,</em> 537 F.3d at 1338–42;</a> <a id="co_link_Iaa783e7fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2016188934&amp;pubNum=0000506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_880&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_880"><em>Cat Tech,</em> 528 F.3d at 880–81</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Having found one plaintiff with standing to maintain this declaratory judgment action, <em>see </em><a id="co_link_Iaa783e80afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2019199716&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_2592&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_2592"><em>Horne v. Flores,</em> 557 U.S. 433, 129 S.Ct. 2579, 2592–93, 174 L.Ed.2d 406 (2009)</a>, we may turn now to the merits of Myriad's appeal of the district court's summary judgment decision, which held all fifteen challenged composition and method claims invalid under <a id="co_link_Iaa783e81afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768ddeafef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"> <span class="co_starPage" id="co_pp_sp_506_1324"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1324&quot; }" alt="metadata" type="hidden">*1324</span> II. Subject Matter Eligibility</div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F122028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF12">12</a><a id="co_anchor_B122028417793"></a> Under the Patent Act, “Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.” <a id="co_link_Iaa783e82afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 101</a>. The Supreme Court has consistently construed <a id="co_link_Iaa783e83afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> broadly, explaining that “[i]n choosing such expansive terms ... modified by the comprehensive ‘any,’ Congress plainly contemplated that the patent laws would be given wide scope.” <a id="co_link_Iaa783e84afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2022394590&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_3225&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_3225"><em>Bilski v. Kappos,</em> ––– U.S. ––––, 130 S.Ct. 3218, 3225, 177 L.Ed.2d 792 (2010)</a> (quoting <a id="co_link_Iaa783e85afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 308, 100 S.Ct. 2204).</a></div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F132028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF13">13</a><a id="co_anchor_B132028417793"></a> The Supreme Court, however, has also consistently held that <a id="co_link_Iaa783e86afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>, although broad, is not unlimited. <a id="co_link_Iaa783e87afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2022394590&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> The Court's precedents provide three judicially created exceptions to <a id="co_link_Iaa783e88afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>'s broad patent-eligibility principles: “ ‘Laws of nature, natural phenomena, and abstract ideas' are not patentable.” <a id="co_link_Iaa783e89afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_1293&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_1293"><em>Mayo,</em> 132 S.Ct. at 1293</a> (quoting <a id="co_link_Iaa783e8aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1981109598&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Diamond v. Diehr,</em> 450 U.S. 175, 185, 101 S.Ct. 1048, 67 L.Ed.2d 155 (1981)</a>). The Court has also referred to those exceptions as precluding the patenting of mental processes, <a id="co_link_Iaa783e8bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1972137547&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Gottschalk v. Benson,</em> 409 U.S. 63, 67, 93 S.Ct. 253, 34 L.Ed.2d 273 (1972)</a>, and products of nature, <a id="co_link_Iaa783e8cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 313, 100 S.Ct. 2204</a> (“[T]he relevant distinction for purposes of <a id="co_link_Iaa783e8dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> is ... between products of nature ... and human-made inventions.”). The Court has explained that, although not required by the statutory text, “[t]he concepts covered by these exceptions are ‘part of the storehouse of knowledge of all men ... free to all men and reserved exclusively to none.’ ” <a id="co_link_Iaa783e8eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2022394590&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_3225&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_3225"><em>Bilski,</em> 130 S.Ct. at 3225</a> (quoting <a id="co_link_Iaa783e8fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Funk Bros. Seed Co. v. Kalo Inoculant Co.,</em> 333 U.S. 127, 130, 68 S.Ct. 440, 92 L.Ed. 588 (1948)</a>).</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F142028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF14">14</a><a id="co_anchor_B142028417793"></a> Plaintiffs challenge under <a id="co_link_Iaa783e90afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> Myriad's composition claims directed to “isolated” DNA molecules, its method claims directed to “analyzing” or “comparing” DNA sequences, and its claim to a method for screening potential <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_15">cancer</a> therapeutics. We address each in turn. Before reviewing the applicability of the Supreme Court's <input id="co_docMarker_19" type="hidden"><em>Mayo</em> holding to the claims of the Myriad patents, however, it is important to state what this appeal is not about. It is not about whether individuals suspected of having an increased risk of developing <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ib73a5554475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ib73a5554475411db9765f9243f53508a_1">breast cancer</a> are entitled to a second opinion. Nor is it about whether the University of Utah, the owner of the instant patents, or Myriad, the exclusive licensee, has acted improperly in its licensing or enforcement policies with respect to the patents. The question is also not whether is it desirable for one company to hold a patent or license covering a test that may save people's lives, or for other companies to be excluded from the market encompassed by such a patent—that is the basic right provided by a patent, <em>i.e.,</em> to exclude others from practicing the patented subject matter. It is also not whether the claims at issue are novel or nonobvious or too broad. Those questions are not before us. It is solely whether the claims to isolated BRCA DNA, to methods for comparing DNA sequences, and to a process for screening potential <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_16">cancer</a> therapeutics meet the threshold test for patent-eligible subject matter under <a id="co_link_Iaa783e96afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 101</a> in light of various Supreme Court holdings, particularly including <em>Mayo</em>. The issue is patent eligibility, not patentability.</div></div><div class="co_paragraph"><div class="co_paragraphText">We would further note, in the context of discussing what this case is not about, that patents on life-saving material and processes, involving large amounts of risky investment, would seem to be precisely the types of subject matter that should be subject to the incentives of exclusive rights. But disapproving of patents on  <span class="co_starPage" id="co_pp_sp_506_1325"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1325&quot; }" alt="metadata" type="hidden">*1325</span> medical methods and novel biological molecules are policy questions best left to Congress, and other general questions relating to patentability and use of patents are issues not before us. As will be seen, on the limited questions before us, we conclude that the composition claims and the screening claim involving growing a transformed host cell meet the standards for patent eligibility, while the claimed methods for “analyzing” or “comparing” do not.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768ddfafef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2">A. Composition Claims: Isolated DNA Molecules</div><div class="co_headtext co_hAlign2">i.</div><div class="co_paragraph"><div class="co_paragraphText">The principal claims of the patents before us on remand relate to isolated DNA molecules. <em>Mayo</em> does not control the question of patent-eligibility of such claims. They are claims to compositions of matter, expressly authorized as suitable patent-eligible subject matter in <a id="co_link_Iaa783e99afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>. As to those claims, the issue of patent-eligibility remains, as it was on the first appeal to this court, whether they claim patent-ineligible products of nature. We hold that they do not. The isolated DNA molecules before us are not found in nature. They are obtained in the laboratory and are man-made, the product of human ingenuity. While they are prepared from products of nature, so is every other composition of matter. All new chemical or biological molecules, whether made by synthesis or decomposition, are made from natural materials. For example, virtually every medicine utilized by today's medical practitioners, and every manufactured plastic product, is either synthesized from natural materials (most often petroleum fractions) or derived from natural plant materials. But, as such, they are different from natural materials, even if they are ultimately derived from them. The same is true of isolated DNA molecules.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768de0afef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2">ii.</div><div class="co_paragraph"><div class="co_paragraphText">Myriad argues that its challenged composition claims to “isolated” DNAs cover patent-eligible compositions of matter within the meaning of <a id="co_link_Iaa783e9aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>. According to Myriad, the district court came to a contrary conclusion by (1) misreading Supreme Court precedent as excluding from patent eligibility all “products of nature” unless “markedly different” from naturally occurring ones; and (2) incorrectly focusing not on the differences between isolated and native DNAs, but on one similarity: their informational content. Rather, Myriad argues, an isolated DNA molecule is patent eligible because it is, as claimed, <input id="co_docMarker_20" type="hidden">“a nonnaturally occurring manufacture or composition of matter” with “a distinctive name, character, and use.” <a id="co_link_Iaa783e9bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2023743738&amp;pubNum=999&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Appellants' Br., 2010 WL 4600106, at 41–42</a> (quoting <a id="co_link_Iaa783e9cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 309–10, 100 S.Ct. 2204).</a> Myriad contends that isolated DNA does not exist in nature and that isolated DNAs, unlike native DNAs, can be used as primers and probes for diagnosing <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_17">cancer</a>. Moreover, Myriad asserts that an ultimately-derived-from “products of nature” exception not only would be unworkable, as every composition of matter is, at some level, composed of natural materials, but also would be contrary to this court's precedents, the PTO's 2001 <em>Utility Examination Guidelines,</em> and Congress's role in enacting the patent laws. Regarding <em>Mayo</em>, Myriad argues that the Supreme Court's decision did not address or alter the established patent-eligibility test for composition claims, such that the standards announced in <em>Chakrabarty</em> still govern this appeal. To the extent that the general principles discussed in <em>Mayo</em> bear on the DNA claims, Myriad maintains that isolated DNA represents a nonnatural, man-made invention distinct from the lack of human ingenuity underlying the method claims there at issue.</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_506_1326"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1326&quot; }" alt="metadata" type="hidden">*1326</span> Plaintiffs respond that claims to isolated DNA molecules fail to satisfy <a id="co_link_Iaa783ea1afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> because such claims cover natural phenomena and products of nature. According to Plaintiffs, Supreme Court precedent establishes that a product of nature is not patent eligible even if, as claimed, it has undergone some highly useful change from its natural form. Rather, Plaintiffs assert, to be patent eligible a composition of matter must also have a distinctive name, character, and use, making it “markedly different” from the natural product. In this case, Plaintiffs conclude that because isolated DNAs retain part of the same nucleotide sequence as native DNAs, they do not have any “markedly different” characteristics. Furthermore, according to Plaintiffs, the isolated DNA claims preempt products and laws of nature, excluding anyone from working with the <em>BRCA</em> genes and the genetic information they convey. Under <em>Mayo</em>, Plaintiffs assert that any structural differences relative to the chromosomal <em>BRCA</em> genes do not add “enough” to the underlying natural genetic sequences to render Myriad's isolated DNA molecules patentable under <a id="co_link_Iaa783ea3afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The government as amicus curiae does not defend the longstanding position of the PTO, a government agency, that isolated DNA molecules are patent eligible, arguing instead for a middle ground. Specifically, the government argues that DNA molecules engineered by man, including cDNAs,<sup id="co_footnoteReference_B00992028417793_ID0EYVAK"><a href="#co_footnote_B00992028417793" class="co_footnoteReference">9</a></sup> are patent-eligible compositions of matter because, with rare exceptions, they do not occur in nature, either in isolation or as contiguous sequences within a chromosome. In contrast, the government asserts, isolated and unmodified genomic DNAs are <em>not</em> patent eligible, but rather patent-ineligible products of nature, since their nucleotide sequences exist because of evolution, not man.</div></div><div class="co_paragraph"><div class="co_paragraphText">At the first oral argument, the government illustrated its position by way of a so-called “magic microscope” test (an invention in and of itself, although probably not patent-eligible). Oral Arg. at 46:50–47:50. According to the government's test then, if an imaginary microscope could focus in on the claimed DNA molecule as it exists in the human body, the claim covers ineligible subject matter. The government thus argued that because such a microscope could focus in on the claimed isolated <input id="co_docMarker_21" type="hidden"><em>BRCA1</em> or <em>BRCA2</em> sequences as they exist in the human body, the claims covering those sequences are not patent eligible. In contrast, the government contended, because an imaginary microscope could not focus <em>in vivo</em> on a cDNA sequence, which is engineered by man to splice together non-contiguous coding sequences (<em>i.e.,</em> exons), claims covering cDNAs are patent eligible.</div></div><div class="co_paragraph"><div class="co_paragraphText">In sum, although the parties and the government appear to agree that isolated DNAs are compositions of matter, they disagree on whether and to what degree such molecules fall within the exception for products of nature. As set forth below, we conclude that the challenged claims to isolated DNAs, whether limited to cDNAs or not, are directed to patent-eligible subject matter under <a id="co_link_Iaa783ea5afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768de1afef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2">iii.</div><div class="co_paragraph"><div class="co_paragraphText">While <em>Mayo</em> and earlier decisions concerning method claim patentability provide valuable insights and illuminate broad, foundational principles, the Supreme Court's decisions in <em>Chakrabarty</em> and <em>Funk Brothers</em> set out the primary framework for deciding the patent eligibility of compositions of matter, including isolated DNA molecules.<sup id="co_footnoteReference_B010102028417793_ID0E3ZAK"><a href="#co_footnote_B010102028417793" class="co_footnoteReference">10</a></sup></div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_506_1327"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1327&quot; }" alt="metadata" type="hidden">*1327</span> In <em>Chakrabarty</em>, the Court addressed the question whether a man-made, living microorganism is a patent-eligible manufacture or composition of matter within the meaning of <a id="co_link_Iaa783eb0afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>. <a id="co_link_Iaa783eb1afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">447 U.S. at 305, 307, 100 S.Ct. 2204.</a> The microorganisms were bacteria genetically engineered with four naturally occurring DNA plasmids, each of which enabled the breakdown of a different component of crude oil. <a id="co_link_Iaa783eb2afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 305, 305 n. 1, 100 S.Ct. 2204.</a> The bacteria, as a result, could break down multiple components of crude oil, a trait possessed by no single naturally occurring bacterium and of significant use in more efficiently treating oil spills. <a id="co_link_Iaa783eb3afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 305, 305 n. 2, 100 S.Ct. 2204.</a> The Court held that the bacteria qualified as patent-eligible subject matter because the “claim is not to a hitherto unknown natural phenomenon, but to a non-naturally occurring manufacture or composition of matter—a product of human ingenuity ‘having a distinctive name, character [and] use.’ ” <a id="co_link_Iaa783eb4afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 309–10, 100 S.Ct. 2204</a> (quoting <a id="co_link_Iaa783eb5afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1887180158&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Hartranft v. Wiegmann,</em> 121 U.S. 609, 615, 7 S.Ct. 1240, 30 L.Ed. 1012 (1887)</a>).</div></div><div class="co_paragraph"><div class="co_paragraphText">To underscore the point, the Court compared Chakrabarty's engineered bacteria with the mixed <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=mproc&amp;entityId=Ia9b13752475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ia9b13752475411db9765f9243f53508a">bacterial cultures</a> found unpatentable in <em>Funk Brothers,</em> again casting this case, more relating to obviousness, in terms of <a id="co_link_Iaa783eb8afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>. <em>See </em><a id="co_link_Iaa783eb9afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1978139495&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Parker v. Flook,</em> 437 U.S. 584, 591, 98 S.Ct. 2522, 57 L.Ed.2d 451 (1978)</a>; <a id="co_link_Iaa783ebaafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1972137547&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Benson,</em> 409 U.S. at 67, 93 S.Ct. 253.</a> In <em>Funk Brothers,</em> the patentee discovered that certain strains of nitrogen-fixing bacteria associated with leguminous plants do not mutually inhibit each other. <a id="co_link_Iaa783ebcafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">333 U.S. at 129–30, 68 S.Ct. 440.</a> Based on that discovery, the patentee produced (and claimed) mixed cultures of nitrogen-fixing species capable of inoculating a broader range of leguminous plants than single-species cultures. <em>Id.</em> The Court held that the bacteria's cooperative qualities were, “like the heat of the sun, electricity, or the qualities of metals,” the “work of nature,” and thus not patentable. <a id="co_link_Iaa783ebeafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 130, 68 S.Ct. 440.</a> The Court also held that applying the newly discovered bacterial compatibility to create a mixed culture was not a patentable advance because no species acquired a different property or use. <a id="co_link_Iaa783ebfafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 131, 68 S.Ct. 440.</a> The <em>Chakrabarty</em> Court thus concluded that what distinguished Chakrabarty's oil-degrading bacteria from the mixed cultures claimed in <em>Funk Brothers,</em> and made the former patent-eligible, was that Chakrabarty's bacteria had <input id="co_docMarker_22" type="hidden">“markedly different characteristics from any [bacterium] found in nature” based on the efforts of the patentee. <a id="co_link_Iaa783ec2afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 310, 100 S.Ct. 2204</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">One distinction, therefore, between products of nature and human-made invention for purposes of <a id="co_link_Iaa783ec3afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> turns on a change in the claimed composition's identity <span class="co_starPage" id="co_pp_sp_506_1328"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1328&quot; }" alt="metadata" type="hidden">*1328</span>  compared with what exists in nature. Specifically, the Supreme Court has drawn a line between compositions that, even if arrayed in useful combinations or harnessed to exploit newly discovered properties, have similar characteristics as in nature, and compositions that human intervention has given “markedly different,” or “distinctive,” characteristics. <a id="co_link_Iaa783ec4afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> (citing <a id="co_link_Iaa783ec5afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1887180158&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Hartranft,</em> 121 U.S. at 615, 7 S.Ct. 1240);</a> <em>see also </em><a id="co_link_Iaa783ec6afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1931123423&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Am. Fruit Growers v. Brogdex Co.,</em> 283 U.S. 1, 11, 51 S.Ct. 328, 75 L.Ed. 801 (1931)</a>. Applying this test to the isolated DNAs in this case, the challenged claims are drawn to patent-eligible subject matter because the claims cover molecules that are markedly different—have a distinctive chemical structure and identity—from those found in nature.</div></div><div class="co_paragraph"><div class="co_paragraphText">It is undisputed that Myriad's claimed isolated DNAs exist in a distinctive chemical form—as distinctive chemical molecules—from DNAs in the human body, <em>i.e.,</em> native DNA. Natural DNA exists in the body as one of forty-six large, contiguous DNA molecules. Each of those DNA molecules is condensed and intertwined with various proteins, including histones, to form a complex tertiary structure known as chromatin that makes up a larger structural complex, a chromosome. <em>See supra,</em> Figure 3. Inside living cells, the chromosomes are further encapsulated within a series of membranes and suspended in a complex intracellular milieu.</div></div><div class="co_paragraph"><div class="co_paragraphText">Isolated DNA, in contrast, is a free-standing portion of a larger, natural DNA molecule. Isolated DNA has been cleaved (<em>i.e.,</em> had covalent bonds in its backbone chemically severed) or synthesized to consist of just a fraction of a naturally occurring DNA molecule. For example, the <em>BRCA1</em> gene in its native state resides on chromosome 17, a DNA molecule of around eighty million nucleotides. Similarly, <em>BRCA2</em> in its native state is located on chromosome 13, a DNA of approximately 114 million nucleotides. In contrast, isolated <em>BRCA1</em> and <em>BRCA2,</em> with introns, each consists of just 80,000 or so nucleotides. And without introns, <em>BRCA2</em> shrinks to approximately 10,200 nucleotides and <em>BRCA1</em> to just around 5,500 nucleotides. Furthermore, claims 5 and 6 of the ′<a id="co_link_Iaa783ec7afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a> cover isolated DNAs, <em>e.g.,</em> primers or probes, having as few as fifteen nucleotides of a <em>BRCA</em> sequence. Accordingly, <em>BRCA1</em> and <em>BRCA2</em> in their isolated states are different molecules from DNA that exists in the body; isolated DNA results from human intervention to cleave or synthesize a discrete portion of a native chromosomal DNA, imparting on that isolated DNA a distinctive chemical identity as compared to native DNA.</div></div><div class="co_paragraph"><div class="co_paragraphText">As the above description indicates, isolated DNA is not just purified DNA. Purification makes pure what was the same material, but was combined, or contaminated, with other materials. Although isolated DNA is removed from its native cellular and chromosomal environment, it has also been manipulated chemically so as to produce a molecule that is markedly different from that which exists in the body. Accordingly, this is not a situation, as in <em>Parke–Davis &amp; Co. v. H.K. Mulford Co.,</em> in which purification of adrenaline resulted in the <em>identical</em> molecule, albeit being “for every practical purpose a new thing commercially and therapeutically.”<input id="co_docMarker_23" type="hidden"> <a id="co_link_Iaa783ec9afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1911104286&amp;pubNum=0000348&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_348_103&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_348_103">189 F. 95, 103 (C.C.S.D.N.Y.1911)</a>. Judge Learned Hand's opinion for the district court in that oft-cited case held the purified “Adrenalin” to be patent-eligible subject matter. <em>Id.</em> The <em>In re Marden</em> cases are similarly inapposite, directed as they are to the patent ineligibility of purified natural elements—ductile uranium, <a id="co_link_Iaa783eccafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1931126314&amp;pubNum=0000350&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">18 CCPA 1046, 47 F.2d 957 (1931)</a>, and vanadium, <a id="co_link_Iaa783ecdafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1931126315&amp;pubNum=0000350&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">18 CCPA 1057, 47 F.2d 958 (1931)</a>—that are inherently ductile in purified form. While purified natural products thus may or may not qualify for patent under <a id="co_link_Iaa783eceafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>, the isolated  <span class="co_starPage" id="co_pp_sp_506_1329"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1329&quot; }" alt="metadata" type="hidden">*1329</span> DNAs of the present patents constitute an <em>a fortiori</em> situation, where they are not only purified; they are different from the natural products in “name, character, and use.” <a id="co_link_Iaa783ecfafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 309–10, 100 S.Ct. 2204.</a><sup id="co_footnoteReference_B011112028417793_ID0E1PBK"><a href="#co_footnote_B011112028417793" class="co_footnoteReference">11</a></sup></div></div><div class="co_paragraph"><div class="co_paragraphText"><em>Parke–Davis</em> and <em>Marden</em> address a situation in which claimed compound A is purified from a physical mixture that contains compound A. In this case, the claimed isolated DNA molecules do not exist in nature within a physical mixture to be purified. They have to be chemically cleaved from their native chemical combination with other genetic materials. In other words, in nature, the claimed isolated DNAs are covalently bonded to such other materials. Thus, when cleaved, an isolated DNA molecule is not a purified form of a natural material, but a distinct chemical entity that is obtained by human intervention. <em>See </em><a id="co_link_Iaa783eddafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 313, 100 S.Ct. 2204</a> (“the relevant distinction [is] between products of nature ... and human-made inventions”). In fact, some forms of isolated DNA may require no purification at all, because DNAs can be chemically synthesized directly as isolated molecules.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F152028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF15">15</a><a id="co_anchor_B152028417793"></a> The above analysis holding the isolated DNA molecules to be patent-eligible subject matter applies to all of the asserted composition claims on appeal in this case. However, as the government has pointed out, claim 2 of the ′<a id="co_link_Iaa783edeafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a> is narrower than claim 1 and reads only on cDNAs, which lack the non-coding introns present in the genomic <em>BRCA1</em> gene.<sup id="co_footnoteReference_B012122028417793_ID0EDYBK"><a href="#co_footnote_B012122028417793" class="co_footnoteReference">12</a></sup> While, as we have held, all of the claimed isolated DNAs are eligible for patent as compositions of matter distinct from natural DNA, the claimed cDNAs are especially distinctive, lacking the non-coding introns present in naturally occurring chromosomal DNA. They are even more the result of human intervention into nature and are hence patent-eligible subject matter. The government, as noted earlier, has agreed with that conclusion. <a id="co_link_Iaa783edfafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2023907031&amp;pubNum=999&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Br. United States, 2010 WL 4853320, at 14–17</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The dissent disparages the significance of a “chemical bond,” presumably meaning a covalent bond, in distinguishing structurally between one molecular species and another. But a covalent bond is the defining boundary between one molecule and another, and the dissent's citation of Linus Pauling's comment that covalent bonds “make it convenient for the chemist to consider [the aggregate] as an independent molecular species” underlines the point.  <span class="co_starPage" id="co_pp_sp_506_1330"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1330&quot; }" alt="metadata" type="hidden">*1330</span> The covalent bonds in this case connect different chemical moieties to one another.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F162028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF16">16</a><a id="co_anchor_B162028417793"></a><a href="#co_anchor_F172028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF17">17</a><a id="co_anchor_B172028417793"></a> Plaintiffs argue that because the claimed isolated DNAs retain the same nucleotide sequence as native DNAs, they do not have any “markedly different” characteristics. This approach, however, looks not at whether isolated DNAs are markedly different—have a distinctive characteristic—from naturally occurring DNAs, as the Supreme Court has directed, but at one similarity, albeit a key one: the information content contained in isolated and native DNAs' nucleotide sequences. Adopting this approach, the district court disparaged the patent eligibility of isolated DNA molecules because their genetic function is to transmit information. We disagree, as it is the distinctive nature of DNA molecules as isolated compositions of matter that determines their patent eligibility rather than their physiological use or benefit. Uses of chemical substances may be relevant to the nonobviousness of these substances or to method claims embodying those uses, but the patent eligibility of an isolated DNA is not negated because it has similar informational properties to a different, more complex natural material. The claimed isolated DNA molecules are distinct from their natural existence as portions of larger entities, and their informational content is irrelevant to that fact. We recognize that biologists may think of molecules in terms of their uses, but genes are in fact materials having a chemical nature and, as such, are best described in patents by their structures rather than by their functions. In fact, many different materials may have the same function (<input id="co_docMarker_24" type="hidden"><em>e.g.,</em> <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3af17fb7475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3af17fb7475111db9765f9243f53508a">aspirin</a>, <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3bda5909475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3bda5909475111db9765f9243f53508a">ibuprofen</a>, and <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3b6b4391475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3b6b4391475111db9765f9243f53508a">naproxen</a>).</div></div><div class="co_paragraph"><div class="co_paragraphText">The district court in effect created a categorical rule excluding isolated genes from patent eligibility. <a id="co_link_Iaa783ee5afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2021662409&amp;pubNum=0004637&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_4637_228&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_228"><em>See SJ Op.,</em> 702 F.Supp.2d at 228–29</a>. But the Supreme Court has “more than once cautioned that courts ‘should not read into the patent laws limitations and conditions which the legislature has not expressed,’ ” <a id="co_link_Iaa783ee6afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2022394590&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_3226&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_3226"><em>Bilski,</em> 130 S.Ct. at 3226</a> (quoting <a id="co_link_Iaa783ee7afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1981109598&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Diehr,</em> 450 U.S. at 182, 101 S.Ct. 1048),</a> and has repeatedly rejected new categorical exclusions from <a id="co_link_Iaa783ee8afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>'s scope, <em>see </em><a id="co_link_Iaa783ee9afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2022394590&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_3227&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_3227"><em>id.</em> at 3227–28</a> (rejecting the argument that business method patents should be categorically excluded from <a id="co_link_Iaa783eeaafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>); <a id="co_link_Iaa783eebafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 314–17, 100 S.Ct. 2204</a> (same for living organisms). Contrary to the conclusions of the district court and the suggestions of Plaintiffs and some amici, <a id="co_link_Iaa783eecafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> applies equally to all putative inventions, and isolated DNA is not and should not be considered a special case for purposes of patent eligibility under existing law. <a id="co_link_Iaa783eedafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2021662409&amp;pubNum=0004637&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_4637_185&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_185"><em>See, e.g., SJ Op.,</em> 702 F.Supp.2d at 185</a> (“DNA represents the physical embodiment of biological information, distinct in its essential characteristics from any other chemical found in nature.”); Appellees' Suppl. Br. at 4–5 (“Unlike other chemicals, the information encoded by DNA reflects its primary biological function....”).</div></div><div class="co_paragraph"><div class="co_paragraphText">Under the statutory rubric of <a id="co_link_Iaa783eeeafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>, isolated DNA is a tangible, man-made composition of matter defined and distinguished by its objectively discernible chemical structure. Whether its unusual status as a chemical entity that conveys genetic information warrants singular treatment under the patent laws as the district court did is a policy question that we are not entitled to address. <em>Cf. </em><a id="co_link_Iaa783eefafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027995535&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_2579&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_2579"><em>Nat'l Fed'n of Indep. Bus. v. Sebelius,</em> ––– U.S. ––––, 132 S.Ct. 2566, 2579, 183 L.Ed.2d 450 (2012)</a> (“[W]e possess neither the expertise nor the prerogative to make policy judgments. Those decisions are entrusted to our Nation's elected leaders, who can be thrown out of office if the people disagree with them.”). Congress is presumed to have been aware of the issue, having enacted a comprehensive patent reform act during the pendency of this case, and it is ultimately for Congress if it wishes to overturn <span class="co_starPage" id="co_pp_sp_506_1331"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1331&quot; }" alt="metadata" type="hidden">*1331</span>  case law and the long practice of the PTO to determine that isolated DNA must be treated differently from other compositions of matter to account for its perceived special function. We therefore reject the district court's unwarranted categorical exclusion of isolated DNA molecules.</div></div><div class="co_paragraph"><div class="co_paragraphText">Because isolated DNAs, not just cDNAs, have a markedly different chemical structure compared to native DNAs, we reject the government's earlier proposed “magic microscope” test, as it misunderstands the difference between science and invention and fails to take into account the existence of molecules as separate chemical entities. The ability to visualize a DNA molecule through a microscope, or by any other means, when it is bonded to other genetic material, is worlds apart from possessing an isolated DNA molecule that is in hand and usable. It is the difference between knowledge of nature and reducing a portion of nature to concrete form, the latter activity being what the patent laws seek to encourage and protect. The government's microscope could focus in on a claimed portion of any complex molecule, rendering that claimed portion patent ineligible, even though that portion never exists as a separate molecule in the body or anywhere else in nature, and may have an entirely different utility. That would discourage innovation. One cannot visualize a portion of a complex molecule, including a DNA containing a particular gene, and will it into isolation as a unique entity. Visualization does not cleave and isolate the particular DNA; that is the act of human invention.<input id="co_docMarker_25" type="hidden"></div></div><div class="co_paragraph"><div class="co_paragraphText">The Supreme Court in <em>Mayo</em> focused on its concern that permitting patents on particular subject matter would prevent use by others of, in <em>Mayo</em>, the correlation recited in the method claims. Plaintiffs argue here that they are preempted from using the patented DNA molecules. The answer to that concern is that permitting patents on isolated genes does not preempt a law of nature. A composition of matter is not a law of nature. Moreover, as indicated earlier, a limited preemption is inherent in every patent: the right to exclude for a limited period of time. <a id="co_link_Iaa783ef2afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS154&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RB&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_7b9b000044381">35 U.S.C. § 154(a)(1)</a> (“Every patent shall contain ... a grant to the patentee, his heirs or assigns, of the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States....”). When the patent expires, the public is entitled to practice the invention of the patent. That is true of all inventions; during the term of the patent, unauthorized parties are “preempted” from practicing the patent, but only for its limited term. The seven patents being challenged here all expire by December 18, 2015.<sup id="co_footnoteReference_B013132028417793_ID0EYFCK"><a href="#co_footnote_B013132028417793" class="co_footnoteReference">13</a></sup> Any preemption thus is limited, very limited in the case of the present patents. Moreover, patents are rarely enforced against scientific research, even during their terms.</div></div><div class="co_paragraph"><div class="co_paragraphText">The remand of this case for reconsideration in light of <em>Mayo</em> might suggest, as Plaintiffs and certain amici state, that the composition claims are mere reflections of a law of nature. Respectfully, they are not, any more than any product of man reflects and is consistent with a law of nature. Everything and everyone comes from nature, following its laws. But the compositions here are not natural products. They are the products of man, albeit following, as all materials do, laws of nature.</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_506_1332"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1332&quot; }" alt="metadata" type="hidden">*1332</span> The dissent indicates that “elemental lithium (like other elements) would not be patentable subject matter, even if it could only be extracted from nature through an isolation process.” But the isolation here is not a simple separation from extraneous materials, but conversion to a different molecular entity. And again, these facts are not before us, so we do not attempt to evaluate the patentability of one form of lithium over another. Courts decide cases; they do not draft comprehensive legal treatises. Suffice it to say, however, that if lithium is found in the earth as other than elemental lithium because it reacts with air and water to form, for example, <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3af0bc82475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3af0bc82475111db9765f9243f53508a">lithium</a> oxide or <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3af0bc82475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3af0bc82475111db9765f9243f53508a_0">lithium</a> hydroxide, it is a different material. A <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3af0bc82475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3af0bc82475111db9765f9243f53508a_1">lithium</a> compound is not elemental <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=I3af0bc82475111db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_I3af0bc82475111db9765f9243f53508a_2">lithium</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F182028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF18">18</a><a id="co_anchor_B182028417793"></a> It is also important to dispute the dissent's analogy to snapping a leaf from a tree. With respect, no one could contemplate that snapping a leaf from a tree would be worthy of a patent, whereas isolating genes to provide useful diagnostic tools and medicines is surely what the patent laws are intended to encourage and protect. Snapping a leaf from a tree is a physical separation, easily done by anyone. Creating a new chemical entity is the work of human transformation, requiring skill, knowledge, and effort. <em>See </em><a id="co_link_Iaa783efdafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_1294&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_1294"><em>Mayo,</em> 132 S.Ct. at 1294</a> (“While a scientific truth ... is not a patentable invention, a novel and useful structure created with the aid of knowledge of scientific truth may be.”) (quoting <a id="co_link_Iaa783efeafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1939125969&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mackay Radio &amp; Tel. Co. v. Radio Corp. of Am.,</em> 306 U.S. 86, 94, 59 S.Ct. 427, 83 L.Ed. 506 (1939)</a>).</div></div><div class="co_paragraph"><div class="co_paragraphText">The dissent also mentions several times in its opinion the “breathtaking[ ]” breadth of certain claims as grounds for objecting to their patentability. However, we do not have here any rejection or invalidation on the various grounds relating to breadth, such as in <input id="co_docMarker_26" type="hidden"><a id="co_link_Iaa783effafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS112&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 112</a>. The issue before us is patent eligibility under <a id="co_link_Iaa783f00afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>, not the adequacy of the patents' disclosure to support particular claims. Nor is it lack of patentability for obviousness, as the dissent intimates, that is before us.</div></div><div class="co_paragraph"><div class="co_paragraphText">The dissent finally attempts to analogize the creation of the isolated DNAs in this case to the removal of a kidney from the human body, indicating that the latter does not create patent-eligible subject matter, hence the claimed isolated DNAs also do not. Such an analogy is misplaced. Extracting a kidney from a body does not result in a patent-eligible composition, as an isolated gene has been and should be. A kidney is an organ, not a well defined composition of matter or an article of manufacture specified by <a id="co_link_Iaa783f01afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>. No one could confuse extensive research needed to locate, identify, and isolate a gene with the extraction of an organ from a body. One is what patents are intended to stimulate research on and hence are properly patent eligible, and the other, while obviously essential to human wellbeing, is not what patents are understood to cover under the patent statute. An isolated DNA is properly characterized as a composition of matter under <a id="co_link_Iaa783f02afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>; no one would so characterize an isolated body organ.</div></div><div class="co_paragraph"><div class="co_paragraphText">Finally, our decision that isolated DNA molecules are patent eligible comports with the longstanding practice of the PTO and the courts. The Supreme Court has repeatedly stated that changes to longstanding practice should come from Congress, not the courts. In <em>J.E.M. Ag Supply, Inc. v. Pioneer Hi–Bred International, Inc.,</em> the Court rejected the argument that plants did not fall within the scope of <a id="co_link_Iaa783f04afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>, relying in part on the fact that “the PTO has assigned utility patents for plants for at least 16 years and there has been no indication from either Congress or agencies with expertise that such coverage is inconsistent with [federal law].”  <span class="co_starPage" id="co_pp_sp_506_1333"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1333&quot; }" alt="metadata" type="hidden">*1333</span> <a id="co_link_Iaa783f05afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2001526212&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">534 U.S. 124, 144–45, 122 S.Ct. 593, 151 L.Ed.2d 508 (2001)</a>; <em>see also </em><a id="co_link_Iaa783f06afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2002330186&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.,</em> 535 U.S. 722, 739, 122 S.Ct. 1831, 152 L.Ed.2d 944 (2002)</a> (“[C]ourts must be cautious before adopting changes that disrupt the settled expectations of the inventing community.” (citing <a id="co_link_Iaa783f07afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1997060689&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Warner–Jenkinson Co. v. Hilton Davis Chem. Co.,</em> 520 U.S. 17, 28, 117 S.Ct. 1040, 137 L.Ed.2d 146 (1997)</a>)); <a id="co_link_Iaa783f08afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2021584873&amp;pubNum=0000506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_1347&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1347"><em>Ariad Pharms., Inc. v. Eli Lilly &amp; Co.,</em> 598 F.3d 1336, 1347 (Fed.Cir.2010)</a> (en banc) (upholding a written description requirement separate from enablement based in part on <em>stare decisis</em> ).</div></div><div class="co_paragraph"><div class="co_paragraphText">In this case, the PTO has issued patents relating to DNA molecules for almost thirty years. In the early 1980s, the Office granted the first human gene patents. <em>See</em> Eric J. Rogers, <a id="co_link_Iaa783f09afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=0362107907&amp;pubNum=4353&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LR&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Can You Patent Genes? Yes and No,</em> 93 J. Pat. &amp; Trademark Off. Soc'y 19 (2010)</a>. It is estimated that the PTO has issued 2,645 patents claiming “isolated DNA” over the past twenty-nine years, J.A. 3710, and that by 2005, had granted 40,000 DNA-related patents relating to, in non-native form, genes in the human genome, Rogers, <a id="co_link_Iaa783f0aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=0362107907&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LR&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>supra</em> at 40.</a> In 2001, the PTO issued <em>Utility Examination Guidelines,</em> which reaffirmed the agency's position that isolated DNA molecules are patent eligible, <a id="co_link_Iaa783f0bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;pubNum=0001037&amp;cite=66FR1092-94&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=FR&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">66 Fed.Reg. 1092–94 (Jan. 5, 2001)</a>, and Congress has not indicated that the PTO's position is inconsistent with <a id="co_link_Iaa783f0cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>. If the law is to be changed, and DNA inventions excluded from the broad scope of <a id="co_link_Iaa783f0dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>, contrary to the settled expectation of the inventing and investing communities, the decision must come, not from the courts, but from Congress. The dissent mentions possible “adverse effects” that may occur if isolated DNAs are held to be patent eligible. But, respectfully, it is the adverse effects on innovation that a holding of ineligibility might cause. Patents encourage innovation and even encourage inventing around; we must be careful not to rope off far-reaching areas of patent eligibility.<input id="co_docMarker_27" type="hidden"></div></div><div class="co_paragraph"><div class="co_paragraphText">Accordingly, we once again conclude that claims 1, 2, 5, 6, and 7 of the ′<a id="co_link_Iaa783f0eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a>; claims 1, 6, and 7 of the ′<a id="co_link_Iaa783f0fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998422488&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=Ia9d8eb20724e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">492 patent</a>; and claim 1 of the ′<a id="co_link_Iaa783f10afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1997377490&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I0e737f30746811d7a94bace56a9eba1c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">473 patent</a> directed to isolated DNA molecules recite patent-eligible subject matter under <a id="co_link_Iaa783f11afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>. <em>Mayo</em> does not change that result. In so doing, we reiterate that the issue before us is <em>patent eligibility,</em> not <em>patentability,</em> about which we express no opinion.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768de2afef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2">III. Method Claims</div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F192028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF19">19</a><a id="co_anchor_B192028417793"></a> We turn next to Myriad's challenged method claims. This court in its now-vacated decision of July 29, 2011, had held method claims 1 of the ′999, ′ 001, and ′<a id="co_link_Iaa783f13afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998348225&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">441 patents</a>, as well as method claims 1 and 2 of the ′<a id="co_link_Iaa783f14afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2000348614&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=Ifd36f5d071f611d796fabc35f7796f7a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">857 patent</a>—all of which consist of analyzing and comparing certain DNA sequences—not to be patent-eligible subject matter on the ground that they claim only abstract mental processes. In light of the Supreme Court's decision in <em>Mayo</em>, we reaffirm that prior holding. The Court made clear that such diagnostic methods in that case essentially claim natural laws that are not eligible for patent. Without expressly analyzing the instant method claims in the context of the Court's reasoning, but in light of the Court's holding, and in view of our own prior reasoning, set forth herein below, those method claims cannot stand.</div></div><div class="co_paragraph"><div class="co_paragraphText">In our prior decision, however, we reversed the district court's holding that claim 20 of the ′<a id="co_link_Iaa783f16afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a> was not eligible for patent. We did so on the ground, <em>inter alia,</em> that, in addition to the step of comparing the cells' growth rates, the claim also recites the steps of growing transformed cells and determining those growth rates. We relied on the fact that those steps were transformative. Although the Court has now held that certain transformative <span class="co_starPage" id="co_pp_sp_506_1334"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1334&quot; }" alt="metadata" type="hidden">*1334</span>  steps are not necessarily sufficient under <a id="co_link_Iaa783f17afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> if the recited steps only rely on natural laws, we once again, even in light of <em>Mayo</em>, arrive at the same conclusion of patent-eligibility because at the heart of claim 20 is a transformed cell, which is made by man, in contrast to a natural material.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768de3afef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2">A. Methods of “Comparing” or “Analyzing” Sequences</div><div class="co_paragraph"><div class="co_paragraphText">Myriad argued that its claims to methods of “comparing” or “analyzing” <em>BRCA</em> sequences satisfy the machine-or-transformation test because each requires a transformation—extracting and sequencing DNA molecules from a human sample—before the sequences can be compared or analyzed. According to Myriad, the district court failed to recognize the transformative nature of the claims by (1) misconstruing the claim term “sequence” as merely information, rather than a physical molecule; and (2) erroneously concluding, in the alternative, that Myriad's proposed transformations were mere data-gathering steps, rather than central to the purpose of the claims.</div></div><div class="co_paragraph"><div class="co_paragraphText">Plaintiffs responded that these method claims are drawn to the abstract idea of comparing one sequence to a reference sequence and preempt a phenomenon of nature—the correlation of genetic mutations with a predisposition to <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_18">cancer</a>. And, according to the Plaintiffs, limiting the claims' application to a specific technological field, <em>i.e., BRCA</em> gene sequences, is insufficient to render the claims patent eligible. Plaintiffs also assert that the claims do not meet the machine-or-transformation test because the claims' plain language includes just the one step of “comparing” or “analyzing” two gene sequences.</div></div><div class="co_paragraph"><div class="co_paragraphText">We renew our conclusion that Myriad's claims to “comparing” or “analyzing” two gene sequences fall outside the scope of <a id="co_link_Iaa783f1aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> because they claim only abstract mental processes. <input id="co_docMarker_28" type="hidden"><em>See </em><a id="co_link_Iaa783f1bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1972137547&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Benson,</em> 409 U.S. at 67, 93 S.Ct. 253</a> (“Phenomena of nature, ... mental processes, and abstract intellectual concepts are not patentable, as they are the basic tools of scientific and technological work.”). The claims recite, for example, a “method for screening a tumor sample,” by “comparing” a first <em>BRCA1</em> sequence from a tumor sample and a second <em>BRCA1</em> sequence from a non-tumor sample, wherein a difference in sequence indicates an alteration in the tumor sample. <a id="co_link_Iaa783f1cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998276467&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I00a2a120720511d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">′001 patent</a> claim 1. This claim thus recites nothing more than the abstract mental steps necessary to compare two different nucleotide sequences: one looks at the first position in a first sequence; determines the nucleotide sequence at that first position; looks at the first position in a second sequence; determines the nucleotide sequence at that first position; determines if the nucleotide at the first position in the first sequence and the first position in the second sequence are the same or different, wherein the latter indicates an alteration; and repeats the process for the next position.</div></div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F202028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF20">20</a><a id="co_anchor_B202028417793"></a> Limiting the comparison to just the <em>BRCA</em> genes or, as in the case of claim 1 of the ′<a id="co_link_Iaa783f1dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998294381&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I65906730720e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">999 patent</a>, to just the identification of particular alterations, fails to render the claimed process patent-eligible. As the Supreme Court has held, “the prohibition against patenting abstract ideas ‘cannot be circumvented by attempting to limit the use of the formula to a particular technological environment.’ ” <a id="co_link_Iaa783f1eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2022394590&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_3230&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_3230"><em>Bilski,</em> 130 S.Ct. at 3230</a> (quoting <a id="co_link_Iaa783f1fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1981109598&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Diehr,</em> 450 U.S. at 191–92, 101 S.Ct. 1048);</a> <em>see also </em><a id="co_link_Iaa783f20afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2022394590&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_3231&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_3231"><em>id.</em> at 3231</a> (“<em>Flook</em> established that limiting an abstract idea to one field of use ... did not make the concept patentable.”). Although the <em>application</em> of a formula or abstract idea in a process may describe patent-eligible subject matter, <a id="co_link_Iaa783f22afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2022394590&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>id.</em> at 3230,</a> Myriad's <span class="co_starPage" id="co_pp_sp_506_1335"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1335&quot; }" alt="metadata" type="hidden">*1335</span>  claims do not apply the step of comparing two nucleotide sequences in a process. Rather, the step of comparing two DNA sequences is the entire process that is claimed.</div></div><div class="co_paragraph"><div class="co_paragraphText">To avoid this result, Myriad attempts to read into its method claims additional, allegedly transformative steps. As described above, Myriad reads into its claims the steps of (1) extracting DNA from a human sample, and (2) sequencing the <em>BRCA</em> DNA molecule, arguing that both steps necessarily precede the step of comparing nucleotide sequences. The claims themselves, however, do not include either of these steps. The claims do not specify any action prior to the step of “comparing” or “analyzing” two sequences; the claims recite just the one step of “comparing” or “analyzing.” Moreover, those terms' plain meaning does not include Myriad's proposed sample-processing steps; neither comparing nor analyzing means or implies “extracting” or “sequencing” DNA or otherwise “processing” a human sample.</div></div><div class="co_paragraph"><div class="co_paragraphText">Myriad claims that “comparing” and “analyzing” take on such meaning when read in light of the patent specifications. Specifically, Myriad argues that the specifications show that the claim term “sequence” refers not to information, but rather to a physical DNA molecule, whose sequence must be determined before it can be compared. That may be true, but the claims only recite mental steps, not the structure of physical DNA molecules.</div></div><div class="co_paragraph"><div class="co_paragraphText">Accordingly, Myriad's challenged method claims are indistinguishable from the claims the Supreme Court found invalid under <a id="co_link_Iaa783f23afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> in <em>Mayo</em>. In <em>Mayo</em>, the patents claimed methods for optimizing the dosage of thiopurine drugs administered to patients with <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Icac9cfe6475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Icac9cfe6475411db9765f9243f53508a">gastrointestinal disorders<input id="co_docMarker_29" type="hidden"></a>. <a id="co_link_Iaa783f27afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_1295&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_1295">132 S.Ct. at 1295.</a> As written, the claimed methods included the steps of (a) “administering” a thiopurine drug to a subject, and/or (b) “determining” the drug's metabolite levels in the subject, wherein the measured metabolite levels are compared with predetermined levels to optimize drug dosage. <em>Id.</em> In holding that the claims satisfied <a id="co_link_Iaa783f29afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>, this court concluded that, in addition to the “administering” step being transformative, the “determining” step was both transformative and central to the purpose of the claims. <a id="co_link_Iaa783f2aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2024172308&amp;pubNum=506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_1357&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1357"><em>Prometheus,</em> 628 F.3d at 1357.</a> However, the Supreme Court held that the steps of administering and determining, combined with a correlative “wherein” clause, were not sufficiently transformative of what was otherwise a claim to a natural law. That holding governs Myriad's claims to methods of “comparing” and “analyzing” DNA sequences.</div></div><div class="co_paragraph"><div class="co_paragraphText">Myriad's other claims do not even include a <a id="co_link_Iaa783f2bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo</em></a>-like step of “determining” the sequence <em>BRCA</em> genes by, <em>e.g.,</em> isolating the genes from a blood sample and sequencing them, or any other putatively transformative step. Rather, the comparison between the two sequences can be accomplished by mere inspection alone. Accordingly, Myriad's claimed methods of comparing or analyzing nucleotide sequences are only directed to the abstract mental process of comparing two nucleotide sequences. As such, we hold claims 1 of the ′<a id="co_link_Iaa783f2cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998294381&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I65906730720e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">999 patent</a>, ′<a id="co_link_Iaa783f2dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998276467&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I00a2a120720511d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">001 patent</a>, and ′<a id="co_link_Iaa783f2eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998348225&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">441 patent</a> and claims 1 and 2 of the ′<a id="co_link_Iaa783f2fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2000348614&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=Ifd36f5d071f611d796fabc35f7796f7a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">857 patent</a> invalid under <a id="co_link_Iaa783f30afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a> for claiming patent-ineligible processes.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768de4afef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2">B. Method of Screening Potential <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_19">Cancer</a> Therapeutics</div><div class="co_paragraph"><div class="co_paragraphText"><a href="#co_anchor_F212028417793" class="co_internalLink co_headnoteLink co_excludeAnnotations co_disableHighlightFeatures" id="co_pp_HNF21">21</a><a id="co_anchor_B212028417793"></a> Lastly, we turn to claim 20 of the ′<a id="co_link_Iaa783f32afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a>, directed to a method for screening potential <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_20">cancer</a> therapeutics via changes in cell growth rates of transformed cells. The parties agree that those transformed cells arose from human effort; <em>i.e.,</em> they are not natural products. Plaintiffs nonetheless challenge claim 20 as directed to the abstract idea of comparing  <span class="co_starPage" id="co_pp_sp_506_1336"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1336&quot; }" alt="metadata" type="hidden">*1336</span> the growth rates of two cell populations and as preempting a basic scientific principle—that a slower growth rate in the presence of a potential therapeutic compound suggests that the compound is a <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_21">cancer</a> therapeutic. Plaintiffs therefore contend that claim 20 is indistinguishable from the claims held ineligible in <em>Mayo</em>. We disagree.</div></div><div class="co_paragraph"><div class="co_paragraphText">Claim 20 recites a method that comprises the steps of (1) growing host cells <em>transformed</em> with an altered <em>BRCA1</em> gene in the presence or absence of a potential <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_22">cancer</a> therapeutic, (2) determining the growth rate of the host cells with or without the potential therapeutic, and (3) comparing the growth rate of the host cells. Claim 20 thus recites a screening method premised on the use of “transformed” host cells. Those cells, like the patent-eligible cells in <em>Chakrabarty</em>, are not naturally occurring. Rather, they are derived by altering a cell to include a foreign gene, resulting in a man-made, transformed cell with enhanced function and utility. <em>See</em> ′<a id="co_link_Iaa783f38afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a> col.27 11.28–33. The claim thus includes more than the abstract mental step of looking at two numbers and “comparing” two host cells' growth rates.</div></div><div class="co_paragraph"><div class="co_paragraphText">In <em>Mayo</em>, the Supreme Court invalidated claims directed to the relationship between concentrations of certain metabolites in the blood and the likelihood that a particular dosage of a thiopurine drug will be optimum, stating that steps of “administering” and “determining,” coupled with a correlative “wherein” clause, were insufficient to differentiate the claimed method from the natural laws encompassed by the claims. In short, <input id="co_docMarker_30" type="hidden">“to transform an unpatentable law of nature into a patent-eligible <em>application</em> of such a law, one must do more than simply state the law of nature while adding the words ‘apply it’.” <a id="co_link_Iaa783f3aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_1294&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_1294">132 S.Ct. at 1294</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Here, claim 20 does do more; it does not simply apply a law of nature. Of course, all activity, whether chemical, biological, or physical, relies on natural laws. But, more to the point here is that claim 20 applies certain steps to transformed cells that, as has been pointed out above, are a product of man, not of nature. The Court, in its evaluation of the <em>Mayo</em> method claims, found that the additional steps of those claims were not sufficient to “transform” the nature of the claims from mere expression of natural laws to patent-eligible subject matter. By definition, however, performing operations, even known types of steps, on, or to create, novel, <em>i.e.,</em> transformed subject matter is the stuff of which most process or method invention consists. All chemical processes, for example, consist of hydrolyzing, hydrogenating, reacting, etc. In situations where the objects or results of such steps are novel and nonobvious, they should be patent-eligible. It is rare that a new reaction or method is invented; much process activity is to make new compounds or products using established processes. Thus, once one has determined that a claimed composition of matter is patent-eligible subject matter, applying various known types of procedures to it is not merely applying conventional steps to a law of nature. The transformed, man-made nature of the underlying subject matter in claim 20 makes the claim patent-eligible. The fact that the claim also includes the steps of determining the cells' growth rates and comparing growth rates does not change the fact that the claim is based on a man-made, non-naturally occurring transformed cell—patent-eligible subject matter.</div></div><div class="co_paragraph"><div class="co_paragraphText">Furthermore, the claim does not cover all cells, all compounds, or all methods of determining the therapeutic effect of a compound. Rather, it is tied to specific host cells <em>transformed</em> with specific genes  <span class="co_starPage" id="co_pp_sp_506_1337"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1337&quot; }" alt="metadata" type="hidden">*1337</span> and grown in the presence or absence of a specific type of therapeutic. Accordingly, we hold that claim 20 of the ′<a id="co_link_Iaa783f3cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a> recites patent-eligible subject matter under <a id="co_link_Iaa783f3dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>. Whether such processes, including claim 20, meet other tests for patentability, such as novelty or nonobviousness, is not before us.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768de5afef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">Conclusion</span></div><div class="co_paragraph"><div class="co_paragraphText">For the foregoing reasons, we affirm the district court's decision to exercise declaratory judgment jurisdiction over this case, we reverse the district court's grant of summary judgment with regard to Myriad's composition claims to isolated DNAs, including cDNAs, we affirm the district court's grant of summary judgment with regard to Myriad's method claims directed to comparing or analyzing gene sequences, and we reverse the district court's grant of summary judgment with regard to Myriad's method claim to screening potential <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_23">cancer</a> therapeutics via changes in cell growth rates of novel, man-made transformed cells.</div></div><div class="co_paragraph"><div class="co_paragraphText"><strong>AFFIRMED IN PART and REVERSED IN PART</strong></div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768de6afef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">Costs</span></div><div class="co_paragraph"><div class="co_paragraphText">Costs to Myriad.</div></div></div></div></div></div></div><div class="co_contentBlock co_briefItState co_opinionBlock"><h2 id="co_concurrance_opinion"></h2><div class="co_docDelivery_dottedLine"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/co_docDelivery_dottedLine.png" alt=""></div><div class="co_contentBlock x_opinionBlockBody"><div class="co_contentBlock x_opinionConcurrance"><div class="co_contentBlock x_concurranceAuthorLineBlock"><div class="co_contentBlock x_concurranceAuthorLine"><a id="co_link_Iaa783f3fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0368246101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">MOORE</a>, Circuit Judge, concurring in part.</div></div><div class="co_contentBlock x_opinionBody"><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768debafef11e79bef99c0ee06c731"><div class="co_paragraph"><div class="co_paragraphText">I join the majority opinion with respect to standing and the patentability of the method claims at issue. I join the majority with respect to claims to isolated cDNA sequences, and concur in the judgment with respect to isolated DNA sequences. I write separately to explain my reasoning.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768decafef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">I.</span></div><div class="co_paragraph"><div class="co_paragraphText">The Patent Act, <a id="co_link_Iaa783f40afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">35 U.S.C. § 101</a>, allows “[w]hoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof”<input id="co_docMarker_31" type="hidden"> to obtain a patent. The plain language of this statute only requires that an invention be “new and useful,” and fall into one of four categories: a “process, machine, manufacture, or composition of matter.” “Congress intended statutory subject matter to ‘include anything under the sun that is made by man.’ ” <a id="co_link_Iaa783f41afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Diamond v. Chakrabarty,</em> 447 U.S. 303, 309, 100 S.Ct. 2204, 65 L.Ed.2d 144 (1980)</a> (quoting the statutory history).</div></div><div class="co_paragraph"><div class="co_paragraphText">While the plain language used by Congress did not limit the scope of patentable subject matter in the statute, the “Court's precedents provide three specific exceptions to <a id="co_link_Iaa783f42afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">§ 101</a>'s broad patent-eligibility principles: ‘laws of nature, physical phenomena, and abstract ideas.’ ” <a id="co_link_Iaa783f43afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2022394590&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_3226&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_3226"><em>Bilski v. Kappos,</em> –––U.S. ––––, 130 S.Ct. 3218, 3226, 177 L.Ed.2d 792 (2010)</a> (quoting <a id="co_link_Iaa783f44afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 309, 100 S.Ct. 2204).</a> These exceptions “rest [ ], not on the notion that natural phenomena are not processes [or other articulated statutory categories], but rather on the more fundamental understanding that they are not the kind of ‘discoveries' that the statute was enacted to protect.” <a id="co_link_Iaa783f45afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1978139495&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Parker v. Flook,</em> 437 U.S. 584, 593, 98 S.Ct. 2522, 57 L.Ed.2d 451 (1978)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Applying the judicially created exception to the otherwise broad demarcation of statutory subject matter in <a id="co_link_Iaa783f46afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> can be difficult. <em>See </em><a id="co_link_Iaa783f47afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Funk Bros. Seed Co. v. Kalo Inoculant Co.,</em> 333 U.S. 127, 134–35, 68 S.Ct. 440, 92 L.Ed. 588 (1948)</a> (Frankfurter, J., concurring) (“[S]uch terms as ‘the work of nature’ and the ‘laws of nature’ ... are vague and malleable.... Arguments drawn from such terms for ascertaining patentability could fairly be employed to challenge almost every patent.”). The analysis is relatively simple if the invention previously existed  <span class="co_starPage" id="co_pp_sp_506_1338"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1338&quot; }" alt="metadata" type="hidden">*1338</span> in nature exactly as claimed. For example, naturally existing minerals, a plant found in the wild, and physical laws such as gravity or E=mc <sup>2</sup> are not patentable subject matter, even if they were “discovered” by an enterprising inventor. <a id="co_link_Iaa783f48afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 309, 100 S.Ct. 2204</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Even when an invention does not exist in nature in the claimed state, it may still be directed to subject matter that is not patentable. For example, in <em>Funk Brothers,</em> the Supreme Court held a patent to a combination of multiple naturally occurring bacterial strains was not patentable. Although there was “an advantage in the combination,” which was apparently “new and useful,” none of the bacterial strains “acquire[d] a different use” in combination. <a id="co_link_Iaa783f4aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Funk Bros.,</em> 333 U.S. at 131–32, 68 S.Ct. 440.</a> The aggregation of the bacterial strains into a single product produced “no new bacteria, no change in the six species of bacteria, and no enlargement of the range of their utility. Each species has the same effect it always had. The bacteria perform in their natural way.... They serve the ends nature originally provided and act quite independently of any effort of the patentee.” <em>Id.</em></div></div><div class="co_paragraph"><div class="co_paragraphText">In contrast, the Supreme Court held bacteria that included extra genetic material introduced by the inventor were “a nonnaturally occurring manufacture or composition of matter—a product of human ingenuity ‘having a distinctive name, character [and] use’ ” and therefore patentable. <a id="co_link_Iaa783f4cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 309–310, 100 S.Ct. 2204</a> (quoting <a id="co_link_Iaa783f4dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1887180158&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Hartranft v. Wiegmann,</em> 121 U.S. 609, 615, 7 S.Ct. 1240, 30 L.Ed. 1012 (1887)</a>). <em>Chakrabarty</em> explained that there is no distinction between inventions based on living and inanimate objects for the purpose of the patent statute; instead, the “relevant distinction” for the <input id="co_docMarker_32" type="hidden"><a id="co_link_Iaa783f4fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> analysis is “between products of nature ... and human-made inventions.” <a id="co_link_Iaa783f50afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 312–13, 100 S.Ct. 2204.</a> Even if the invention was based on nature, and resulted in a living organism, it may fall within the scope of <a id="co_link_Iaa783f51afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>. For example, “the work of the plant breeder ‘in aid of nature’ was patentable invention” because “ ‘a plant discovery resulting from cultivation is unique, isolated, and is not repeated by nature, nor can it be reproduced by nature unaided by man.’ ” <a id="co_link_Iaa783f52afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em></a> (quoting S.Rep. No. 315, 71st Cong., 2d Sess., 6–8 (1930)). In <em>Chakrabarty</em>, the intervention of man resulted in bacteria with “markedly different characteristics” from nature and “the potential for significant utility,” resulting in patentable subject matter. <a id="co_link_Iaa783f56afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 310, 100 S.Ct. 2204.</a></div></div><div class="co_paragraph"><div class="co_paragraphText"><em>Funk Brothers</em> and <em>Chakrabarty</em> do not stake out the exact bounds of patentable subject matter. Instead, each applies a flexible test to the specific question presented in order to determine whether the claimed invention falls within one of the judicial exceptions to patentability. <em>Funk Brothers</em> indicates that an invention which “serve[s] the ends nature originally provided” is likely unpatentable subject matter, but an invention that is an “enlargement of the range of ... utility” as compared to nature may be patentable. <a id="co_link_Iaa783f5aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">333 U.S. at 131, 68 S.Ct. 440.</a> Likewise, <em>Chakrabarty</em> illustrates that an invention with a distinctive name, character, and use, e.g., markedly different characteristics with the potential for significant utility, is patentable subject matter. <a id="co_link_Iaa783f5cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">447 U.S. at 309–10, 100 S.Ct. 2204.</a> Although the two cases result in different outcomes, the inquiry itself is similar.</div></div><div class="co_paragraph"><div class="co_paragraphText">Courts applied an analogous patentability inquiry long before <em>Funk Brothers</em> or <em>Chakrabarty</em>. In one notable case, Judge Learned Hand held that purified adrenaline, a natural product, was patentable subject matter. Judge Hand explained that even if the claimed purified adrenaline  <span class="co_starPage" id="co_pp_sp_506_1339"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1339&quot; }" alt="metadata" type="hidden">*1339</span> were “merely an extracted product without change, there is no rule that such products are not patentable.” <a id="co_link_Iaa783f5fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1911104286&amp;pubNum=0000348&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_348_103&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_348_103"><em>Parke–Davis &amp; Co. v. H.K. Mulford Co.,</em> 189 F. 95, 103 (S.D.N.Y.1911)</a>. This is because “while it is of course possible logically to call this a purification of the principle” the resulting purified adrenaline was “for every practical purpose a new thing commercially and therapeutically.” <em>Id.</em> Similarly, in a case applying the Patent Act of 1952,<sup id="co_footnoteReference_B01412028417793_ID0EJLEK"><a href="#co_footnote_B01412028417793" class="co_footnoteReference">1</a></sup> purified vitamin B–12, another natural product, was also held patentable subject matter within the meaning of <a id="co_link_Iaa783f61afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>. <a id="co_link_Iaa783f62afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1958110285&amp;pubNum=0000350&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Merck &amp; Co. v. Olin Mathieson Chem. Corp.,</em> 253 F.2d 156 (4th Cir.1958)</a>. The Fourth Circuit explained that purified vitamin B–12 was “far from the premise of the [naturally occurring] principle.... The new product, not just the method, had such advantageous characteristics as to replace the [naturally occurring] liver products. What was produced was, in no sense, an old product.” <a id="co_link_Iaa783f63afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1958110285&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 162–63.</a> These purified pharmaceutical cases are both consistent with Supreme Court precedent: the purified substance was “a new thing ... therapeutically,” <a id="co_link_Iaa783f64afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1911104286&amp;pubNum=348&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_348_103&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_348_103"><em>Parke–Davis,</em> 189 F. at 103,</a> and had such “advantageous characteristics” that what was produced by purification “was, in no sense, an old product.” <a id="co_link_Iaa783f65afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1958110285&amp;pubNum=350&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_350_162&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_162"><em>Merck,</em> 253 F.2d at 162–63.</a> In other words, the purified natural products were held to have “markedly different characteristics,” as compared to the impure products, which resulted in “the potential for significant utility.” <a id="co_link_Iaa783f66afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 310, 100 S.Ct. 2204</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">In contrast, mere purification of a naturally occurring element is typically insufficient to make it patentable subject matter. For example, our predecessor court held that claims to purified vanadium and purified uranium were not patentable subject matter since these were naturally occurring elements with inherent physical properties unchanged upon purification. <input id="co_docMarker_33" type="hidden"><em>See </em><a id="co_link_Iaa783f68afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1931126315&amp;pubNum=0000350&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_350_959&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_959"><em>In re Marden,</em> 18 CCPA 1057, 47 F.2d 958, 959 (1931)</a> (“[P]ure vanadium is not new in the inventive sense, and, it being a product of nature, no one is entitled to a monopoly of the same.”); <a id="co_link_Iaa783f69afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1931126314&amp;pubNum=0000350&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>In re Marden,</em> 18 CCPA 1046, 47 F.2d 957 (1931)</a> (“ductile uranium” not patentable because uranium is inherently ductile). Likewise, claims to purified ductile tungsten were not patentable subject matter since pure tungsten existed in nature and was inherently ductile. <a id="co_link_Iaa783f6aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1928132561&amp;pubNum=0000350&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_350_643&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_643"><em>General Electric Co. v. De Forest Radio Co.,</em> 28 F.2d 641, 643 (3d Cir.1928)</a>. In each of these cases, purification did not result in an element with new properties. Instead, the court held the naturally occurring element inherently had the same characteristics and utility (e.g. ductility) as the claimed invention. Consistent with <em>Funk Brothers</em> and <em>Chakrabarty</em>, the claims all fell within the laws of nature exception.</div></div><div class="co_paragraph"><div class="co_paragraphText">As illustrated by these examples, courts have long applied the principles articulated in <em>Funk Brothers</em> and <em>Chakrabarty</em> to different factual scenarios in order to determine whether an invention, as claimed, falls into the laws of nature exception. I see no reason to deviate from this longstanding flexible approach in this case.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768dedafef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">II.</span></div><div class="co_paragraph"><div class="co_paragraphText">We reconsider whether the claims at issue in this case are directed to patentable subject matter following the remand from the Supreme Court in light of its opinion in <a id="co_link_Iaa783f6fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Mayo Collaborative Services v. Prometheus Laboratories, Inc.,</em> ––– U.S. ––––, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)</a> <a id="co_link_Iaa783f70afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">(<em>Prometheus</em> ).</a> While the <em>Prometheus <span class="co_starPage" id="co_pp_sp_506_1340"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1340&quot; }" alt="metadata" type="hidden">*1340</span> </em> decision does not control the outcome in this case, it is nonetheless instructive regarding the scope of the law of nature exception. As an initial matter, the <em>Prometheus</em> discussion of laws of nature (process claims) clearly ought to apply equally to manifestations of nature (composition claims). Myriad's argument that <em>Prometheus</em> is constrained to methods is an untenable position.</div></div><div class="co_paragraph"><div class="co_paragraphText">As the <em>Prometheus</em> court explained: “If a law of nature is not patentable, then neither is a process reciting a law of nature, unless that process has additional features that provide practical assurance that the process is more than a drafting effort designed to monopolize the law of nature itself.” <a id="co_link_Iaa783f75afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_1297&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_1297"><em>Id.</em> at 1297</a>. <em>Prometheus</em> did not, however, overturn <em>Funk Brothers</em> or <em>Chakrabarty</em>; cases clearly more analogous to the one before us. Using the framework of <em>Funk Brothers</em> and <em>Chakrabarty</em> in conjunction with the direction of <em>Prometheus</em>, the applicable principles are: (1) laws of nature/manifestations of nature are not patentable; (2) a composition of matter with “markedly different characteristics” from that found in nature with the potential for significant utility is directed to patentable subject matter.</div></div><div class="co_paragraph"><div class="co_paragraphText">Does the isolation process change the DNA from an unpatentable manifestation of nature into a patentable composition of matter? <a id="co_link_Iaa783f7cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1299.</a> Does the claimed isolated DNA have markedly different characteristics with the potential for significant utility, e.g., an “enlargement of the range of ... utility” as compared to nature? <a id="co_link_Iaa783f7dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 309–310, 100 S.Ct. 2204;</a> <a id="co_link_Iaa783f7eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Funk Bros.,</em> 333 U.S. at 131, 68 S.Ct. 440</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The isolated DNA claims of the patents in suit fall into two categories. The first category of claims is directed to isolated sequences that are identical to naturally occurring gene sequences. These include claims encompassing both the isolated full length gene sequence (e.g. claim 1 of ′<a id="co_link_Iaa783f7fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a>), which are thousands of nucleotides, and claims to shorter isolated DNA strands, with as few as fifteen nucleotides, whose nucleotide sequence is found on the chromosome (e.g. claim 5 of ′<input id="co_docMarker_34" type="hidden"><a id="co_link_Iaa783f80afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a>). The second category of claims is directed to isolated DNA sequences that are different from the naturally occurring gene sequences. These include claims to isolated cDNA molecules (e.g. claim 2 of the ′<a id="co_link_Iaa783f81afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a>), which differ from the natural gene sequence in that the introns are removed, and are the opposite (complementary) sequence of the naturally occurring RNA.</div></div><div class="co_paragraph"><div class="co_paragraphText">The cDNA claims present the easiest analysis. Although the plaintiffs (now plaintiff) in the suit argue, and the district court held, that cDNA falls within the “laws of nature” exception to <a id="co_link_Iaa783f82afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> patentability, the claimed cDNA sequences do <em>not</em> exist in nature. Moreover, since cDNA has all of the introns removed, and only contains the coding nucleotides, it can be used to express a protein in a cell which does <em>not</em> normally produce it. Of course, the claimed isolated cDNA is inspired by nature—after all naturally occurring RNA is the template upon which cDNA is constructed. Because it is used as a template, however, cDNA has a complementary sequence of nucleotides, and therefore has a <em>completely different</em> nucleotide sequence than the RNA. Moreover, DNA has a different chemical structure than RNA, including a different base (T instead of U, respectively) and sugar units (deoxyribose instead of <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=gdrug&amp;entityId=Ife6b3add6c7111e18b05fdf15589d8e8&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ife6b3add6c7111e18b05fdf15589d8e8">ribose</a>, respectively). This results in, among other things, greater stability for the DNA sequence as compared to the RNA sequence.</div></div><div class="co_paragraph"><div class="co_paragraphText">cDNA sequences thus have a distinctive character and use, with markedly different chemical characteristics from either the naturally occurring RNA or any continuous <span class="co_starPage" id="co_pp_sp_506_1341"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1341&quot; }" alt="metadata" type="hidden">*1341</span>  DNA sequence found on the chromosome. The claimed isolated cDNA sequences are the creation of man, made using biological tools and the naturally occurring mRNA as a template. cDNA is therefore not one of the “ ‘manifestations of ... nature, free to all men and reserved exclusively to none’ ” that falls outside of the patent system. <a id="co_link_Iaa783f84afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 309, 100 S.Ct. 2204</a> (quoting <a id="co_link_Iaa783f85afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Funk Bros.,</em> 333 U.S. at 130, 68 S.Ct. 440).</a> I decline to extend the laws of nature exception to reach entirely manmade sequences of isolated cDNA, even if those sequences are inspired by a natural template. I therefore join the majority opinion with respect to the claims to cDNA sequences.<sup id="co_footnoteReference_B01522028417793_ID0EMAFK"><a href="#co_footnote_B01522028417793" class="co_footnoteReference">2</a></sup></div></div><div class="co_paragraph"><div class="co_paragraphText">DNA sequences that have the same pattern of DNA bases as a natural gene, in whole or in part, present a more difficult issue. Unlike the isolated cDNA molecules, whose sequence is not present in nature, the isolated DNA claims include nucleotide sequences which are found in the human body, albeit as part of a much larger molecule, the chromosome. To the extent the majority rests its conclusion on the chemical differences between genomic and isolated DNA (breaking the covalent bonds), I cannot agree that this is sufficient to hold that the claims to human genes are directed to patentable subject matter. I agree that isolated genes are a different molecule and are therefore not squarely analogous to unpatentable minerals, created by nature without the assistance of man. The claimed isolated DNA molecules, which are truncations (with different ends) of the naturally occurring DNA found as part of the chromosome in nature, are not naturally produced without the intervention of man.</div></div><div class="co_paragraph"><div class="co_paragraphText">I begin with the short isolated sequences such as those covered by claim 5 which is directed to “an isolated DNA having at least 15 nucleotides of the DNA of claim 1.” This claim covers a sequence as short as 15 nucleotides and arguably as long as the entire gene. For this claim to be patent eligible, all of the sequences ranging from the 15 nucleotide sequence to the full gene must be patentable subject matter. The shorter isolated DNA sequences have a variety of applications and uses in isolation that are new and distinct as compared to the sequence as it occurs in nature. For example, these sequences can be used as primers in a diagnostic screening process to detect gene mutations. These smaller isolated DNA sequences—including isolated radiolabeled sequences mirroring those on the chromosome—can also be used as the basis for probes. Naturally occurring DNA cannot do this. Unlike the isolated DNA, naturally occurring DNA simply does not have the requisite chemical and physical properties needed to perform these functions.<input id="co_docMarker_35" type="hidden"></div></div><div class="co_paragraph"><div class="co_paragraphText">The ability to use isolated DNA molecules as the basis for diagnostic genetic testing is clearly an “enlargement of the range of ... utility” as compared to nature. <a id="co_link_Iaa783f87afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Funk Bros.,</em> 333 U.S. at 131, 68 S.Ct. 440.</a> In <em>Prometheus</em>, the Supreme Court held that the claims at issue were not directed to patentable subject matter because they merely “set forth laws of nature—namely, relationships between concentrations of certain metabolites in the blood and the likelihood that a dosage of a thiopurine drug will prove ineffective or cause harm.” <a id="co_link_Iaa783f89afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_1296&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_1296">132 S.Ct. at 1296–97.</a> The claimed relationship was “a consequence of  <span class="co_starPage" id="co_pp_sp_506_1342"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1342&quot; }" alt="metadata" type="hidden">*1342</span> the ways in which thiopurine compounds are metabolized by the body—entirely natural processes.” <a id="co_link_Iaa783f8aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2027337692&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1297.</a></div></div><div class="co_paragraph"><div class="co_paragraphText">There is no suggestion that the human body naturally uses 15–mers as primers to synthesize DNA, or that the attendant process of “probing” a patient's DNA to detect a mutation is somehow a natural law. The ability to use a short strand of DNA as a primer or probe to determine whether a patient has a mutation is a new and important utility substantially different from the role of that DNA as it occurs in nature. Indeed, many of the plaintiffs in this case submitted declarations indicating that they wanted to either offer such testing or receive such testing. Unlike <em>Prometheus</em>, the claims to short isolated strands of DNA are not directed to the relationship between the mutation and <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Iaf34f5c3475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Iaf34f5c3475411db9765f9243f53508a_24">cancer</a>, but rather to a new tool that can be used to determine if that relationship exists. The short isolated DNA sequences have markedly different properties which are directly responsible for their new and significant utility. <a id="co_link_Iaa783f8dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 309–10, 100 S.Ct. 2204.</a> It is not the chemical change alone, but that change combined with the different and beneficial utility that leads me to conclude that small isolated DNA fragments are patentable subject matter. <a id="co_link_Iaa783f8eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 310, 100 S.Ct. 2204.</a></div></div><div class="co_paragraph"><div class="co_paragraphText">In fact, much of the dissent's analysis with regard to the full gene would seem to support my conclusion that small isolated DNA molecules are directed to patent-eligible subject matter. The dissent explains why the baseball bat is directed to patent eligible subject matter: “man has defined the parts that are to be retained and the parts that are to be discarded, and he has molded the retained portion into a product that bears little resemblance to that which occurs naturally.” Dissent at 1353. The exact same thing is true with regard to primer and probe claims. Man has whittled the chromosomal DNA molecule down to a 15 nucleotide sequence—defining the parts to be retained and discarded.<sup id="co_footnoteReference_B01632028417793_ID0EYHFK"><a href="#co_footnote_B01632028417793" class="co_footnoteReference">3</a></sup> And the result is a product with a function (primer or probe) that is entirely different from the full gene from which it was obtained.<sup id="co_footnoteReference_B01742028417793_ID0E6HFK"><a href="#co_footnote_B01742028417793" class="co_footnoteReference">4</a></sup> I conclude that the small, isolated DNA molecules are an alteration of the natural product “with markedly different characteristics from any found in nature and one having the potential for significant utility.” <a id="co_link_Iaa783f8fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">447 U.S. at 310, 100 S.Ct. 2204</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Turning now to the longer strands of isolated DNA, isolated strands which include most or all of the gene present a more difficult case. Some of the claims at issue, for example ′<a id="co_link_Iaa783f90afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a> claim 5, are genus claims, drafted broadly enough to include both short fragments as well as the entire isolated gene sequence. While I ultimately conclude that these longer isolated sequences, including the isolated  <span class="co_starPage" id="co_pp_sp_506_1343"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1343&quot; }" alt="metadata" type="hidden">*1343</span> gene sequence as a whole, are also patentable subject matter, I do so for a reason different than for the shorter sequences.<input id="co_docMarker_36" type="hidden"></div></div><div class="co_paragraph"><div class="co_paragraphText">All of the same structural arguments apply to any length of isolated DNA so, like the shorter strands, an isolated DNA coding for a gene does have a literal chemical difference from the gene as it appears on the chromosome. Unlike the shorter strands of isolated DNA, the chemical and structural differences in the isolated gene do not clearly lead to an “enlargement of the range of ... utility” as compared to nature. <a id="co_link_Iaa783f91afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Funk Bros.,</em> 333 U.S. at 131, 68 S.Ct. 440.</a> For example, the full length gene is too large to be used as a probe. <em>See</em> J.A. 4322 (a probe is a DNA molecule usually 100–1,000 bases long). Likewise, an entire isolated gene appears unsuitable for use as a primer in genetic screening for mutations in that same gene. <em>See</em> J.A. 4323 (Primers “are complementary to an exact location of a much larger target DNA molecule.”). The isolated full length gene does not clearly have a new utility and appears to simply serve the same ends devised by nature, namely to act as a gene encoding a protein sequence.</div></div><div class="co_paragraph"><div class="co_paragraphText">If I were deciding this case on a blank canvas, I might conclude that an isolated DNA sequence that includes most or all of a gene is not patentable subject matter. The scope of the law of nature/manifestation of nature exception was certainly enlarged in <em>Prometheus</em>. But we do not decide this case on a blank canvas. Congress has, for centuries, authorized an expansive scope of patentable subject matter. Likewise, the United States Patent Office has allowed patents on isolated DNA sequences for decades, and, more generally, has allowed patents on purified natural products for centuries. There are now thousands of patents with claims to isolated DNA, and some unknown (but certainly large) number of patents to purified natural products or fragments thereof.<sup id="co_footnoteReference_B01852028417793_ID0E6MFK"><a href="#co_footnote_B01852028417793" class="co_footnoteReference">5</a></sup> As I explain below, I believe we must be particularly wary of expanding the judicial exception to patentable subject matter where both settled expectations and extensive property rights are involved.<sup id="co_footnoteReference_B01962028417793_ID0EGNFK"><a href="#co_footnote_B01962028417793" class="co_footnoteReference">6</a></sup></div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768deeafef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">III.</span></div><div class="co_paragraph"><div class="co_paragraphText">For more than a decade the Patent Office's policy has been that “[a]n isolated and purified DNA molecule that has the same sequence as a naturally occurring gene is eligible for a patent because ... that DNA molecule does not occur in that isolated form in nature....” <a id="co_link_Iaa783f96afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=l&amp;pubNum=0001037&amp;cite=UUID(I368E38B0307811DAB1EA8A3AF7542D25)&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=CP&amp;fi=co_pp_sp_1037_1092&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_1037_1092">66 Fed.Reg. 1092, 1093 (Jan. 5, 2001)</a>. I do not agree  <span class="co_starPage" id="co_pp_sp_506_1344"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1344&quot; }" alt="metadata" type="hidden">*1344</span> with the dissent's characterization of the PTO position as perfunctory. The PTO concluded that isolated DNA is patentable because it is different from what is found in nature—the process of synthesizing it or isolating it changes it. While the PTO lacks substantive rule making authority, it is not without expertise in this area. The explicit statement of the Patent Office's position on isolated DNA, however, is simply a continuation of a longstanding and consistent policy of allowing patents for isolated natural products. <em>See <a id="co_link_Iaa783f97afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=l&amp;pubNum=0001037&amp;cite=UUID(I368E38B0307811DAB1EA8A3AF7542D25)&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=CP&amp;fi=co_pp_sp_1037_1092&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_1037_1092">id.</a></em> (noting <a id="co_link_Iaa783f98afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1873169649&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=Ie2e7e5331c1911db80c2e56cac103088&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S. Patent 141,072</a>, claiming “[y]east, free from organic germs of disease,” issued to Louis Pasteur in 1873); <em>cf. </em><a id="co_link_Iaa783f99afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1970100510&amp;pubNum=350&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>In re Bergstrom,</em> 57 CCPA 1240, 427 F.2d 1394 (1970)</a> (isolated prostaglandins patentable). According to the Patent Office, isolated DNA is no different from the isolated natural products of <em><a id="co_link_Iaa783f9aafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1911104286&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Parke–Davis.</a> See</em> <a id="co_link_Iaa783f9bafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=l&amp;pubNum=0001037&amp;cite=UUID(I368E38B0307811DAB1EA8A3AF7542D25)&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=CP&amp;fi=co_pp_sp_1037_1093&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_1037_1093">66 Fed.Reg. at 1093</a> (quoting <a id="co_link_Iaa783f9cafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1911104286&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Parke–Davis</em> ).</a></div></div><div class="co_paragraph"><div class="co_paragraphText">Even before the current guidelines formalized the Patent Office's position, it granted patents to human genes in the early 1980s, and subsequently issued thousands of patents on “isolated DNA.” Majority at 1332–33. In fact, claims similar to the ones at issue in this case have been the focal point of important litigation. For example, <input id="co_docMarker_37" type="hidden"><a id="co_link_Iaa783f9dafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1991048875&amp;pubNum=0000350&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Amgen, Inc. v. Chugai Pharmaceutical Co.,</em> 927 F.2d 1200 (Fed.Cir.1991)</a> involved a claim to “ ‘[a] purified and isolated DNA sequence consisting essentially of a DNA sequence encoding human erythropoietin.’ ” <a id="co_link_Iaa783f9eafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1991048875&amp;pubNum=0000350&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_350_1203&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_1203"><em>Id.</em> at 1203–04</a> (quoting <a id="co_link_Iaa783f9fafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1987255753&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I0ef6725072dd11d7b0409d11d16b6b13&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">U.S. Patent No. 4,703,008</a>, claim 2). We affirmed that this claim was valid and infringed. <a id="co_link_Iaa783fa0afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1991048875&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 1219.</a> Erythropoietin, also known as EPO, went on to become the biggest-selling biotechnology drug developed to that point, resulted in billions of dollars in sales, and accounted for over 50% of Amgen's revenue in 1997. <a id="co_link_Iaa783fa1afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2001079767&amp;pubNum=0004637&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_4637_77&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_4637_77"><em>Amgen, Inc. v. Hoechst Marion Roussel, Inc.,</em> 126 F.Supp.2d 69, 77 (D.Mass.2001)</a>. Isolated DNA claims, at least in the case of Amgen, represent crucial and exceedingly valuable property rights.</div></div><div class="co_paragraph"><div class="co_paragraphText">The settled expectations of the biotechnology industry—not to mention the thousands of issued patents—cannot be taken lightly and deserve deference. This outpouring of scientific creativity, spurred by the patent system, reflects a substantial investment of time and money by the biotechnology industry to obtain property rights related to DNA sequences. The type of fundamental alteration in the scope of patentable subject matter argued in this case “risk[s] destroying the legitimate expectations of inventors in their property.” <a id="co_link_Iaa783fa2afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2002330186&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.,</em> 535 U.S. 722, 739, 122 S.Ct. 1831, 152 L.Ed.2d 944 (2002)</a>. I believe leaving intact the settled expectations of property owners is particularly important in light of the large number of property rights involved, both to isolated DNA and to purified natural products generally.</div></div><div class="co_paragraph"><div class="co_paragraphText">The Supreme Court has warned that “courts must be cautious before adopting changes that disrupt the settled expectations of the inventing community.” <a id="co_link_Iaa783fa3afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2002330186&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 739, 122 S.Ct. 1831.</a> The settled expectations of the inventing community with respect to isolated DNA claims are built upon the broad language of the statute, judicial precedent, such as <em>Parke–Davis</em> and <em>Merck,</em> and the Patent Office's longstanding policy and practice. Neither <em>Funk Brothers</em> nor <em>Chakrabarty</em> purported to overrule either the early cases or the Patent Office's practice; indeed, as discussed <em>supra,</em> these cases weigh the same considerations as <em>Parke–Davis</em> and <em>Merck.</em> “ ‘To change so substantially the rules of the game now,’ ” after more than a century of practice, “ ‘could very well subvert the  <span class="co_starPage" id="co_pp_sp_506_1345"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1345&quot; }" alt="metadata" type="hidden">*1345</span> various balances the PTO sought to strike when issuing the numerous patents which have not yet expired and which would be affected by our decision.’ ” <a id="co_link_Iaa783faaafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2002330186&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Festo,</em> 535 U.S. at 739, 122 S.Ct. 1831</a> (quoting <a id="co_link_Iaa783fabafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1997060689&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Warner–Jenkinson Co. v. Hilton Davis Chem. Co.,</em> 520 U.S. 17, 32 n. 6, 117 S.Ct. 1040, 137 L.Ed.2d 146 (1997)</a>).</div></div><div class="co_paragraph"><div class="co_paragraphText">Although the Patent Office has consistently followed the same policy for a decade (and arguably a century or more), the United States, as an amicus, now argues that the Patent Office's published guidelines are incorrect and a misstatement of the law. In place of these guidelines, the government suggested that a “magic microscope” would provide a useful metaphor for guiding our <a id="co_link_Iaa783facafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> analysis. The magic microscope, however, would not see the claimed DNA molecules at issue in this case. An isolated DNA molecule has different chemical bonds as compared to the “unisolated” sequence in the chromosome (the ends are different). In short, the claimed molecules cannot be seen in nature through the magic microscope. While you may be able to see the order of DNA nucleotides in the chromosome, the isolated fragment of DNA is a different molecule. Creating the claimed isolated DNA sequences therefore results in a distinctly unnatural molecule.<input id="co_docMarker_38" type="hidden"><sup id="co_footnoteReference_B02072028417793_ID0E14FK"><a href="#co_footnote_B02072028417793" class="co_footnoteReference">7</a></sup> Even the dissent agrees that the isolated DNA molecules at issue require cleaving chemical bonds, though it disputes the importance of the resulting distinct “ ‘molecular species.’ ” Dissent at 1350–51 (quoting Linus Pauling, <em>The Nature of the Chemical Bond</em> 6 (3d ed.1960)).</div></div><div class="co_paragraph"><div class="co_paragraphText">The dissent claims that the Patent Office's past views are “substantially undermined by the position the government has taken in this case.” Dissent at 1357–58. The Patent Office's prior practice, however, is particularly important since it resulted in a large number of property rights over the past decades. If the government decided to change course in the Patent Office, and decline to issue new patents to isolated genes, it would not impact these existing property rights. This, however, is not what the government argues in this case. Instead the government argues for an entirely different interpretation of the law that would destroy existing property rights. Although the dissent points out that <em>Chakrabarty</em> overturned the Patent Office's practice of denying patents to microorganisms, there is a clear difference between allowing additional patent protection where none previously existed, and denying patent protection decades (or centuries) after the fact, thereby eliminating a large number of property rights. <em>Chakrabarty</em>, consistent with the broad language of the statute, allowed additional patents where none previously existed. In contrast, the government proposes to destroy existing property rights based on a judge made exception to that same broad language. This is a dramatic step that I believe is best left to the Congress.</div></div><div class="co_paragraph"><div class="co_paragraphText">Nevertheless, the government claims that “this is a pure question of law” and  <span class="co_starPage" id="co_pp_sp_506_1346"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1346&quot; }" alt="metadata" type="hidden">*1346</span> that we can therefore feel free to ignore the years of Patent Office practice and the accompanying expectations that practice created within the industry. The government argues that we should not defer to the broad language (all but unchanged since 1793) provided by Congress in the patent statute, or allow Congress to decide whether it is necessary to correct the Patent Office's practice through legislation. It is tempting to use our judicial power in this fashion, especially when the patents in question raise substantial moral and ethical issues related to awarding a property right to isolated portions of human DNA—the very thing that makes us humans, and not chimpanzees.</div></div><div class="co_paragraph"><div class="co_paragraphText">The invitation is tempting, but I decline the opportunity to act where Congress has chosen not to. Congress at least implicitly approved of the Patent Office's policy of awarding patents on genes and DNA sequences. For example, Congress included, as part of the Patent Office's appropriations, language affirming the Patent Office's interpretation of <a id="co_link_Iaa783fafafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> to prohibit patents on human organisms. Consolidated Appropriations Act, 2004, <a id="co_link_Iaa783fb0afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=l&amp;pubNum=1077005&amp;cite=UUID(IB331FB4050-F011D8A74D8-7B95E93B7F0)&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=SL&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">Pub.L. No. 108–199, § 634, 118 Stat. 3</a>, 101. Although Congress was aware “that there are many institutions ... that have extensive patents on human genes,” 149 Cong. Rec. H7248, H7274, it explicitly declined to implement legislation to “affect any of those current existing patents.” <a id="co_link_Iaa783fb2afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=0296433719&amp;pubNum=0100003&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=TV&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">149 Cong. Rec. E2417–01</a>. To the contrary, it made clear that the language related to “human organisms” was not intended to change the Patent Office's policy with respect to claims to genes, stem cells, or other similar inventions.<sup id="co_footnoteReference_B02182028417793_ID0EJDGK"><a href="#co_footnote_B02182028417793" class="co_footnoteReference">8</a></sup> Far from oblivious to the patenting of genes, Congress introduced and declined to pass several bills which would put a moratorium on gene patents,<sup id="co_footnoteReference_B02292028417793_ID0EQDGK"><a href="#co_footnote_B02292028417793" class="co_footnoteReference">9</a></sup> authorize funding for the study of whether genes ought to be patentable,<input id="co_docMarker_39" type="hidden"><sup id="co_footnoteReference_B023102028417793_ID0EXDGK"><a href="#co_footnote_B023102028417793" class="co_footnoteReference">10</a></sup> and exempt from patent infringement anyone who uses patented genes for non-commercial research purposes or medical practitioners who use genetic diagnostic tests.<sup id="co_footnoteReference_B024112028417793_ID0E5DGK"><a href="#co_footnote_B024112028417793" class="co_footnoteReference">11</a></sup> Congress is obviously aware of the issues presented in this case and I believe “[a]ny recalibration of the standard of [patentability] remains in its hands.” <a id="co_link_Iaa783fb3afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2025432402&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_2252&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_2252"><em>Microsoft Corp. v. i4i Ltd.,</em> –––U.S. ––––, 131 S.Ct. 2238, 2252, 180 L.Ed.2d 131 (2011)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">The judiciary cannot engage in an <em>ad hoc</em> innovation-based analysis, which is why the exceptions to patentability apply  <span class="co_starPage" id="co_pp_sp_506_1347"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1347&quot; }" alt="metadata" type="hidden">*1347</span> only to the clearest cases: a new mineral discovered in the earth, or a new plant found in the wild, or E=mc <sup>2</sup>, or the law of gravity. It is Congress, with “the constitutional authority and the institutional ability to accommodate fully the varied permutations of competing interests that are inevitably implicated by such new technology,” <a id="co_link_Iaa783fb8afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1984103021&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Sony Corp. of America v. Universal City Studios, Inc.,</em> 464 U.S. 417, 431, 104 S.Ct. 774, 78 L.Ed.2d 574 (1984)</a>, who must decide whether it is necessary to change the scope of <a id="co_link_Iaa783fb9afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> to exclude the kind of isolated DNA claims at issue here. It is not clear to me that <em>Chakrabarty, Funk Brothers</em>, or <em>Prometheus</em> leads inexorably to the conclusion that isolated DNA molecules are not patentable subject matter. I decline the invitation to broaden the law of nature exception.</div></div><div class="co_paragraph"><div class="co_paragraphText">Given the complicated technology and conflicting incentives at issue here, any change must come from Congress. <em>See </em><a id="co_link_Iaa783fbdafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1972137547&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Gottschalk v. Benson,</em> 409 U.S. 63, 72–73, 93 S.Ct. 253, 34 L.Ed.2d 273 (1972)</a> (A <a id="co_link_Iaa783fbeafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> analysis raises “considerable problems ... which only committees of Congress can manage, for broad powers of investigation are needed, including hearings which canvass the wide variety of views which those operating in this field entertain. The technological problems tendered [by the parties] ... indicate to us that considered action by the Congress is needed.”).</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa768defafef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">IV.</span></div><div class="co_paragraph"><div class="co_paragraphText">“The rule that the discovery of a law of nature cannot be patented rests ... on the ... fundamental understanding that they are not the kind of ‘discoveries' that the statute was enacted to protect.” <a id="co_link_Iaa783fbfafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1978139495&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Flook,</em> 437 U.S. at 593, 98 S.Ct. 2522.</a> Is an isolated kidney patentable? Probably not, but as far as I can tell nobody ever thought isolating organs from someone's body was the kind of discovery “that the statute was enacted to protect.” In contrast, purifying or isolating natural products has historically been exactly the kind of discovery protected by the patent statutes. There is a century-long history of affirming patent protection for isolated and purified biological products ranging from hormones to vitamins to proteins to antibiotics. These inventions must have seemed miraculous at the time, providing previously unknown therapeutic options to treat sickness. The fact that these molecules might have existed in nature did not foreclose patent protection in view of the extraordinary benefits accessible to man after isolation.</div></div><div class="co_paragraph"><div class="co_paragraphText">The Patent Office has, for more than a decade, affirmatively stated its belief that isolated DNA is patentable for the same reasons as isolated vitamins or hormones. There is no indication from Congress that this view is wrong; to the contrary, it appears Congress also believes DNA is patentable. This long-term policy of protecting isolated DNA molecules has resulted in an explosion of innovation in the biotechnology industry, an industry which, unlike the financial services industry or even the software industry, depends on patents to survive. Holding isolated DNA not patentable would destroy long settled industry expectations for no reason other than a gut feeling that DNA is too close to nature to be patentable, an arbitrary decision based on a judge-made exception. I believe that isolated DNA fragments, which have both chemical changes from the naturally occurring genomic DNA as well as new utility, are <input id="co_docMarker_40" type="hidden">“the kind of ‘discoveries' that the statute was enacted to protect.” I therefore decline to extend the “laws of nature” exception to include isolated DNA sequences.</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_506_1348"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1348&quot; }" alt="metadata" type="hidden">*1348</span> This case typifies an observation by the late Chief Judge Markey, our first Chief Judge, that “[o]nly God works from nothing. Men must work with old elements.” <a id="co_link_Iaa783fc0afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1985109098&amp;pubNum=0000350&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_350_1556&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_350_1556"><em>Fromson v. Advance Offset Plate, Inc.,</em> 755 F.2d 1549, 1556 n. 3 (Fed.Cir.1985)</a> (quotation, citations omitted). Human DNA is, for better or worse, one of the old elements bequeathed to men to use in their work. The patents in this case revealed a new molecular understanding about ourselves; “the inventions most benefiting mankind are those that ‘push back the frontiers of chemistry, physics, and the like.’ ” <a id="co_link_Iaa783fc1afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 316, 100 S.Ct. 2204</a> (quoting <a id="co_link_Iaa783fc2afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1950117303&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Great A. &amp; P. Tea Co. v. Supermarket Corp.,</em> 340 U.S. 147, 154, 71 S.Ct. 127, 95 L.Ed. 162 (1950)</a>). We cannot, after decades of patents and judicial precedent, now call human DNA fruit from the poisonous tree, and punish those inquisitive enough to investigate, isolate, and patent it. “Our task ... is the narrow one of determining what Congress meant by the words it used in the statute; once that is done our powers are exhausted.” <a id="co_link_Iaa783fc3afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 318, 100 S.Ct. 2204.</a> This inquiry does not have moral, ethical, or theological components. <em>Cf. </em><a id="co_link_Iaa783fc4afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>id.</em> at 316–17, 100 S.Ct. 2204</a> (“[W]e are without competence to entertain” arguments about “the grave risks” generated by genetic research.). “The choice we are urged to make is a matter of high policy for resolution within the legislative process after the kind of investigation, examination, and study that legislative bodies can provide and courts cannot.” <a id="co_link_Iaa783fc5afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 317, 100 S.Ct. 2204.</a> The patents in this case might well deserve to be excluded from the patent system, but that is a debate for Congress to resolve. I will not strip an entire industry of the property rights it has invested in, earned, and owned for decades unchallenged under the facts of this case.</div></div></div></div></div></div></div><div class="co_contentBlock co_briefItState co_opinionBlock"><h2 id="co_cipdip_opinion"></h2><div class="co_docDelivery_dottedLine"><img src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/co_docDelivery_dottedLine.png" alt=""></div><div class="co_contentBlock x_opinionBlockBody"><div class="co_contentBlock x_opinionCipdip"><a id="co_link_Iaa783fc6afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=h&amp;pubNum=176284&amp;cite=0112582701&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">BRYSON</a>, Circuit Judge, concurring in part and dissenting in part:<div class="co_contentBlock x_opinionBody"><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa7728f3afef11e79bef99c0ee06c731"><div class="co_paragraph"><div class="co_paragraphText">I concur with the portions of this court's judgment that are directed to standing, the patentability of the cDNA claims, and the patentability of the method claims. I respectfully dissent from the court's holding that Myriad's BRCA gene claims and its claims to gene fragments are patent-eligible. In my view, those claims are not directed to patentable subject matter, and the court's decision, if sustained, will likely have broad consequences, such as preempting methods for whole-genome sequencing, even though Myriad's contribution to the field is not remotely consonant with such effects.</div></div><div class="co_paragraph"><div class="co_paragraphText">In its simplest form, the question in this case is whether an individual can obtain patent rights to a human gene. From a common-sense point of view, most observers would answer, “Of course not. Patents are for inventions. A human gene is not an invention.” The essence of Myriad's argument in this case is to say that it has not patented a human gene, but something quite different—an <em>isolated</em> human gene, which differs from a native gene because the process of extracting it results in changes in its molecular structure (although not in its genetic code). We are therefore required to decide whether the process of isolating genetic material from a human DNA molecule makes the isolated genetic material a patentable invention. The court concludes that it does; I conclude that it does not.</div></div><div class="co_paragraph"><div class="co_paragraphText">At the outset, it is important to identify the inventive contribution underlying Myriad's patents. Myriad was not the first to map a BRCA gene to its chromosomal location. That discovery was made by a team of researchers led by Dr. Mary–Claire King. <input id="co_docMarker_41" type="hidden"><em>See</em> Jeff M. Hall et al., <em>Linkage <span class="co_starPage" id="co_pp_sp_506_1349"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1349&quot; }" alt="metadata" type="hidden">*1349</span>  of Early–Onset Familial <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ib73a5554475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ib73a5554475411db9765f9243f53508a_2">Breast Cancer</a> to Chromosome 17q21,</em> 250 Science 1684 (1990). And Myriad did not invent a new method of nucleotide sequencing. Instead, it applied known sequencing techniques to identify the nucleotide order of the BRCA genes.<sup id="co_footnoteReference_B02512028417793_ID0EOXGK"><a href="#co_footnote_B02512028417793" class="co_footnoteReference">1</a></sup> Myriad's discovery of those sequences entailed difficult work, and the identified sequences have had important applications in the fight against <a href="https://1.next.westlaw.com/Link/Document/FullText?entityType=disease&amp;entityId=Ib73a5554475411db9765f9243f53508a&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.Default)" class="co_link co_drag ui-draggable" id="co_link_Ib73a5554475411db9765f9243f53508a_3">breast cancer</a>. But the discovery of the sequences is an unprotectable fact, just like Dr. King's discovery of the chromosomal location of the BRCA1 gene.</div></div><div class="co_paragraph"><div class="co_paragraphText">Of course, Myriad is free to patent applications of its discovery. As the first party with knowledge of the sequences, Myriad was in an excellent position to claim applications of that knowledge. Many of its unchallenged claims are limited to such applications. <em>See, e.g.,</em> ′<a id="co_link_Iaa783fc9afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998348225&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=Ibce1a8d0722911d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">441 patent</a>, claim 21; <a id="co_link_Iaa783fcaafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998422488&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=Ia9d8eb20724e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">′492 patent</a>, claim 22; <a id="co_link_Iaa783fcbafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">′282 patent</a>, claim 9. Yet some of Myriad's challenged composition claims effectively preempt any attempt to sequence the BRCA genes, including whole-genome sequencing. In my view, those claims encompass unpatentable subject matter, and a contrary ruling is likely to have substantial adverse effects on research and treatment in this important field.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa7728f4afef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">I</span></div><div class="co_paragraph"><div class="co_paragraphText">As the majority and concurring opinions explain, the DNA claims at issue in this case fall into three categories: claims that cover the isolated BRCA genes (claim 1 of the ′<a id="co_link_Iaa783fccafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a>, claim 1 of the ′<a id="co_link_Iaa783fcdafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1997377490&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I0e737f30746811d7a94bace56a9eba1c&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">473 patent</a>, and claims 1 and 6 of the ′<a id="co_link_Iaa783fceafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998422488&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=Ia9d8eb20724e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">492 patent</a>); claims that cover only the BRCA cDNA (claims 2 and 7 of the ′<a id="co_link_Iaa783fcfafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a> and claim 7 of the ′<a id="co_link_Iaa783fd0afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998422488&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=Ia9d8eb20724e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">492 patent</a>); and claims that cover portions of the BRCA genes and cDNA as small as 15 nucleotides long (claims 5 and 6 of the ′<a id="co_link_Iaa783fd1afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a>). I first address the claims to the BRCA genes.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa7728f5afef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">A</span></div><div class="co_paragraph"><div class="co_paragraphText">In the seminal case of <a id="co_link_Iaa783fd2afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Diamond v. Chakrabarty,</em> 447 U.S. 303, 100 S.Ct. 2204, 65 L.Ed.2d 144 (1980)</a>, the Supreme Court held that an artificial life form could be patented. In the course of its opinion, and critically for purposes of its reasoning, the Court stated that not all living things or other items found in nature were subject to patenting. The Court explained that although the language of <a id="co_link_Iaa783fd3afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a> of the Patent Act is broad, it is not the case that it “has no limits or that it embraces every discovery.” <a id="co_link_Iaa783fd4afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.</em> at 309, 100 S.Ct. 2204.</a> The Court then set forth the general proposition that “laws of nature, physical phenomena, and abstract ideas have been held not patentable.” <em>Id.</em> As examples, the Court noted that “a new mineral discovered in the earth or a new plant found in the wild is not patentable subject matter.” Thus, even though a mineral or a plant is a “composition of matter,” and could be viewed as falling within a broad construction of <a id="co_link_Iaa783fd6afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>, the Court explained that those “manifestations of ... nature” are not patentable subject matter, but are “free to all men and reserved exclusively to none.” <a id="co_link_Iaa783fd7afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Id.,</em></a> quoting <a id="co_link_Iaa783fd8afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Funk Bros. Seed Co. v. Kalo Inoculant Co.,</em> 333 U.S. 127, 130, 68 S.Ct. 440, 92 L.Ed. 588 (1948)</a>; <em>see also </em><a id="co_link_Iaa783fd9afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2022394590&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_708_3225&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_708_3225"><em>Bilski v. Kappos,</em> ––– U.S. ––––, 130 S.Ct. 3218, 3225, 177 L.Ed.2d 792 (2010)</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText"> <span class="co_starPage" id="co_pp_sp_506_1350"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1350&quot; }" alt="metadata" type="hidden">*1350</span> The Court in <em>Chakrabarty</em> held the artificial life form at issue in that case to be patentable because the claim was “not to a hitherto unknown natural phenomenon, but to a nonnaturally occurring manufacture or composition of matter—a product of human ingenuity ‘having a distinctive name, character [and] use.’ ” <a id="co_link_Iaa783fdbafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">447 U.S. at 309–10, 100 S.Ct. 2204,</a> quoting <a id="co_link_Iaa783fdcafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1887180158&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Hartranft v. Wiegmann,</em> 121 U.S. 609, 615, 7 S.Ct. 1240, 30 L.Ed. 1012 (1887)<input id="co_docMarker_42" type="hidden"></a>. In distinguishing between naturally occurring substances and nonnaturally occurring manufactures, the Court relied heavily on its earlier decision in <em>Funk Brothers,</em> in which the inventor discovered that certain useful bacterial strains did not exert an inhibitive effect on one another. Based on that discovery, the inventor obtained a patent on a mixed culture of those non-inhibitive strains. The Supreme Court held the product unpatentable, however, because the bacteria remained structurally and functionally the same as in their natural state. <a id="co_link_Iaa783fdeafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1948116775&amp;pubNum=708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Funk Bros.,</em> 333 U.S. at 131, 68 S.Ct. 440.</a> By contrast, because Chakrabarty had produced “a new bacterium with markedly different characteristics from any found in nature and one having the potential for significant utility,” the Court held Chakrabarty's invention to be patentable. <a id="co_link_Iaa783fdfafef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 310, 100 S.Ct. 2204</a>.</div></div></div><div class="co_contentBlock co_briefItState co_section" id="co_anchor_Iaa7728f6afef11e79bef99c0ee06c731"><div class="co_headtext co_hAlign2"><span class="co_smallCaps">B</span></div><div class="co_paragraph"><div class="co_paragraphText">Myriad's claims to the isolated BRCA genes seem to me to fall clearly on the “unpatentable” side of the line the Court drew in <em>Chakrabarty</em>. Myriad is claiming the genes themselves, which appear in nature on the chromosomes of living human beings. The only material change made to those genes from their natural state is the change that is necessarily incidental to the extraction of the genes from the environment in which they are found in nature. While the process of extraction is no doubt difficult, and may itself be patentable, the isolated genes are not materially different from the native genes. In this respect, the genes are analogous to the “new mineral discovered in the earth,” or the “new plant found in the wild” that the Supreme Court referred to in <em>Chakrabarty</em>. It may be very difficult to extract the newly found mineral or to find, extract, and propagate the newly discovered plant. But that does not make those naturally occurring items the products of invention.</div></div><div class="co_paragraph"><div class="co_paragraphText">The same is true for human genes. Like some minerals, they are hard to extract from their natural setting. Also like minerals, they can be used for purposes that would be infeasible if they remained in their natural setting. And the process of extracting minerals, or taking cuttings from wild plants, like the process of isolating genetic material, can result in some physical or chemical changes to the natural substance. But such changes do not make extracted minerals or plant cuttings patentable, and they should not have that effect for isolated genes. In each case, merely isolating the products of nature by extracting them from their natural location and making those alterations that are attendant to their extraction does not give the extractor the right to patent the products themselves.</div></div><div class="co_paragraph"><div class="co_paragraphText">The majority characterizes the isolated genes as new molecules and considers them different substances from the corresponding native DNA.<sup id="co_footnoteReference_B02622028417793_ID0EZIHK"><a href="#co_footnote_B02622028417793" class="co_footnoteReference">2</a></sup> Because the native BRCA genes are chemically bonded to other <span class="co_starPage" id="co_pp_sp_506_1351"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1351&quot; }" alt="metadata" type="hidden">*1351</span>  genes and histone proteins, the majority concludes that cleaving those bonds to isolate the BRCA genes turns the isolated genes into “different materials.” Yet there is no magic to a chemical bond that requires us to recognize a new product when a chemical bond is created or broken, but not when other atomic or molecular forces are altered.<sup id="co_footnoteReference_B02732028417793_ID0EFJHK"><a href="#co_footnote_B02732028417793" class="co_footnoteReference">3</a></sup> A chemical bond is merely a force between two atoms or groups of atoms strong enough “to make it convenient for the chemist to consider [the aggregate] as an independent molecular species.” Linus Pauling, <em>The Nature of the Chemical Bond</em> 6 (3d ed.1960). Weaker interatomic forces will be broken when, for example, a dirty diamond is cleaned with water or another solvent, but that does not make the clean diamond a human-made invention. <input id="co_docMarker_43" type="hidden"><em>See </em><a id="co_link_Iaa783fe2afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1931123423&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Am. Fruit Growers, Inc. v. Brogdex Co.,</em> 283 U.S. 1, 12, 51 S.Ct. 328, 75 L.Ed. 801 (1931)</a> (cleaning a shell by acid and then grinding off a layer with an emery wheel did not convert it into a different product). Nor should it make a difference for purposes of patentability if the portion of a wild plant that is collected for purposes of later regeneration is separated from the original plant by chemical means or by scissors.</div></div><div class="co_paragraph"><div class="co_paragraphText">If the changes in the DNA molecule that occur as part of the process of isolation render the gene claims patentable, the same analysis would seem to apply to chemical elements that do not appear in their atomic form in nature. For example, isolated lithium does not occur naturally because it reacts with air and water and thus is found in nature only as part of a chemical compound, ionically bound to other elements. Robert E. Krebs, <em>The History and Use of Our Earth's Chemical Elements</em> 48 (2d ed.2006). Once isolated, lithium has many industrial applications, and in order to isolate lithium, it is necessary to break ionic bonds in the lithium compounds that are found in nature. But it seems plain that elemental lithium (like other elements) would not be patentable subject matter, even if it could only be extracted from nature through an isolation process.</div></div><div class="co_paragraph"><div class="co_paragraphText">The principles underlying that analysis apply to genetic material as well. In order to isolate the BRCA gene, it is necessary to break chemical bonds that hold the gene in its place in the body, but the genetic coding sequence that is the subject of each of the BRCA gene claims remains the same whether the gene is in the body or isolated. If we are to apply the conventional nomenclature of any field to determine whether Myriad's isolated DNA claims are “new,” it would seem to make more sense to look to genetics, which provides the language of the claims, than to chemistry. Aside from Myriad's cDNA claims, its composition claims are not defined by any particular chemical formula. For example, claim 1 of the ′<a id="co_link_Iaa783fe3afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">282 patent</a> covers all isolated DNAs coding for the BRCA1 protein, with the protein being  <span class="co_starPage" id="co_pp_sp_506_1352"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1352&quot; }" alt="metadata" type="hidden">*1352</span> defined by the amino acid sequence encoded by the naturally occurring BRCA1 gene. From a molecular perspective, that claim covers a truly immense range of substances from the cDNA that is 5,914 nucleotides long to the isolated gene that contains more than 120,000 nucleotides. And the patent does not define the upper end of that range because the patent does not identify a unique nucleotide sequence for the 120,000–nucleotide–long isolated BRCA1 gene. Instead, the patent contains a sequence that is just 24,000 nucleotides long with numerous gaps denoted “vvvvvvvvvvvv.” <a id="co_link_Iaa783fe4afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1998357609&amp;pubNum=0004074&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=PA&amp;docFamilyGuid=I8da08b90722e11d7a07084608af77b15&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">′282 patent</a>, fig. 10. An almost incalculably large number of new molecules could be created by filling in those gaps with almost any nucleotide sequence, and all of those molecules would fall within the scope of claim 1. Included in that set are many important molecular variations to the BRCA1 gene that Myriad had not yet discovered and could not have chemically described. Yet those molecules would share only one unifying characteristic: each would code for the same protein as the naturally occurring BRCA1 gene.</div></div><div class="co_paragraph"><div class="co_paragraphText">From a genetic perspective, that claim covers one “composition of matter”—the BRCA1 gene. The isolated BRCA genes are identical to the BRCA genes found on chromosomes 13 and 17. They have the same sequence, they code for the same proteins, and they represent the same units of heredity. It is true that the claimed molecules have been cleaved and that they possess terminal groups that differ from those found on naturally occurring genes. The majority attaches significance to those facts. But the function of the isolated DNA molecules is attributable not to the nature of the isolation process or to the identity of the terminal groups on the molecules; the function of the claimed molecules is dictated by the nucleotide sequence of the gene—a sequence that is determined by nature and that appears in nature exactly as it appears in the claimed isolated DNA. During the transcription phase of protein synthesis, the BRCA genes are separated from chromosomal proteins. The transcription process then proceeds from a starting point called the promoter to a stopping point often called the terminator. James D. Watson et al., <input id="co_docMarker_44" type="hidden"><em>Molecular Biology of the Gene</em> 382, 394–96 (6th ed.2008). The only difference between the naturally occurring BRCA genes during transcription and the claimed isolated DNA is that the claimed genes have been isolated according to nature's predefined boundaries, i.e., at points that preserve the ability of the gene to express the protein for which it is coded.</div></div><div class="co_paragraph"><div class="co_paragraphText">In that respect, extracting a gene is akin to snapping a leaf from a tree. Like a gene, a leaf has a natural starting and stopping point. It buds during spring from the same place that it breaks off and falls during autumn. Yet prematurely plucking the leaf would not turn it into a human-made invention. <em>See </em><a id="co_link_Iaa783fe5afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=2022715339&amp;pubNum=0000506&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;fi=co_pp_sp_506_1295&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)#co_pp_sp_506_1295"><em>Intervet Inc. v. Merial Ltd.,</em> 617 F.3d 1282, 1295 (Fed.Cir.2010)</a> (Dyk, J., concurring in part and dissenting in part). That would remain true if there were minor differences between the plucked leaf and the fallen autumn leaf, unless those differences imparted “markedly different characteristics” to the plucked leaf. <a id="co_link_Iaa783fe6afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=Y&amp;serNum=1980116775&amp;pubNum=0000708&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=RP&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)"><em>Chakrabarty,</em> 447 U.S. at 310, 100 S.Ct. 2204</a>.</div></div><div class="co_paragraph"><div class="co_paragraphText">Another example underscores the problem with characterizing the isolated gene as a patentable invention. A human kidney is a product of nature; it does not become a patentable invention when it is removed from the body, even if the patentee has developed an improved procedure for extracting the kidney, and even if the  <span class="co_starPage" id="co_pp_sp_506_1353"><input class="co_starPageMetadataItem" value="{ &quot;pageset&quot;: &quot;S09042298fbd411e1b11ea85d0b248d27&quot;, &quot;pageNumber&quot;: &quot;1353&quot; }" alt="metadata" type="hidden">*1353</span> improved procedure results in some physical or chemical changes to the kidney at the points where the kidney was attached to the host body. But if that is so, then why should an isolated gene be treated differently for purposes of <a id="co_link_Iaa783fe7afef11e79bef99c0ee06c731" class="co_link" href="https://1.next.westlaw.com/Link/Document/FullText?findType=L&amp;pubNum=1000546&amp;cite=35USCAS101&amp;originatingDoc=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;refType=LQ&amp;originationContext=document&amp;transitionType=DocumentItem&amp;contextData=(sc.CustomDigest)">section 101</a>? While the isolation of a gene involves the alteration of a single molecule, it is difficult to accept that it should make a difference, for purposes of patentability, whether the isolated substance is part of a single molecule, as in the case of the BRCA genes, or part of a very large aggregation of molecules, as in the case of a kidney.</div></div></div></div></div></div></div></div><input class="co_chunkNumber" value="0" type="hidden"></div><input id="co_document_metaInfo_Iefd1c172e7ba11e1b11ea85d0b248d27" value="{&quot;FirstLineCite&quot;:null,&quot;PU&quot;:null,&quot;accessControl&quot;:null,&quot;accessionNumber&quot;:&quot;&quot;,&quot;acquirerCompany&quot;:null,&quot;activeDate&quot;:null,&quot;additionalLinks&quot;:null,&quot;agreementDisplayDate&quot;:null,&quot;announcementDate&quot;:null,&quot;articleTitle&quot;:null,&quot;borrower&quot;:null,&quot;caseRequired&quot;:null,&quot;ciCompany&quot;:null,&quot;cicOfficer&quot;:null,&quot;cipOfficer&quot;:null,&quot;cite&quot;:&quot;689 F.3d 1303&quot;,&quot;citeAbbreviation&quot;:null,&quot;citePrimary&quot;:null,&quot;city&quot;:null,&quot;collection&quot;:&quot;w_cs_fed3&quot;,&quot;compoundTitle&quot;:null,&quot;containerId&quot;:null,&quot;containerType&quot;:null,&quot;contentType&quot;:&quot;Cases&quot;,&quot;contentTypeId&quot;:&quot;1&quot;,&quot;correlationIds&quot;:null,&quot;country&quot;:null,&quot;countryDocumentCountry&quot;:null,&quot;countryDocumentGuid&quot;:null,&quot;court&quot;:&quot;C.A.Fed. (N.Y.)&quot;,&quot;courtDocumentType&quot;:null,&quot;courtNumber&quot;:&quot;4242&quot;,&quot;courtYear&quot;:&quot;C.A.Fed. (N.Y.),2012.&quot;,&quot;date&quot;:&quot;August 16, 2012&quot;,&quot;dateFile&quot;:&quot;August 16, 2012&quot;,&quot;dealDate&quot;:null,&quot;dealTrackPublishDate&quot;:null,&quot;dealType&quot;:null,&quot;dealValue&quot;:null,&quot;description&quot;:null,&quot;docFamilyGuid&quot;:&quot;Iefd1c173e7ba11e1b11ea85d0b248d27&quot;,&quot;docGuid&quot;:&quot;Iefd1c172e7ba11e1b11ea85d0b248d27&quot;,&quot;docLink&quot;:&quot;https://1.next.westlaw.com/Document/Iefd1c172e7ba11e1b11ea85d0b248d27/View/FullText.html?originationContext=document&amp;contextData=(sc.CustomDigest)&amp;needToInjectTerms=False&quot;,&quot;documentTitle&quot;:null,&quot;edgarFileNumber&quot;:null,&quot;entityId&quot;:null,&quot;expertType&quot;:null,&quot;fileName&quot;:null,&quot;fileNumber&quot;:&quot;&quot;,&quot;fileSize&quot;:0,&quot;fileType&quot;:null,&quot;filerCik&quot;:null,&quot;filerName&quot;:null,&quot;filingDate&quot;:null,&quot;filingYear&quot;:null,&quot;firmName&quot;:null,&quot;formNumber&quot;:null,&quot;formSubType&quot;:null,&quot;formType&quot;:null,&quot;formTypeDisplay&quot;:null,&quot;formVolume&quot;:null,&quot;functionalCite&quot;:&quot;689 F.3d 1303&quot;,&quot;fundFirmCompoundTitle&quot;:null,&quot;fundLocation&quot;:null,&quot;fundName&quot;:null,&quot;fundTargetSize&quot;:null,&quot;fundType&quot;:null,&quot;fundYear&quot;:null,&quot;fundraisingStatus&quot;:null,&quot;getTocData&quot;:false,&quot;hasDraftingNotes&quot;:null,&quot;hasVideoContent&quot;:null,&quot;impersonationKey&quot;:null,&quot;inlineKeyCiteFlagsIncluded&quot;:false,&quot;inlineKeyCiteFlagsResolutionStatus&quot;:null,&quot;insiderName&quot;:null,&quot;ip_assignmentsAction&quot;:null,&quot;ip_citeParallel&quot;:null,&quot;ip_derwentPublishedDate&quot;:null,&quot;ip_docket&quot;:null,&quot;ip_documentDate&quot;:&quot;August 16, 2012&quot;,&quot;ip_issuedDate&quot;:null,&quot;ip_litAlertAttorney&quot;:null,&quot;ip_patStatCode&quot;:null,&quot;ip_patentOwner&quot;:null,&quot;ip_publishedDate&quot;:null,&quot;ip_shortTitle&quot;:null,&quot;isDisplayMiniReport&quot;:false,&quot;isGatewayDocument&quot;:false,&quot;isLargeDocument&quot;:false,&quot;isPersistedContent&quot;:false,&quot;isPublicRecordsBlockedByPermissibleUse&quot;:false,&quot;isPublicRecordsBlockedBySocialSecurityAdmin&quot;:false,&quot;isPublicRecordsDocument&quot;:false,&quot;isRefsAndAnnos&quot;:false,&quot;isRegChangeDocument&quot;:false,&quot;isSearchable&quot;:null,&quot;isSecureContent&quot;:false,&quot;issueDate&quot;:null,&quot;issuerName&quot;:null,&quot;jobDescription&quot;:null,&quot;judge&quot;:&quot;LOURIE, Circuit Judge.&quot;,&quot;jurisAbbrev&quot;:null,&quot;jurisdiction&quot;:&quot;NY&quot;,&quot;jurisdictionFacet&quot;:&quot;Federal|**|Cts. of Appeals|**|Federal Cir.&quot;,&quot;jurisdictionText&quot;:&quot;New York&quot;,&quot;knos&quot;:null,&quot;lastRoundExitComb&quot;:null,&quot;legacyId&quot;:&quot;2028417793&quot;,&quot;letterType&quot;:null,&quot;locationOfIncorporation&quot;:null,&quot;maxOfferingPrice&quot;:null,&quot;natureOfTransaction&quot;:null,&quot;newsImageHrefLarge&quot;:null,&quot;newsImageHrefSmall&quot;:null,&quot;normalizedDocType&quot;:null,&quot;normalizedFormType&quot;:null,&quot;offeringType&quot;:null,&quot;organizationName&quot;:null,&quot;originatingDoc&quot;:null,&quot;pageCount&quot;:null,&quot;persistedDocGuid&quot;:null,&quot;plcFirmStyleAvailable&quot;:false,&quot;plcResourceName&quot;:&quot;&quot;,&quot;portfolioCompanyLocation&quot;:null,&quot;portfolioCompanyName&quot;:null,&quot;prMetaInfo1&quot;:null,&quot;prMetaInfo2&quot;:null,&quot;prMetaInfo3&quot;:null,&quot;prMetaInfo4&quot;:null,&quot;prMetaInfo5&quot;:null,&quot;primaryEditorialService&quot;:null,&quot;profileType&quot;:null,&quot;pubSeries&quot;:null,&quot;publishDate&quot;:null,&quot;questionText&quot;:null,&quot;redlined&quot;:false,&quot;registrationDate&quot;:null,&quot;renditionId&quot;:&quot;I24CA6A081DD211B29BE0DB00C20F256E&quot;,&quot;royaltyId&quot;:&quot;0&quot;,&quot;rulebookNViews&quot;:null,&quot;serialNumber&quot;:&quot;2028417793&quot;,&quot;status&quot;:null,&quot;subContentType&quot;:&quot;Caselaw - NRS&quot;,&quot;subContentTypeId&quot;:&quot;27&quot;,&quot;subTitle&quot;:null,&quot;targetCompany&quot;:null,&quot;testimonyType&quot;:null,&quot;titleHtml&quot;:&quot;Association for Molecular Pathology v. U.S. Patent and Trademark Office&quot;,&quot;titleText&quot;:&quot;Association for Molecular Pathology v. U.S. Patent and Trademark Office&quot;,&quot;totalAmountIssuedWithCurrency&quot;:null,&quot;totalPages&quot;:&quot;&quot;,&quot;trademarkStatus&quot;:null,&quot;transactionAmountWithCurrency&quot;:null,&quot;transactionValue&quot;:null,&quot;valuationComb&quot;:null,&quot;viewExpressions&quot;:&quot;EDR|EZ5|E3I|P3D|000&quot;,&quot;westlawDatabaseIdentifier&quot;:&quot;AWFED2&quot;,&quot;westlawDocumentNumber&quot;:&quot;1391218&quot;}" type="hidden"><input id="co_document_documentNavigation_Search_Search-v1-results-navigation-i0ad6ad3e0000016314b8705c8686bce0-Nav-CUSTOMDIGEST-fragmentIdentifier-Iefd1c172e7ba11e1b11ea85d0b248d27-startIndex-1-contextData--28sc.CustomDigest-29-transitionType-CustomDigestItem_CUSTOMDIGEST_337" value="{&quot;AnswerSnippetId&quot;:null,&quot;CurrentDocumentGuid&quot;:&quot;Iefd1c172e7ba11e1b11ea85d0b248d27&quot;,&quot;CurrentPosition&quot;:337,&quot;CurrentWatsonAnswerText&quot;:null,&quot;EnableConceptCounts&quot;:false,&quot;HighlightPoints&quot;:null,&quot;HighlightTerms&quot;:null,&quot;InPlanUrl&quot;:null,&quot;IsSnapSnippet&quot;:false,&quot;ListCount&quot;:718,&quot;Message&quot;:null,&quot;NextDocument&quot;:{&quot;SkipLinkOutDoc&quot;:false,&quot;Title&quot;:&quot;Bancorp Services, L.L.C. v. Sun Life Assur. Co. of Canada (U.S.)&quot;,&quot;Url&quot;:&quot;/Document/I78d8c8a4d76411e1b343c837631e1747/View/FullText.html?navigationPath=Search%2Fv1%2Fresults%2Fnavigation%2Fi0ad6ad3e0000016314b8705c8686bce0%3FNav%3DCUSTOMDIGEST%26fragmentIdentifier%3DI78d8c8a4d76411e1b343c837631e1747%26startIndex%3D1%26contextData%3D%2528sc.CustomDigest%2529%26transitionType%3DCustomDigestItem&amp;listSource=Search&amp;list=CUSTOMDIGEST&amp;rank=338&amp;grading=na&amp;sessionScopeId=35b024c40cf4110fbdaaf6a30272ec9b29310adb8108a3d6fb727f98020766f7&amp;originationContext=Custom%20Digest&amp;transitionType=CustomDigestItem&amp;contextData=%28sc.CustomDigest%29&amp;listPageSource=1b34510ac2bede0102300be6a61ae1f3#co_anchor_F82028287013&quot;},&quot;NovusQueryType&quot;:null,&quot;NovusSearchResult&quot;:null,&quot;NumberOfSnips&quot;:0,&quot;ParagraphId&quot;:null,&quot;PreviousDocument&quot;:{&quot;SkipLinkOutDoc&quot;:false,&quot;Title&quot;:&quot;Association for Molecular Pathology v. U.S. Patent and Trademark Office&quot;,&quot;Url&quot;:&quot;/Document/Iefd1c172e7ba11e1b11ea85d0b248d27/View/FullText.html?navigationPath=Search%2Fv1%2Fresults%2Fnavigation%2Fi0ad6ad3e0000016314b8705c8686bce0%3FNav%3DCUSTOMDIGEST%26fragmentIdentifier%3DIefd1c172e7ba11e1b11ea85d0b248d27%26startIndex%3D1%26contextData%3D%2528sc.CustomDigest%2529%26transitionType%3DCustomDigestItem&amp;listSource=Search&amp;list=CUSTOMDIGEST&amp;rank=336&amp;grading=na&amp;sessionScopeId=35b024c40cf4110fbdaaf6a30272ec9b29310adb8108a3d6fb727f98020766f7&amp;originationContext=Custom%20Digest&amp;transitionType=CustomDigestItem&amp;contextData=%28sc.CustomDigest%29&amp;listPageSource=1b34510ac2bede0102300be6a61ae1f3#co_anchor_F132028417793&quot;},&quot;ReturnTo&quot;:{&quot;SkipLinkOutDoc&quot;:false,&quot;Title&quot;:&quot;list&quot;,&quot;Url&quot;:&quot;/Search/Results.html?jurisdiction=CTAF&amp;contentType=CUSTOMDIGEST&amp;querySubmissionGuid=i0ad6ad3e0000016314b8705c8686bce0&amp;tocGuid=I4aee2539c6f64c1812a4c2f3395c2607&amp;categoryPageUrl=Home%2FWestKeyNumberSystem&amp;searchId=i0ad6ad3a0000016314b861eab2033b51&amp;collectionSet=w_cs_cd_toc&amp;transitionType=ReturnToList&amp;contextData=%28sc.CustomDigest%29#Iefd1c172e7ba11e1b11ea85d0b248d27&quot;},&quot;SearchQuery&quot;:null,&quot;SearchQueryType&quot;:null,&quot;SearchWithinQuery&quot;:null,&quot;SecondaryHighlightTerms&quot;:null,&quot;ShowSkipOutOfPlanOption&quot;:false}" type="hidden"><div id="co_nrsOutline" class="co_hideState"></div><input id="co_documentContentCacheKey" value="WestlawNext|none|Iefd1c172e7ba11e1b11ea85d0b248d27|||||||Search|Search/v1/results/navigation/i0ad6ad3e0000016314b8705c8686bce0?Nav=CUSTOMDIGEST&amp;fragmentIdentifier=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;startIndex=1&amp;contextData=%28sc.CustomDigest%29&amp;transitionType=CustomDigestItem|CUSTOMDIGEST|337|False|True|{&quot;HighlightPoints&quot;:null,&quot;HighlightTerms&quot;:null,&quot;SearchWithinQuery&quot;:null,&quot;SecondaryHighlightTerms&quot;:null}|False|||False|False|||True|S|False|Core|||001|False|False|False|False|False|" type="hidden"><input id="co_documentFlagInfo" value="{&quot;docGuid&quot;:&quot;Iefd1c172e7ba11e1b11ea85d0b248d27&quot;,&quot;flags&quot;:[{&quot;categoryId&quot;:&quot;kcJudicialHistory&quot;,&quot;id&quot;:&quot;direct.history.strong&quot;,&quot;link&quot;:&quot;https://1.next.westlaw.com/Link/RelatedInformation/Flag?docGuid=Iefd1c172e7ba11e1b11ea85d0b248d27&amp;originationContext=docHeaderFlag&amp;transitionType=Document&amp;contextData=%28sc.CustomDigest%29&quot;,&quot;metadata&quot;:{&quot;citation&quot;:&quot;569 U.S. 576&quot;,&quot;court&quot;:&quot;U.S.&quot;,&quot;docFamilyGuid&quot;:&quot;Id30a7040d41311e2a98ec867961a22de&quot;,&quot;docGuid&quot;:&quot;Id30a4943d41311e2a98ec867961a22de&quot;,&quot;liveDate&quot;:&quot;June 13, 2013&quot;,&quot;subsequentDetermination&quot;:&quot;N&quot;,&quot;title&quot;:&quot;Association for Molecular Pathology v. Myriad Genetics, Inc.&quot;,&quot;titleLink&quot;:&quot;https://1.next.westlaw.com/Document/Id30a4943d41311e2a98ec867961a22de/View/FullText.html?listSource=RelatedInfo&amp;list=NegativeCitingReferences&amp;rank=0&amp;originationContext=docHeader&amp;transitionType=NegativeTreatment&amp;contextData=%28sc.CustomDigest%29&quot;,&quot;treatmentPhrase&quot;:&quot;Affirmed in Part, Reversed in Part by&quot;},&quot;type&quot;:&quot;direct.history&quot;,&quot;value&quot;:&quot;strong&quot;}],&quot;metas&quot;:[{&quot;contentType&quot;:&quot;CASELAW&quot;,&quot;docCollection&quot;:&quot;w_cs_fed3&quot;,&quot;docFamilyGuid&quot;:&quot;Iefd1c173e7ba11e1b11ea85d0b248d27&quot;,&quot;legacyId&quot;:&quot;2028417793&quot;,&quot;sourcePubId&quot;:&quot;506&quot;}]}" type="hidden">




							<div id="co_chunkNavTwo"><div class="co_chunkPagination" id="co_bottomChunkNav"><ul class="co_navFooter_pagination" id="co_bottomDocumentChunkNavFooter_pagination"><li><strong>Part:</strong></li><li><a id="co_bottomPreviousChunkButton" class="co_prev co_tbButton co_disabled" href=""><span class="icon25 icon_prev_arrow">Previous Part</span></a></li><li><label><span class="co_accessibilityLabel">Go To Document Part</span><input id="co_bottomCurrentChunkStatus" size="1" maxlength="4" type="text"></label> of <strong id="co_bottomChunkCountStatus">2</strong></li><li><a id="co_bottomNextChunkButton" class="co_next co_tbButton" href=""><span class="icon25 icon_next_arrow">Next Part</span></a></li></ul><div class="co_clear"></div><div></div></div></div></div>

				</div>
			</div>
		</div>
	</div>
	<!-- LEFT COLUMN -->  
	<div id="co_leftColumn">
		<div class="co_innertube">
			<div id="coid_website_folderingWidgetDiv"></div>
		</div>
	</div>
			<!-- RIGHT COLUMN -->
			<div id="co_rightColumn" class="co_addFocusCorrection">
				<div class="co_innertube">		
					<div id="coid_website_relatedInfoIPWidgetDiv" style="display: none;" aria-expanded="false">
					</div>




<div id="coid_website_documentToolWidgetDiv"></div>
		<div id="coid_website_relatedInfoWidgetDiv"> </div>
		<div id="coid_website_recommendedDocuments" class="co_recommendedDocumentContainer">
		</div>

<div id="downloadUserDocument"></div>
					<div id="downloadUserDocument"></div>
				</div>
			</div>

 <input class="hideTopTopics" id="hideTopTopics" name="hideTopTopics" type="hidden">
		<div class="co_clear"></div>
	</div>


	<!-- BEGIN FOOTER -->
	<div id="co_footerContainer"><div id="co_cookiePolicyContainer">
	<div class="co_cookiePolicyContent">
			<h3><b>Our policy towards the use of cookies</b></h3>
			<p>All Thomson Reuters websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.</p>
			<ul class="co_inlineList">
				<li>
					<a id="coid_website_cookiePolicyLinkOut" href="javascript:void(0)">Read cookie policy</a>
				</li>
				<li>
					<a id="coid_website_closeCookiePolicy" href="javascript:void(0)">Close</a>
				</li>
			<p></p>
			<button type="button" id="coid_website_cookiePolicyAcknowledged" title="Close message to acknowledge cookie policy" class="co_absolute">
				<span class="icon25 icon_close_x"></span>
			</button>
	</ul></div>
</div>


		
		<div class="co_innertube co_clearfix" id="co_footer" style="display: none;">







<div class="co_floatLeft">
	<div id="co_footerLinks">
		<ul class="co_inlineList">
					<li><a id="coid_websiteFooter_userSettings" href="javascript:void(0);"><span class="icon25 icon_gear_document"></span>Preferences</a></li>
				<li><a id="coid_websiteFooter_helplink" href="javascript:void(0);"><span class="icon25 icon_question_mark"></span>Training &amp; Support</a></li>
				
					<li><a id="coid_websiteFooter_signofflink" href="javascript:void(0);"><span class="icon25 icon_exit_door"></span>Sign Off</a></li>

		</ul>
	</div>
	<div id="co_footerCopyright">
		<ul class="co_inlineList">

			<li>Westlaw. <a href="/Copyright?transitionType=Default&amp;contextData=(sc.Default)"> © 2018</a> Thomson Reuters</li>
			<li><a id="coid_websiteFooter_privacyPolicyLink" href="javascript:void(0)">Privacy Statement</a></li>
			<li><a href="/Accessibility?transitionType=Default&amp;contextData=(sc.Default)">Accessibility</a></li>
				<li id="co_footer_supplier"><a id="coid_website_supplierTerms" href="javascript:void(0);">Supplier Terms</a></li>
				<li id="co_footerContactUs"><a href="/ContactUs?transitionType=Default&amp;contextData=(sc.Default)">Contact Us</a></li>
				<li id="co_footerCs">1-800-REF-ATTY (1-800-733-2889)</li>
				<li id="co_footer_improve"><strong><a id="coid_websiteFooter_pageSurvey" href="javascript:void(0);">Improve Westlaw</a></strong></li>
		</ul>


	</div>
</div>





<div id="co_trLogo" class="co_floatRight">

	<a id="co_trLogo_link" href="#">
		<img alt="Thomson Reuters" src="https://ia.next.westlaw.com/StaticContent_40.1.1015/images/v2/co_logo_thomsonReuters.png" width="134" height="30">
	</a>
</div>



		</div>
	</div>
			<div id="coid_Trmr" style="display:none; visibility:hidden"></div>
		</div>
	</div>
	
	<!--static content version number-->
<script type="text/javascript">





	
		window['Server/Routing'] = {
			Search: 'search.int.next.westlaw.com',
			TypeAhead: 'typeahead.int.next.westlaw.com',
			Nlu: 'nlu.int.next.westlaw.com',
			Document: 'document.int.next.westlaw.com',
			Foldering: 'foldering.int.next.westlaw.com',
			CSS: 'ca.next.westlaw.com/StaticContent_40.1.1015',
			Images: 'ia.next.westlaw.com/StaticContent_40.1.1015',
			JavaScript: 'ja.next.westlaw.com/StaticContent_40.1.1015',
			RelatedInfo: 'relatedinfo.int.next.westlaw.com',
			Events: 'events.int.next.westlaw.com',
			KM: 'NONE',
			RequestDirector: 'www.westlaw.com',
			SocialPlatform: 'https://community-sso.thomsonreuters.com',
			Sync: 'sync.westlaw.com',
			Video: 'v1.next.westlaw.com',
			FormsAssembly: 'formsassembly.int.forms.westlaw.com',
			Publishing: 'publishing.int.next.westlaw.com',
			WebContent: 'webcontent.int.next.westlaw.com',
			Alert: 'alert.int.next.westlaw.com',
			Report: 'report.int.next.westlaw.com',
			ProductMetadata: 'pmd.int.next.westlaw.com/pmd',
			Website: '1.next.westlaw.com',
			WebsiteDefault: '1.next.westlaw.com',
			HistoryListener: 'historylistener.int.next.westlaw.com',
			FormsAssemblyTest: ''
		};
	
		
			if (window.location.host !== '1.next.westlaw.com') {
				window['Server/Routing'].ProxiedWebsite = '1.next.westlaw.com';
				window['Server/Routing'].Website = window.location.host;
				window['Server/Routing'].WebsiteDefault = window.location.host;
			}
		
</script>

<script type="text/javascript"></script>

	<script type="text/javascript" src="https://1.next.westlaw.com/v2/js/UrlRouting.40.1.1013.0.js"></script>
	
	<script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="https://ja.next.westlaw.com/StaticContent_40.1.1015/External/vendor/datejs@1.0/cultures/en-US.js"></script>
<script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="https://ja.next.westlaw.com/StaticContent_40.1.1015/v2/Products/WestlawNext/js/LocalizationResources/Localized/Messages.js"></script>

	
<script type="text/javascript">

	







</script>





















	
	














<script type="text/javascript">
window['Server/User'] = {
  "FirmName": "SEOUL NATIONAL UNIV (LV A)",
  "_AlertsIsAdmin": false,
  "_FeatureExposure": "Released",
  "ClientId": "SEOUL NU - WL NEXT",
  "_AlertsAccessFunctionalityTurnedOn": true,
  "_AlertsAccessCategoryApplied": false,
  "_ShowErrorDetails": false,
  "OnePassUserName": "5405685",
  "OnePassUserNameEncoded": "5405685",
  "ClientMatter": {
    "ClientId": "SEOUL NU - WL NEXT",
    "CompositeClientMatter": "SEOUL NU - WL NEXT",
    "DefaultClientId": "Seoul NU - WL Next",
    "ClientIdPromptText": "",
    "IsClientNonChargeable": "False",
    "NoClientId": "False",
    "TrackableCode": "D",
    "UserTurnedTrackingOn": false
  },
  "ClientReportingAttributes": {
    "PracticeArea": "",
    "ResearchReasonCode": "",
    "ResearchDescription": ""
  },
  "BillingMethodForDisplayOnly": "TRANSACTIONAL",
  "HasFlashPlayer": false,
  "IsUltra": true,
  "CustomerStorageKey": "E41F133AB8A01ED395E1D85D67D9406C",
  "SessionCreatedDateTime": "04/30/2018 04:03:25",
  "HasLoggedAggregateNotificationCount": false
};


window['Server/ViewModelData'] = {
  "DocumentGuid": "Iefd1c172e7ba11e1b11ea85d0b248d27",
  "DocumentCitation": "689 F.3d 1303",
  "DocumentTitle": "Association for Molecular Pathology v. U.S. Patent and Trademark Office",
  "DocumentMetaDescription": "View on Westlaw or start a FREE TRIAL today, Association for Molecular Pathology v. U.S. Patent and Trademark Office, Cases",
  "ViewType": "FullText",
  "Rank": 337,
  "Grading": "na",
  "KMEnableTermNavigation": false,
  "KMEnableDocumentNavigation": false,
  "LegacyId": "2028417793",
  "DocumentSource": {
    "Key": "1b15b8ff27ee46e3968baecc2f04316f",
    "NavigationPath": "Search/v1/results/navigation/i0ad6ad3e0000016314b8705c8686bce0?Nav=CUSTOMDIGEST&fragmentIdentifier=Iefd1c172e7ba11e1b11ea85d0b248d27&startIndex=1&contextData=%28sc.CustomDigest%29&transitionType=CustomDigestItem",
    "ListSource": "Search",
    "List": "CUSTOMDIGEST",
    "ListPageSourceKey": "1b34510ac2bede0102300be6a61ae1f3"
  },
  "HasDraftingNotes": false,
  "HasDocumentSections": false,
  "EnableBestPortion": true,
  "SubContentTypeId": "27",
  "DisableDocMetaInfoRetrievalOnWarningPage": false,
  "TermNavigationPreference": "AllTerms",
  "ShowMainToolbar": true,
  "ShowRelatedAnalysis": false,
  "ListSource": "Search",
  "IsRelatedFullTextView": false,
  "KeyCiteAlertWarning": "None",
  "DocketTrackWarning": "None",
  "DocumentSections": [],
  "RulebookMode": false,
  "RulebookModeContent": false,
  "NotesOfDecisionsCount": 0,
  "TocReportDocGuids": [],
  "TocReportViewMode": false,
  "IsMedLitStubDocument": false,
  "TrackableCode": "D",
  "NonTrackableCode": "H",
  "FullTocOnDoc": false,
  "ViewExpressions": []
};


window['Server/WidgetDomIds'] = {
  "DocToolbar": "co_docToolbar",
  "DocDisplay": "coid_website_documentWidgetDiv",
  "DocTools": "coid_website_documentToolWidgetDiv",
  "DocTopToolbar": "co_docTopToolbar",
  "DocRightToolbar": "co_newDocToolbar",
  "TopTopics": "coid_website_relatedInfoWidgetDiv",
  "DocBottomToolbar": "co_docFooterToolbar"
};


window['Server/PageData'] = {
  "DocumentTabView": {
    "IsSkipOutOfPlanChecked": false,
    "IsUserDocument": false,
    "UserDocumentData": {
      "documentGuid": "Iefd1c172e7ba11e1b11ea85d0b248d27"
    },
    "HasProfileSubTab": false,
    "DisplayOptions": {
      "showMainToolbar": true,
      "isNewDocumentView": false,
      "disableDocToolbar": false,
      "isAbstractView": false,
      "chunkSize": "L",
      "chunkableHeadnotes": false,
      "doCompleteSizeChecking": true,
      "ViewType": "FullText",
      "stickyHeader": true,
      "displayRelatedContentLink": true,
      "snippetRelocationInfo": {
        "contentType": "Cases",
        "subContentTypeId": "27"
      }
    },
    "ShowMainToolbar": true,
    "DocumentPersisted": false,
    "DocumentGuidNotFound": false,
    "ContentType": "Cases",
    "ExpandDocumentLevelTOC": true
  },
  "CobaltPageHeader": {
    "ShowPauseLink": false,
    "ShowCommunityContainer": false,
    "EnablePageHeaderV2": true,
    "ShowBetaFeedbackLink": false,
    "Notifications": {
      "HideNotificationToastAfterDuration": false,
      "NotificationClickGoDirectlyToAlerts": false
    }
  },
  "CompartmentStartPageId": "",
  "CobaltMasterFooterInSession": {
    "TRLogoImageLinkUrl": "http://www.thomsonreuters.com",
    "ShowWhatIsNewLink": false,
    "Unreleased": false,
    "IsAnonymousSession": false,
    "ShowMyContacts": false,
    "ShowPromotions": false,
    "ShowResetPromotions": false,
    "ShowCampusPolicy": false,
    "IsTransferContentAvailable": false,
    "ShowProductStartGuide": false,
    "HelpGuideDisplayName": "",
    "HelpGuideFileName": "",
    "HelpGuidePath": "",
    "CampusPolicyDisplayName": "",
    "CampusPolicyPath": "",
    "ShowAnalyticsLink": false,
    "AnalyticsPath": "Session/SignOn.html?transitionType=Default&contextData=(sc.Default)",
    "ShowMyAccountLink": false,
    "MyAccountPath": "WESTLAW/Common/Landing/MyAccountLanding",
    "LegalSolutionsLink": "http://legalsolutions.thomsonreuters.com/law-products/westlaw-legal-research/training-support",
    "SupplierTermsUrl": "http://legalsolutions.com/westlaw-additional-terms",
    "PrivacyPolicyPath": "https://www.thomsonreuters.com/en/privacy-statement.html"
  },
  "ActOnTracking": {
    "EnableActOnTracking": false,
    "ActOnTrackingInstanceId": ""
  },
  "CobaltPage": {
    "SetInCache": [
      {
        "Vertical": "Global",
        "Name": "ResultsPerPage",
        "Value": 20
      },
      {
        "Vertical": "Global",
        "Name": "ResultsPerPageAllowableValues",
        "Value": [
          "100",
          "20",
          "50"
        ]
      },
      {
        "Vertical": "Global",
        "Name": "Locale",
        "Value": ""
      },
      {
        "Vertical": "Global",
        "Name": "TimeZone",
        "Value": "Central Standard Time"
      },
      {
        "Vertical": "Global",
        "Name": "MultiFacetsEnabled",
        "Value": false
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_CASE",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_ANALYTICAL",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_PENDINGREG",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_PENDINGLEG",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_KNOWHOW",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "JurisdictionsContentType",
        "Value": "default"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_DOCKET",
        "Value": "CASE_TITLE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_BRIEF",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_TRIAL-TRANSCRIPTS",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_ADMINDECISION",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_FORM",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_NEWS",
        "Value": "DATE_DESCENDING"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_ORAL-ARGUMENTS",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "InstantSuggestions",
        "Value": true
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_TCO",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultNews_DuplicateIdentifier",
        "Value": false
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_REGULATION",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_EXPERTWITNESS",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "SliderDetail",
        "Value": "default"
      },
      {
        "Vertical": "Search",
        "Name": "ViewExpression",
        "Value": ""
      },
      {
        "Vertical": "Search",
        "Name": "DefaultPage",
        "Value": "ALL"
      },
      {
        "Vertical": "Search",
        "Name": "JurisdictionsGlobal",
        "Value": "CTAF"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_PMM",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_STATUTE",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "DefaultSortType_JURYVERDICT",
        "Value": "RELEVANCE"
      },
      {
        "Vertical": "Search",
        "Name": "SuppressRecentFiltersTooltip",
        "Value": false
      },
      {
        "Vertical": "Document",
        "Name": "HeadnotesDualColumnView",
        "Value": false
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorRulesSet",
        "Value": "standard"
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorItalicizeTitle",
        "Value": false
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorParallelCites",
        "Value": "CAFormat"
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorUseForCopyWithReference",
        "Value": true
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorCitationStyle",
        "Value": "LegalBriefs"
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorIncludeHistory",
        "Value": true
      },
      {
        "Vertical": "Document",
        "Name": "CiteAdvisorUnderlineTitle",
        "Value": true
      },
      {
        "Vertical": "Document",
        "Name": "HideHeadnotesBox",
        "Value": false
      },
      {
        "Vertical": "Foldering",
        "Name": "ShowAnnotationsPreferenceKey",
        "Value": "checked"
      },
      {
        "Vertical": "Website",
        "Name": "ShowKeyboardInstructions",
        "Value": true
      },
      {
        "Vertical": "Website",
        "Name": "DocumentFullscreenShowTerms",
        "Value": true
      },
      {
        "Vertical": "Website",
        "Name": "NewFeatureLightboxDisplayBlackList",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DocumentFullscreenTextSize",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DocumentFullscreenMargin",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DeliveryOptionSelected",
        "Value": "None"
      },
      {
        "Vertical": "Website",
        "Name": "DocumentFullscreenShowLinks",
        "Value": true
      },
      {
        "Vertical": "Website",
        "Name": "LastViewNotificationDate",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DocumentDisplayTextSize",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DisplaySearchTerms",
        "Value": true
      },
      {
        "Vertical": "Website",
        "Name": "KnowHowSpeedReadExpandAll",
        "Value": true
      },
      {
        "Vertical": "Website",
        "Name": "DocumentDisplayFont",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DocumentDisplayMargin",
        "Value": ""
      },
      {
        "Vertical": "Website",
        "Name": "DocumentFullscreenFont",
        "Value": ""
      },
      {
        "Vertical": "SAP",
        "Name": "PLAN ICONS",
        "Value": "NO"
      },
      {
        "Vertical": "SAP",
        "Name": "SKIP OUT OF PLAN",
        "Value": "NO"
      },
      {
        "Vertical": "SAP",
        "Name": "WARNING FLAG",
        "Value": "N"
      }
    ],
    "PingSync": "false",
    "ViewData": {
      "IsSponsorSession": true,
      "SearchWidgetParameters": {
        "search": {
          "renderCustomPageSearchWidget": false,
          "categoryPageTitle": "291 PATENTS",
          "isCategoryPageTopical": false,
          "topicKeyText": "291 PATENTS",
          "filters": {
            "jurisdiction": "CTAF",
            "sequence": 0,
            "content": "CUSTOMDIGEST",
            "index": false,
            "customDigest": true,
            "collectionSets": [
              "w_cs_cd_toc"
            ],
            "tocNode": "I4aee2539c6f64c1812a4c2f3395c2607",
            "keyNumber": "291",
            "displayJurisdictionSelector": true,
            "displayAdvancedSearchLink": false,
            "categoryPageUrl": "Home/WestKeyNumberSystem",
            "categoryPageContentType": "CUSTOMDIGEST",
            "categoryPageCheckboxLimit": 0,
            "resultsLimit": 0,
            "categoryPageAlertClippable": false,
            "isAdvancedSearchTemplatePage": false
          },
          "CustomPageSetForZone": false,
          "supportedFeatures": [],
          "skipSpellCheck": false,
          "browseHierarchyPathFromRoot": []
        },
        "SearchCompartmentName": "WestlawNext",
        "SearchDropDownItems": [],
        "grading": "na",
        "searchWidgetPosition": "Default",
        "hideSearchWidget": false,
        "makeSearchWidget": true,
        "prefersForceTnc": false,
        "prefersForceTncSingleQuote": true,
        "forceTncCounter": 0,
        "forceTncCounterThreshold": 5,
        "enableFavoriteSearch": false,
        "dynamicPage": false,
        "isAdvancedSearchTemplatePage": false
      },
      "ShowClientIdWidget": true,
      "OpenFindDropDown": false,
      "TimeoutInMinutes": 90,
      "FeatureConfigurations": {
        "FOLDERS": false,
        "HISTORY": true,
        "FOLDER_SHARING": false,
        "HIGHLIGHTS": false,
        "NOTES": false,
        "ANNOTATIONS": false,
        "BLOCK NOTES SHARING": false,
        "CONTACTS": false,
        "FAVORITES": false,
        "USER PROFILE": false,
        "KM": false,
        "FolderCachingDisabled": true,
        "KM IPAD": false,
        "SAO_INVITING": true,
        "SAO_SAMEEMAILDOMAIN": false,
        "CASENOTEBOOKEXPORT": false,
        "DOWNLOADDELIVERY": true,
        "DROPBOXDELIVERY": false,
        "EMAILDELIVERY": true,
        "EMAILWITHREFERENCEDELIVERY": false,
        "KINDLEDELIVERY": false,
        "PRINTDELIVERY": true,
        "KEYCITEALERTS": false,
        "LEGACYALERTACCESS": false,
        "BLOCKPERSISTENTINFO": true,
        "BLOCK100KANCILLARY": false,
        "DISPLAYMASHUPCHARGEWARNING": false,
        "SHOWCHARGEONWARNINGSCREEN": false,
        "SHOWCHARGELINKONWARNINGSCREEN": false,
        "USERISTRANSACTIONAL": true,
        "USER FORM UPLOAD": false,
        "MATTERUPLOADUSERDOC": false,
        "FOLDERUPLOADUSERDOC": false,
        "DISPLAY SESSION PAUSE LINK": false,
        "PASSTHRUPDFS": false,
        "processRIHistoryAsynchronously": true,
        "processDocumentHistoryAsynchronously": true,
        "PRINTBLANKFORMS": false,
        "WFBTRIALBLOCKSHARE": false,
        "ATTORNEY PORTAL": false,
        "SMALLLAWWORKBENCHMATTERTREE": false,
        "JUDICIALCHAMBERS": false,
        "CITATIONUS": false,
        "CITATIONCAN": false,
        "MYPLANSTATICDOC": true,
        "ALLOWFOLDERSHAREACROSSORGS": true,
        "BLOCKFOLDERSHAREFROMORGS": true,
        "ALLOWOFFLINEACCESS": false,
        "WEBHOSTEDCLIENTID": false,
        "WEBHOSTEDCLIENTIDIPAD": false,
        "WEBHOSTEDCLIENTIDSELECTION": false,
        "PRERELCONTENTFEAT": false,
        "ALERTS": false,
        "ALERTS ENHANCED": false,
        "ISEMULATEUSER": false,
        "WCLP": false,
        "NEWSLETTER": false,
        "KCALERT": false,
        "COINV ALERTS": false,
        "CITRANSITION": false,
        "BLCALERT": false,
        "DKTALERT": false,
        "DKTTRACK": true,
        "PUBALERT": false,
        "CWALERT": false,
        "POB ALERT": false,
        "POB WATCH": false,
        "CWALERTPremium": false,
        "CAPITOLWATCH": false,
        "ALERT SUMMARY REPORT": false,
        "WCLP CONTINUOUS": false,
        "KCALERT CONTINUOUS": false,
        "CWALERT CONTINUOUS": false,
        "POBA CONTINUOUS": false,
        "POBW CONTINUOUS": false,
        "NEWSLETTER DLY": false,
        "NEWSLETTER WKDY": false,
        "KCALERT DLY SINGLE": false,
        "KCALERT WKDY SINGLE": false,
        "BIALERT DLY SINGLE": false,
        "BLCALERT DAILY": false,
        "BLCALERT MULTI DAILY": false,
        "CWALERT DAILY": false,
        "BIALERT WKDY SINGLE": false,
        "BLCALERT BIWEEKLY": false,
        "BLCALERT CONTINUOUS": false,
        "WCLP WEEKLY": false,
        "NEWSLETTER WEEKLY": false,
        "KCALERT WEEKLY": false,
        "BIALERT WEEKLY": false,
        "BLCALERT WEEKLY": false,
        "DKTALERT WEEKLY": false,
        "DKTTRACK WEEKLY": true,
        "POBA WEEKLY": false,
        "POBW WEEKLY": false,
        "WCLP BIWEEKLY": false,
        "KCALERT BIWEEKLY": false,
        "BIALERT BIWEEKLY": false,
        "DKTALERT BIWEEKLY": false,
        "DKTTRACK BIWEEKLY": true,
        "NEWSLETTER BIWEEKLY": false,
        "POBA BIWEEKLY": false,
        "POBW BIWEEKLY": false,
        "WCLP MONTHLY": false,
        "NEWSLETTER MONTHLY": false,
        "KCALERT MONTHLY": false,
        "BIALERT MONTHLY": false,
        "BLCALERT MONTHLY": false,
        "DKTALERT MONTHLY": false,
        "DKTTRACK MONTHLY": true,
        "POBA MONTHLY": false,
        "POBW MONTHLY": false,
        "WCLP DLY SINGLE": false,
        "WCLP DLY MULT": false,
        "WCLP WKDY SINGLE": false,
        "WCLP WKDY MULT": false,
        "PUBALERT DLY SINGLE": false,
        "PUBALERT WKDY SINGLE": false,
        "DKTALERT WKDY SINGLE": false,
        "DKTALERT DLY SINGLE": false,
        "DKTTRACK WKDY SINGLE": true,
        "DKTTRACK DLY SINGLE": true,
        "CAPITOLWATCHTRACK DLY SINGLE": false,
        "CAPITOLWATCHTRACK DLY MULT": false,
        "CAPITOLWATCHTRACK WKDY SINGLE": false,
        "CAPITOLWATCHTRACK WKDY MULT": false,
        "CAPITOLWATCHTRACK WEEKLY": false,
        "CAPITOLWATCHTRACK BIWEEKLY": false,
        "CAPITOLWATCHTRACK MONTHLY": false,
        "POBA DLY SINGLE": false,
        "POBA DLY MULT": false,
        "POBA WKDY SINGLE": false,
        "POBA WKDY MULT": false,
        "POBW DLY SINGLE": false,
        "POBW DLY MULT": false,
        "POBW WKDY SINGLE": false,
        "POBW WKDY MULT": false,
        "showMatterTree": false,
        "WELCOME TO WLN BOX": false,
        "dataRoomReadSource": "Original",
        "dataRoomWriteDestination": "Single",
        "dataRoomFoldersWriteDestination": "SingleDataRoom",
        "showNapaContent": true,
        "PublicRecordsAccess": false,
        "PublicRecordsEnhancedSecurity": false,
        "PublicRecordsBlockRoaming": false,
        "PublicRecordsBlockHomeTrust": false,
        "PublicRecordsAllowRoamTrust": false,
        "PublicRecordsBypassCountry": false,
        "PublicRecordsBlockIPUndefined": false,
        "PublicRecordsBlockUndefinedTrust": false,
        "PublicRecordsDowngradeEmailIPRoaming": false,
        "PublicRecordsDowngradeEmailIPUndefined": false,
        "PublicRecordsUnmaskRoam": false,
        "DISABLE PR ANC MASK": false,
        "PublicRecordsSsnOnlyOK": false,
        "ReversePhoneGateway": false,
        "QSentReport": false,
        "CreditHeaderContentDatabaseGroup": false,
        "PolkGateway": false,
        "PolkReport": false,
        "DriversLicenseRecordsContentDatabaseGroup": false,
        "UCC COLUMN RESULTS": false,
        "matterTreeType": "None",
        "ISCAMPUSUSER": false,
        "ISCAMPUSNEWSUSER": false,
        "ISCAMPUSBUSINESSUSER": false,
        "isUnreleasedFeatureExposure": false,
        "WLANALYTICS ACCESS": false,
        "NEWSALERTAUTHOR": false,
        "NEWSALERTEDITOR": false,
        "UNRELEASED CAT PAGES": false,
        "INTERNAL ADMIN LIMITS": false,
        "DATAROOMALERTS": false,
        "DLVRY SESSION LIMIT": false,
        "DLVRY DAILY LIMIT": false,
        "DLVRY SESSION LIMIT PRAC LAW": false,
        "DLVRY DAILY LIMIT PRAC LAW": false,
        "DLVRY SESSN LIMIT PRAC LAW TRL": false,
        "DLVRY DAILY LIMIT PRAC LAW TRL": false,
        "CONTENT DLVRY RSTRCT": true,
        "BLOCKAUWLN": false,
        "BLOCKCANWLN": false,
        "BLOCKHKWLN": false,
        "BLOCKUKWLN": false,
        "ALERTS ADDRESS BOOK": true,
        "ALERTS BATCH PROCESSING": false,
        "ALERTS CALENDARING": true,
        "ALERTS FUNCTIONALITY": true,
        "ECHACCESS": false,
        "PMD VERSION": "5209",
        "USER ACADEMIC": true,
        "USER CORPORATE": false,
        "USER DEVELOPER": false,
        "USER GOVERNMENT": false,
        "USER INTERNAL": false,
        "USER LARGE LAW": false,
        "USER MEDIUM LAW": false,
        "USER SMALL LAW": false,
        "SIGNOFF SURVEY": false,
        "INLINE KC CASES BRIEF": false,
        "BYPASS WARN INLINE KC": false,
        "BLOCK PL ITEMS": false,
        "PRACTICAL LAW": false,
        "PRDCT PLCUK": false,
        "PRDCT PLCAU": false,
        "DISABLE PL REL CONTENT CACHE": false,
        "HISTORY UI": true,
        "EDSECTIONALLOW": false,
        "TAPSELECTED": false,
        "REDLINING": false,
        "WLNBYPASSBLOCK": false,
        "BLOCK NATIVE SIGNIN": false,
        "BLC ZONE": false,
        "CUSTOM PAGES": false,
        "CUSTOM PAGES READ": false,
        "CUSTOM PAGE ADMIN": false,
        "ELIBRARIES CP ZONE": false,
        "TYPE AHEAD": false,
        "PATRONHELP": false,
        "HISTORY RETENTION 1": false,
        "HISTORY RETENTION 180": false,
        "BLC POWERSEARCH": false,
        "PRDCT CORRECTIONAL": false,
        "EASY EDIT": false,
        "ENHANCED RB": false,
        "ENHANCED RB STICKY": false,
        "WMGRAPHICAL": false,
        "PRPTSUBSCRIBER": false,
        "BLOCK PRPT BLC": false,
        "PLCT DISPLAY LEGAL ANALYTICS": false,
        "PRPT SMALL": false,
        "PRPT CORPCOUNSEL": false,
        "PRPT LARGE": false,
        "BLOCK PRPT LARGE PAGES": false,
        "PRPT GOVT": false,
        "PRPT NONTRACKABLE": false,
        "PRPT KM LITIGATION": false,
        "PRPT KM TRANSACTIONAL": false,
        "WAYWO": false,
        "AnonymousSession": false,
        "AnonymousSessionBlock": false,
        "SOCIAL PLATFORM": false,
        "BLOCK TNP PLUS": false,
        "TNP TEPC CALC": false,
        "TNP CORTC CALC": false,
        "APFF ACCESS": false,
        "TDRC": false,
        "FPC": false,
        "FPP": false,
        "TAXHYPERION NLTR": false,
        "WCO ACCESS": false,
        "BLOCKMYSTARTPAGELINK": false,
        "TNP CEC CALC": false,
        "TNPNATLANG": false,
        "TAXNEWSCATEGORIES": false,
        "TNPDIGMCMECHAN": false,
        "TNPDIGBROWN": false,
        "TNPDIGNIKOLAKAKIS": false,
        "TNPDIGHAYHOETAXATION": false,
        "TNPDIGKERZNER": false,
        "TNPDIGSCHWARTZ": false,
        "TNPDIGINNES": false,
        "TNPDIGARON": false,
        "TNPDIGCARR": false,
        "TNPDIGGAMBLE": false,
        "TNPDIGTAXATIONOFREALESTATE": false,
        "TNPDIGBROOKS": false,
        "TNPDIGMUNRO": false,
        "TNPDIGTHAW": false,
        "TNPDIGVINER": false,
        "TNPDIGFRIEDLANDER": false,
        "TNPDIGBUTCHER": false,
        "TNPDIGALEXANDER": false,
        "TNPDIGHAYHOECASELAW": false,
        "TNPDIGHAYHOEFEDPROVLEGIS": false,
        "TNPDIGHAYHOEGOVPUBLICATIONS": false,
        "TNPDIGJOLIN": false,
        "TNPDIGSTILLABOWER": false,
        "TNPDIGCASESINDEXCITATOR": false,
        "TNPDIGSEGUIN": false,
        "TNPDIGWISE": false,
        "TNPDIGBOWEN": false,
        "TNPDIGBISCOTT": false,
        "TNPDIGEDMUNDS": false,
        "TNPDIGMANNGUIDETOREVIEW": false,
        "TNPDIGCOMPILATIONENGAGEMENTS": false,
        "TNPDIGGUIDETOESTATEANDTRUSTS": false,
        "TNPDIGITIZATION": false,
        "TNPLITIGATOR": false,
        "TNPCROSSREFFILTER": false,
        "RESULTLISTEASYEDIT": false,
        "RESULTLISTQDRAFT": false,
        "DISPLAY TEST PREF TAB": false,
        "BlindLog": false,
        "EncryptLog": false,
        "MASS EMAILER": false,
        "ADCVERREDLININGTOGGLE": false,
        "ENVHEALTHSAFETYPRACPG": false,
        "INSURCOMPLIANCEPRACPG": false,
        "BLOCK WLN PATRON": false,
        "DSP INT HEADNOTE INFO": false,
        "PRDCT WLNLINKS": false,
        "GAO LH PDFS OPEN IN LINKS": false,
        "WLNLINKS UK": false,
        "BLOCK WLNLINKS EMBEDDED LINKS": false,
        "BLOCK LICENSE AGREEMENT": false,
        "FIRMSTYLE": false,
        "SMART BREADCRUMB DISPLAY": false,
        "IRS WLN PAGE": false,
        "FORMSAUTOSHAREOFF": false,
        "WLNPLTRACK": false,
        "WLNPL GOVTHOMEPAGE": false,
        "WLNPL CORPHOMEPAGE": false,
        "WLNPL DEFAULTHOMEPAGE": true,
        "ENABLE-LEGI-GOV-LINKS": false,
        "ENABLE BAILII LINKS": false,
        "BLOCK SHARE NOTE LINK": false,
        "BLCCAN ZONE": false,
        "BLCCAN SUBSCRIBER": false,
        "BLOCKBLCCAN": true,
        "BLOCKBLC": false,
        "WM SEARCH RESULTS": false,
        "WMHK SEARCH RESULTS": false,
        "WMAU SEARCH RESULTS": false,
        "TAX PWC USER": false,
        "TAX KPMG USER": false,
        "COPY USER DATA": false,
        "ASSIGNCLIENTFILE": false,
        "RESEARCH REPORT": false,
        "FOLDER ANALYSIS": false,
        "FOLDER ANALYSIS ADDL CONTENT": false,
        "TIME ZONE AUSTRALIA": false,
        "TIME ZONE NEW ZEALAND": false,
        "EY WLN PAGE": false,
        "FOLDER DESCRIPTION": false,
        "ENABLE CONTRACT EXPRESS": false,
        "CONTRACT EXPRESS PL AU": false,
        "CONTRACT EXPRESS PL US": false,
        "ASK-EDITOR": false,
        "BLOCK OPEN WEB": false,
        "PLUK SUBSCRIBER": false,
        "WLUK SUBSCRIBER": false,
        "LIBRARY SUBSCRIBER": false,
        "CHECKPOINTDIRECTLINK": false,
        "BLOCKCHECKPOINTLINKS": false,
        "LINK BUILDER": false,
        "BCICALCULATOR": false,
        "PLUK-ENAB-ALLCONTACTS": false,
        "ALLOW ICLR": true,
        "BLOCK PROVIEW FEDERATED SEARCH": false,
        "DOC ANALYSIS": false,
        "DT DocAnalysis": false,
        "GENERATE WLUK TRANSTOKEN": false,
        "WFB USEMOCKFORMS": false,
        "BLOCKSESSIONPAUSEDISPLAY": false,
        "PWC WLN PAGE": false,
        "KPMG WLN PAGE": false,
        "CROSSBORDER DASHBOARD": false,
        "TR DISCOVER SEARCH": false,
        "VIRTUAL ASSISTANT": false,
        "BLCDEALTRACKALERT": false,
        "BLCDEALTRACKALERT BIWEEKLY": false,
        "BLCDEALTRACKALERT CONTINUOUS": false,
        "BLCDEALTRACKALERT DAILY": false,
        "BLCDEALTRACKALERT MONTHLY": false,
        "BLCDEALTRACKALERT MULTIDAY": false,
        "BLCDEALTRACKALERT WEEKLY": false,
        "EY MIGRATION POP UP": false,
        "KPMG MIGRATION POP UP": false,
        "PWC MIGRATION POP UP": false,
        "IRS MIGRATION POP UP": false,
        "TAX MIGRATE": false,
        "SEARCH TABS": false,
        "JOURNAL PURCHASE FORM": false,
        "WLUK EDITORS PICKS TAB": false,
        "LEGAL LIT ANALYTICS": false,
        "UKMATTERMAPS": false,
        "USMATTERMAPS": false,
        "DISPLAY PL MESSAGE 1": false,
        "DISPLAY PL MESSAGE 2": false,
        "GRADING TOOL": false,
        "MODERN DOC DISPLAY": false,
        "INDIGO SEARCH": false,
        "INDIGO DISPLAY": false,
        "PSEUDO BLOCK INDIGO DISPLAY": true,
        "INDIGO DISPLAY PREF": false,
        "INDIGO HOT DOCS": false,
        "INDIGO RESEARCH REPORT": false,
        "COMPARE BLACKLINING": false,
        "NOTIFICATION CENTER": false,
        "PRIOR USER INTERACTIONS": false,
        "COLD START": false,
        "TOC FOR CASES": false,
        "MATERIAL KEY FACT FILTER": false,
        "PROCEDURAL POSTURE FILTER": false,
        "FAVORITE SEARCHES": false,
        "FOLDER KEYCITE CHANGE": false,
        "FOLDER RECOMMEND CHANGE": false,
        "FOLDER RECOMMEND ALERT": false,
        "RECENT FILTERS": false,
        "SEARCH RESULT CITING REFS": false,
        "SEARCH RESULT NEG HISTORY": false,
        "QUESTIONANSWERING": false,
        "ITDEPENDS": false,
        "ITDEPENDSQUESTIONANSWER": false,
        "WLUK DOC ALERTS": false,
        "WLUK JCL ALERTS": false,
        "PA REGULATIONS STATUS FILTER": false,
        "ALWAYS CLIENT ID PROMPT": false,
        "PL US BANNER": false,
        "ANSWERS FEEDBACK": false,
        "KC IMPLIED OVERRULINGS": false,
        "ENHANCED THEME": false,
        "DOC ANALYZER TOUR": false,
        "LIT ANALYTICS TOUR": false,
        "HOME PAGE TOUR": false,
        "BUSINESS DEVELOPMENT PL US": false,
        "WLNPL SLF HOMEPAGE": false
      },
      "IsUserMigrated": false,
      "SupportedFeatures": [
        "PRACTICALLAW",
        "ALERTS",
        "BROWSE",
        "BROWSEPREVIEW",
        "CASEEVALUATORWLN",
        "CDN",
        "CLIENTID",
        "CONTACTS",
        "CONTENTTYPEDELIVERYLIMIT",
        "COREUI",
        "CUSTOMPAGES",
        "DELIVERY",
        "DOCKETS",
        "DOCUMENTORDERING",
        "DOCUMENTS",
        "DROPBOX",
        "ERRORS",
        "FAVORITESORGANIZER",
        "FINDANDPRINT",
        "FOLDERS",
        "FOLDERSEXTERNALSHARING",
        "GLOSSARY",
        "WAYWO",
        "IOS",
        "IPAD",
        "FACTORANALYSIS",
        "KEYNUMBERSEARCH",
        "KM",
        "LINKIN",
        "LINKOUT",
        "LIVECHAT",
        "MOBILE",
        "MYPLAN",
        "NYOFFICALDIGEST",
        "PRICINGGUIDE",
        "PROMOTIONS",
        "PUBLICATIONFAVORITES",
        "RELATEDINFORMATION",
        "RELATEDTOPICS",
        "REPORTSHARED",
        "REVERSEPROXY",
        "SEARCH",
        "SHAREPOINTSEARCH",
        "SHAREPOINTWIDGETS",
        "SOCIALPLATFORM",
        "SURVEY",
        "USERAGREEMENT",
        "USERDOCUMENTS",
        "USEREMULATION",
        "USERSETTINGS",
        "BANKRUPTCYEXPLORER",
        "BUSINESSINVESTIGATOR",
        "BUSINESSLAWCENTER",
        "CASENOTEBOOK",
        "DUNANDBRADSTREETBUSINESS",
        "EXPERIANBUSINESSCREDIT",
        "EXPERTDUEDILIGENCE",
        "EXPERTEVALUATOR",
        "MATTERBENCHMARKING",
        "RECENTHISTORY",
        "WEB2MASHUP",
        "AUTHORITYCOMPILER",
        "SEARCHTEMPLATEPREVIEW",
        "PEOPLEMAP",
        "PUBLICRECORDS",
        "DOCKETGATEWAY",
        "WEBCONTENT",
        "PROFESSIONAL",
        "SUGGESTEDDOCUMENTS",
        "EMBEDDEDTEXT",
        "PRODUCTVIEW",
        "PRIVATEFILES",
        "STATEQACOMPARE",
        "SOURCELINK",
        "PMDPROTECTEDCONTENT",
        "ROADRUNNER",
        "REDLINE",
        "SUPERBROWSE",
        "TOCREPORTVIEW",
        "DATACOMPARISONREPORT",
        "GRAPHICALFACETS",
        "COPYUSERDATA",
        "SHAREDNOTES",
        "RESEARCHACCELERATOR",
        "WEBINARS",
        "READINGMODE",
        "ANALYTICS",
        "HIDESEARCHTERMHIGHLIGHTINGPREFERENCE",
        "MONETIZATION",
        "SHOWDOCUMENTANALYZEROVERVIEWPREFERENCE",
        "SHOWLITANALYTICSOVERVIEWPREFERENCE",
        "SHOWHOMEPAGEOVERVIEWPREFERENCE",
        "FOUNDATION"
      ],
      "ActiveBrowserPingInitialWaitInMinutes": 3,
      "ActiveBrowserPingFrequencyInMinutes": 3,
      "ShowClientIdToast": false,
      "DataRoomFeatures": [],
      "SocialPlatformProductId": "140",
      "MaxFileUploadSize": 157286400,
      "SnapEngageScriptUrl": "",
      "DeliveryQueueQueried": false,
      "DeliveryQueueTotal": 0,
      "DeliveryQueueInProgress": 0,
      "DeliveryQueueDocketsInProgress": 0,
      "DeliveryQueueInError": 0,
      "DeliveryQueueNotification": 0
    },
    "WidgetDomIds": {
      "FooterDivId": "co_footer",
      "ErrorSummaryWidget": "coid_website_errorsSummaryPlaceHolder",
      "DockWidget": "co_dockContainer",
      "RecentFoldersWidget": "co_recentFoldersContainer",
      "RecentHistoryWidget": "co_recentHistoryContainer",
      "FrequentFavoritesWidget": "co_frequentFavoritesContainer",
      "AlertsCenter": "co_alertsCenterContainer",
      "ClientIdWidget": "co_clientIdContainer",
      "SignOff": "co_signOffContainer",
      "WhatIsNext": "co_whatIsNextContainer",
      "SearchWidget": "coid_website_searchWidget"
    },
    "RedirectError": {
      "Show": false
    },
    "DomStorageHasBeenCleared": false,
    "LiveChat": {
      "Show": false,
      "Options": {
        "QueueNumber": 0
      }
    },
    "WelcomeLightbox": {
      "Show": false
    },
    "SyncInitiated": false,
    "SyncCapable": false,
    "SubscriptionRenewalBanner": {
      "Show": false
    },
    "IsBusinessLawCenter": false
  },
  "TabScripts": {
    "DocSource": "1b15b8ff27ee46e3968baecc2f04316f",
    "DocGuid": "Iefd1c172e7ba11e1b11ea85d0b248d27",
    "NavigationPath": "Search/v1/results/navigation/i0ad6ad3e0000016314b8705c8686bce0?Nav=CUSTOMDIGEST&fragmentIdentifier=Iefd1c172e7ba11e1b11ea85d0b248d27&startIndex=1&contextData=%28sc.CustomDigest%29&transitionType=CustomDigestItem",
    "ListSource": "Search",
    "List": "CUSTOMDIGEST",
    "Rank": 337,
    "DocumentVersionNumber": 0
  }
};


window['Server/KM'] = {
  "SessionId": "",
  "FirmName": "",
  "FirmLogoUri": "",
  "FirmWelcomeUri": "",
  "Protocol": "http"
};


window['Server/Configuration'] = {
  "CompartmentName": "WestlawNext",
  "CookieDomain": "next.westlaw.com",
  "EnableIpad": false,
  "EnableIphone": false,
  "IsIPadAppRenderingMode": false,
  "IsIPhoneAppRenderingMode": false,
  "IOSNativeVersion": "0.0.0",
  "EnableSync": false,
  "EnableDeliveryQueue": true,
  "EnableDeliveryWidget": true,
  "ProductName": "WestlawNext",
  "ProductDisplayName": "Westlaw",
  "ProductDisplayDelimiter": "|",
  "ProductViewName": "none",
  "DailyDeliveryLimit": -1,
  "DailyDeliveryCount": -1,
  "SessionDeliveryLimit": 20,
  "SupportedAlertTypes": [
    "WestClip",
    "KeyCite",
    "DocketAlert",
    "DocketTrack",
    "DealTrack",
    "PublicationAlert",
    "Newsletter",
    "BusinessInvestigator",
    "CourtWire",
    "BusinessLawCenterAlert",
    "PeopleMap",
    "CapitolWatchTrack"
  ],
  "EnableDataRoomAlerts": true,
  "GlobalizationKeyMode": "Default",
  "IsAnonymousSession": false,
  "EnableAccessibleLightbox": true,
  "EnableContactsPaging": true,
  "IsCrawlerSession": false,
  "IsGlobalizationI18NLocaleEnabled": false,
  "IsGlobalizationI18NLibraryLookupEnabled": true,
  "IsProcessCategoryPagesWithDifferentLocalesOn": false,
  "OverrideResultsPerPage": 0,
  "UseExpandableToc": true,
  "Locale": "en-US",
  "IsSmartFoldersEnabled": true,
  "IsFeatureOverlayEnabled": true,
  "IsTRDiscoverEnabled": true,
  "IsVideoTourEnabled": true,
  "IsBestPortionNavigationEnabled": true,
  "UsePageHeaderV2": true,
  "UseTypeAhead": true,
  "UseSnapshots": true,
  "IsBriefAnalyzerEnabled": true,
  "IsChargeableByDefaultForSession": true,
  "IsIssueFinderEnabled": true,
  "IsWestlawAnswersEnabled": true,
  "IsSharedHighlightsEnabled": true,
  "IsRealTimeNotificationEnabled": true,
  "EnableA11YLightboxKeyboardScroll": true,
  "IsA11YRedesignedHeaderEnabled": true,
  "IsA11YPreferencesLightboxEnabled": true,
  "SpeechToTextCustomizationIdOverride": "default",
  "InfrastructureAccessControls": [
    "iac-a11y-asbuilder-tmpl",
    "iac-a11y-header-redesign",
    "iac-accessible-clientid-widget",
    "iac-add-timezone",
    "iac-alert-admin-settings",
    "iac-alert-ny-sct-hourly",
    "iac-alerts-cal",
    "iac-alerts-customerinfo-olc",
    "iac-alerts-cw",
    "iac-alerts-docket-guid",
    "iac-alerts-productaware-history",
    "iac-alerts-standart-email-format",
    "iac-all-citations",
    "iac-allow-robots-indexing-sitemap-wln",
    "iac-analyticsclientidfeaturesenabled",
    "iac-analytics-related-filings",
    "iac-annotation-filtering",
    "iac-anonymous-cdn",
    "iac-appcommand",
    "iac-asm-policy",
    "iac-au-compartments",
    "iac-au-seo",
    "iac-autosuggest-au",
    "iac-batch-getsynopsis",
    "iac-bestlaw-tracking",
    "iac-blc-filersearch",
    "iac-blc-fs-next",
    "iac-blc-redlining",
    "iac-blc-ri-agreementsenh",
    "iac-blc-ri-newpathway",
    "iac-blc-ri-privateequity",
    "iac-blind-encrypted",
    "iac-blind-encrypted-header-enabled",
    "iac-block-uk-westlaw",
    "iac-blt-alertfulltext",
    "iac-blt-alert-type-mna-trans",
    "iac-blt-alert-type-sec-insider",
    "iac-blt-alert-type-sec-noninsider",
    "iac-blt-feature18",
    "iac-blt-feature3",
    "iac-blt-hoovers",
    "iac-blt-incorporationdata",
    "iac-blt-news",
    "iac-blt-oct2014-release",
    "iac-blt-officerlinks",
    "iac-blt-report-advisors",
    "iac-blt-securities",
    "iac-blt-securities-alerts",
    "iac-blt-subsidiaries",
    "iac-blt-table-sections",
    "iac-blt-tagged-sections",
    "iac-blt-tickercik",
    "iac-blt-webkitpdf",
    "iac-blt-xmlmindrtf",
    "iac-businesslawcenter-tdr",
    "iac-canadian-content",
    "iac-casetracking",
    "iac-change-uk-ntz-clientid",
    "iac-cig-addfoldereditem",
    "iac-cig-facet-orphan",
    "iac-cig-group-orphan",
    "iac-cig-orphan",
    "iac-cig-orphan-ind",
    "iac-cig-report-orphan",
    "iac-ci-resultlist",
    "iac-citation-reordering",
    "iac-client-chargeable-by-default",
    "iac-clientid-new-validation",
    "iac-concourselibrary-wln",
    "iac-content-finder",
    "iac-correct-dock-user-property-value",
    "iac-courtexpress",
    "iac-cpet-browseparts-novus",
    "iac-cr-effective-date-display",
    "iac-crossborder-dashboard",
    "iac-crossborder-itg",
    "iac-display-applied-filter-names-on-ssp",
    "iac-display-recent-items",
    "iac-docanalyzer-caselc-atlaslc",
    "iac-docanalyzer-cited-statutes",
    "iac-docanalyzer-filter",
    "iac-docanalyzer-footnotes",
    "iac-docanalyzer-rdintegration",
    "iac-docanalyzer-relevantportion",
    "iac-docanalyzer-secondarysources",
    "iac-docanalyzer-statutes",
    "iac-docanalyzer-ui-march-release",
    "iac-doc-medical-entities-link-out",
    "iac-docversioning-wln",
    "iac-dpa-browse-juris-landing-pg",
    "iac-dpa-curated",
    "iac-dpa-delivery-watson-answer",
    "iac-dpa-enforcementmap",
    "iac-dpa-featured-content",
    "iac-dpa-keyword-newjurs",
    "iac-dpa-keyword-novus",
    "iac-dpa-knowledgegraph",
    "iac-dpa-related-concepts",
    "iac-dpa-usabilla",
    "iac-dpa-watson-v11",
    "iac-dpa-watson-v12",
    "iac-dr-client-missed",
    "iac-dtp-bankruptcy-claims",
    "iac-dtp-dktptynmtbl",
    "iac-dtp-experts",
    "iac-dtp-openweb",
    "iac-dyn-stem-exceptions",
    "iac-enable-news-summary-alerts-delivery",
    "iac-enacted-legislation-link",
    "iac-enhanced-search-term-tooltip",
    "iac-factoranalysis-history",
    "iac-fa-searchbilling",
    "iac-fastdom-standarddocument",
    "iac-feature-overlay",
    "iac-findandprint",
    "iac-firmlibrary-wln",
    "iac-foldering-get-descendants-new",
    "iac-folderingshareacrossorgs",
    "iac-forcesignon-orphansession",
    "iac-gateway-do",
    "iac-get-renewalandtrialdata",
    "iac-grantonlyfacsinsessionbindings",
    "iac-guid-chasing-disable",
    "iac-hide-docket-monthly-frequency",
    "iac-hide-territorial-options",
    "iac-historical-datacorrections",
    "iac-image-module",
    "iac-improved-navigation",
    "iac-indigo-coldstart",
    "iac-indigo-cpet-browseparts",
    "iac-indigo-display-pref",
    "iac-indigo-fav-searches",
    "iac-indigo-folder-kc-change",
    "iac-indigo-folder-recommend-change",
    "iac-indigo-hot-docs",
    "iac-indigo-notification-center",
    "iac-indigo-paymenttype",
    "iac-indigo-pui",
    "iac-indigo-recent-filters",
    "iac-indigo-research-report",
    "iac-indigo-statutes-compare",
    "iac-indigo-typeahead",
    "iac-inlinehtmldelivery-dockettrackalert",
    "iac-internationalfind",
    "iac-ios-newadvancedsearch",
    "iac-ip2-markman",
    "iac-ip-trademark-viennacode-facet",
    "iac-itdepends",
    "iac-itg-tab",
    "iac-kc-alerts-patents",
    "iac-kc-citing-references",
    "iac-kc-citing-refs-enhanced-sw",
    "iac-kc-flags",
    "iac-kc-flags-green-c-by-boolean",
    "iac-kc-judicial-history",
    "iac-kc-negative-treatment",
    "iac-kc-rules-affected-by",
    "iac-kc-statutes-affected-by",
    "iac-kc-table-of-authorities",
    "iac-kc-validity",
    "iac-kc-wave-the-white-flag",
    "iac-keycite-nod-redesign-old-rels",
    "iac-keycite-sort-by-court-level",
    "iac-keynumber-facets",
    "iac-km-aliveserverconnection",
    "iac-km-fiacctprefs",
    "iac-la-case-outcomes",
    "iac-la-case-types",
    "iac-la-courts",
    "iac-la-delivery",
    "iac-la-law-firms",
    "iac-linkbuilder-docandcatpages",
    "iac-linkbuilder-searchresultspages",
    "iac-linkbuilder-topic-search",
    "iac-linkouturl-pubandserial",
    "iac-log-prdct-wlus-deny",
    "iac-lt-dpa-watson-integration",
    "iac-master-page",
    "iac-mattermaps-deliver-image",
    "iac-mattermaps-editmap",
    "iac-matters-by-number-wln",
    "iac-medlit",
    "iac-modal-footnotes",
    "iac-modernization-wln-ios-doc",
    "iac-most-cited-sort",
    "iac-move-menus-down",
    "iac-multipart-pdf",
    "iac-new-newsletter-template",
    "iac-newsroom-images",
    "iac-non-unique-cites",
    "iac-novustimezone",
    "iac-nyofficial-digestlink",
    "iac-oversized-and-error-email-delivery",
    "iac-pa-regulations-status-facets",
    "iac-partytype-checkbox",
    "iac-patron-category-page",
    "iac-pdf-multipart-check",
    "iac-planz-application-enabled",
    "iac-plconnect-tasks-and-synonyms",
    "iac-plconnect-tasks-ux-redesign",
    "iac-plc-rss-feeds",
    "iac-plct-crossclientid",
    "iac-plct-crossproductclientid",
    "iac-plct-globalsearch",
    "iac-plct-linkbuilder",
    "iac-plct-smalllawfirmmgmt",
    "iac-plct-ssrulebooks",
    "iac-plct-startupssmallbus",
    "iac-plct-viewalltasks",
    "iac-plc-viewonlydraftingnotes",
    "iac-plc-waywo",
    "iac-plplus-application-enabled",
    "iac-plplus-calendar",
    "iac-pl-scrollissues",
    "iac-pluk-asset-page-enable-wln-links",
    "iac-pluk-cdn-available-for-ip",
    "iac-plus-clientidinsession",
    "iac-plus-clientidpromptpltowl",
    "iac-plus-documentononepage",
    "iac-plus-feedback",
    "iac-plus-homebanner",
    "iac-plus-knowhowbooleanquery",
    "iac-plus-linkbuilder",
    "iac-plus-notesformating",
    "iac-plus-searchcontext",
    "iac-plus-truncatejurinsearch",
    "iac-plus-unhideannotations",
    "iac-plus-viewmorelessdetails",
    "iac-portalmanager-combined",
    "iac-portalmanager-contentlinks",
    "iac-portalmanager-findbypartyname",
    "iac-portalmanager-search",
    "iac-practical-law-display-changes",
    "iac-practicallaw-itg-dropdown",
    "iac-practical-law-subheadings",
    "iac-practiceareas-asterisknote",
    "iac-practicepoint-smartsearch-onesynonym",
    "iac-practicepoint-smartsearch-synonyms",
    "iac-practicepoint-smartsearch-treatises",
    "iac-practitioner-insights-alerts-no-logo",
    "iac-pr-add-bing",
    "iac-pr-addfoldereditem",
    "iac-pr-entity-extraction",
    "iac-pr-fein-plus3",
    "iac-price-guide-link",
    "iac-pricing-guide-redirect",
    "iac-privacy-policy",
    "iac-pr-polkrpt",
    "iac-pr-qsentrpt",
    "iac-pr-section-delivery",
    "iac-pr-ssn-only-search",
    "iac-pr-use-pipl-v5",
    "iac-public-record-prod-gateway",
    "iac-public-records",
    "iac-public-records-alerts",
    "iac-public-records-firstamerican",
    "iac-public-records-report-excel-delivery",
    "iac-public-records-report-filtering",
    "iac-pubrec-real-time-monitor",
    "iac-qanda",
    "iac-qanda-pinpoint",
    "iac-qanda-typeahead",
    "iac-raise-document-limit",
    "iac-ra-no-rank1docs-cache",
    "iac-remove-nyor-hard-coded-collections",
    "iac-remove-securedatatoken",
    "iac-research-accel",
    "iac-research-accel-synopsis",
    "iac-ri-bill-activity",
    "iac-ri-bill-tracking",
    "iac-ri-capitol-watch",
    "iac-ri-category-delivery",
    "iac-ri-citestyles-endpoint-v2-enable",
    "iac-ri-context-analysis",
    "iac-ri-editorial-materials",
    "iac-ri-filings",
    "iac-ri-fnd-newpathway",
    "iac-ri-form-families",
    "iac-ri-legislative-timeline",
    "iac-ri-no-single-rn-uds-post",
    "iac-ri-notes-of-decisions",
    "iac-ri-opinions",
    "iac-ri-professional-references",
    "iac-ri-reduce-uds-rn-data",
    "iac-ri-topics",
    "iac-ri-versions",
    "iac-sb-list-items-delivery",
    "iac-search-como-group1",
    "iac-search-como-group2",
    "iac-search-como-group3",
    "iac-search-como-group4",
    "iac-search-como-group6",
    "iac-search-como-group7",
    "iac-search-como-group8",
    "iac-search-como-public-records",
    "iac-search-como-recodocs",
    "iac-search-como-reghist",
    "iac-search-custom-nyor-reranking",
    "iac-search-delivery-group1",
    "iac-search-delivery-group2",
    "iac-search-delivery-group3",
    "iac-search-delivery-group4",
    "iac-search-delivery-group5",
    "iac-search-firmcentral",
    "iac-search-knowhowrankoption",
    "iac-search-matterroom",
    "iac-search-nl-thresholding-option",
    "iac-search-pmd-result-types",
    "iac-search-result-duplicate-identifier",
    "iac-search-suggestions",
    "iac-search-within-favourites-plcuk",
    "iac-searchwithin-ios",
    "iac-shared-highlights",
    "iac-share-folders-with-cobalt-contacts",
    "iac-sharing-with-the-same-domain",
    "iac-show50statesurvey-inlineflags",
    "iac-small-law-survey-redirect",
    "iac-smartbreadcrumb-add-navid",
    "iac-smartbreadcrumbs-au",
    "iac-smartfolders-ss",
    "iac-snapshots-state",
    "iac-snowdonia-beta",
    "iac-sortoption-courtlevel-pref",
    "iac-starpages-plcuk",
    "iac-staticqa",
    "iac-staticqa-history",
    "iac-staticqa-searchbilling",
    "iac-statutes-new-ast-pdfs",
    "iac-superbrowse-mult-gradeheads",
    "iac-superbrowse-paging",
    "iac-taxpage-eylogo",
    "iac-term-frequency-sorting",
    "iac-transfer-content",
    "iac-trd-alternate-search",
    "iac-trd-juris-facet",
    "iac-trd-legalanalytics",
    "iac-trd-lpafacet-subsearch",
    "iac-trillium-crsw-doc-enhance",
    "iac-trillium-link",
    "iac-uk-a11y-clientid-lightbox",
    "iac-uk-clientid",
    "iac-uk-compartments",
    "iac-uk-fd-and-fs",
    "iac-uk-keywordfinder",
    "iac-uk-linkbuilder",
    "iac-uk-linkbuilder-copy",
    "iac-uk-nonpltracking",
    "iac-uk-performance-new-static-content-or",
    "iac-unlink-unmigrated",
    "iac-use-new-training-user",
    "iac-userdoclink-wln",
    "iac-us-knowhow-algorithm",
    "iac-v3inapplibrary",
    "iac-validity-highlighting",
    "iac-verify-eaddress-against-existance",
    "iac-webinars",
    "iac-website-throttle",
    "iac-westsearch-cases-keynumberfacet",
    "iac-westsearch-cases-partyfacet",
    "iac-westsearch-cases-synopsis",
    "iac-westsearch-cases-topicfacet",
    "iac-westsearch-enhancements",
    "iac-without-flash-dependencies",
    "iac-wln-cig-linkedreport",
    "iac-wlndoc-sharednotes",
    "iac-wln-global-search-judicial-chambers",
    "iac-wln-historicalheader",
    "iac-wln-ios-display-toa",
    "iac-wln-newfiletype",
    "iac-wlnopenweb-serverbrowsepage",
    "iac-wln-ri-tabs",
    "iac-wln-save-snippet",
    "iac-wln-strong-downgrade-email",
    "iac-wlntax-blue-flag",
    "iac-wln-toc-keyciteflag",
    "iac-wl-startpage",
    "iac-wl-striphash",
    "iac-wordsphrases-snippet-support"
  ],
  "IsTypeAheadNewUiEnabled": true,
  "ContactsPageSize": 300,
  "ShowPrivacyPolicy": true,
  "ShowCookiePolicy": true,
  "ResearchReportDocumentLimit": 1000,
  "IsSaveSnippetEnabled": true,
  "IsHideAnnotationsSharedByInactiveUsersEnabled": true,
  "AllowPauseOnLinkOut": true,
  "IsMaintainDocumentPositionRIEnabled": true,
  "IsFormsEngine2Enabled": false,
  "IsFormsEngine2DownloadEnabled": false,
  "IsIndigoDisplayEnabled": false
};


window['Server/Mobile'] = {
  "IsNativeIPad": false,
  "IsNativeIPhone": false
};


window['Server/Messages'] = {
  "ProductName": "Westlaw",
  "ProductSupportNumber": "1-800-WESTLAW (1-800-937-8529)"
};


window['Server/Net'] = {
  "PageContextData": "(sc.CustomDigest)",
  "CacheScopeList": [
    "^/RelatedInfo/v[3456]/keycite/content/",
    "^/RelatedInfo/v3/content/json/",
    "^/RelatedInfo/v1/wlncCaselawHistory\\\\?",
    "^/RelatedInfo/v1/wlncCitingReferences\\\\?",
    "^/RelatedInfo/v1/wlncCourtDocs\\\\?",
    "^/RelatedInfo/v1/wlncLegalMemos\\\\?",
    "^/RelatedInfo/v1/kcJudicialHistory\\\\?",
    "^/RelatedInfo/v1/kcCitingReferences\\\\?",
    "^/RelatedInfo/v1/riFilings\\\\?",
    "^/RelatedInfo/v1/kcNegativeTreatment\\\\?",
    "^/RelatedInfo/v1/kcTableOfAuthorities\\\\?",
    "^/RelatedInfo/v1/kcBillDrafts\\\\?",
    "^/RelatedInfo/v1/kcLegislativeMaterials\\\\?",
    "^/RelatedInfo/v1/kcRegulatoryHistory\\\\?",
    "^/RelatedInfo/v1/kcValidity\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnAgreements\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnAgreementsTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnSecCommentLetters\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnSecCommentLettersTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingsAndDisclosures\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingsAndDisclosuresTwoStepViaMA\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingsAndDisclosuresExhibits\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingsAndDisclosuresExhibitsTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingsAndDisclosuresExhibitsTwoStepViaMAAndFD\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnMergersAndAcquisitions\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnMergersAndAcquisitionsEnhanced\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnMergersAndAcquisitionsEnhancedTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnMergersAndAcquisitionsRelated\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnRandPTransactionFullTextCategory\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnRandPTransactionFullTextCategoryTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFilingFullTextCategory\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFundsInvestments\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFundsInvestmentsV2\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFundsInvestmentsTwoStepViaMA\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnFundsInvestmentsTwoStepViaFDAndMA\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnPefundsFundsFirms\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnAgreementsEnh\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnAgreementsEnhTwoStep\\\\?",
    "^/RelatedInfo/v1/corporatezone/wlnAgreementsEnhTwoStepViaMA\\\\?",
    "^/RelatedInfo/v1/tnpCases\\\\?",
    "^/RelatedInfo/v1/tnpCommentary\\\\?",
    "^/RelatedInfo/v1/tnpCompliance\\\\?",
    "^/RelatedInfo/v1/tnpGovernmentDocuments\\\\?",
    "^/RelatedInfo/v1/tnpHistory\\\\?",
    "^/RelatedInfo/v1/tnpHistoryAndTreatments\\\\?",
    "^/RelatedInfo/v1/tnpLegislation\\\\?",
    "^/Search/v1/search/external/results",
    "^/Search/v3/search/results",
    "^/Search/v1/results",
    "^/Document/v1/fulltext/",
    "^/Document/v1/list/fulltext/",
    "^/Document/v1/Mobile/FullText/",
    "^/Document/v1/fixedheader/",
    "^/Document/v1/list/fixedheader/",
    "^/Document/v1/list/Mobile/Fulltext/",
    "^/Document/v[12]/MetaInfo/"
  ],
  "SessionScope": "35b024c40cf4110fbdaaf6a30272ec9b29310adb8108a3d6fb727f98020766f7",
  "UserScope": "5405685",
  "CacheScope": "0c216288dae57a5f31c9899aee2c4d4f"
};


window['Server/Events'] = {
  "PageEventIdentifier": "824d6bd723b04c86930cd5f6e245a909",
  "PageName": "Cobalt.Website.ServerPage.Document",
  "ResourceToken": "v1|1bc6689129a0e6602cbf394497d36ebad6f63e3183d696afcfe742d8afa2fbf1"
};

</script>


	
	

<!-- View Path: ~/Document/Views/DocumentTabView.cshtml -->
<script type="text/javascript">
window.__viewName = '~/Document/Views/DocumentTabView.cshtml';
</script>
<script type="text/javascript" crossorigin="anonymous" charset="utf-8" src="https://ja.next.westlaw.com/StaticContent_40.1.1015/webpack/Products/WestlawNext/webpack-loader.js"></script>

	

<div id="co_searchDisableDiv" class="co_screenOverlay co_hideState"></div></body></html>